Subspecialty Training in Infectious Diseases at Emory

Transcription

Subspecialty Training in
Infectious Diseases at Emory
Division of Infectious Diseases
Department of Medicine
49 Jesse Hill, Jr. Drive SE
Atlanta, Georgia 30303
Phone: (404) 616-3600
FAX: (404) 880-9305
Email: [email protected]
Or visit us at:
http://medicine.emory.edu/id/
Electron micrograph of Neisseria meningitidis
Contents
I.
Letter from Drs. Stephens, Armstrong, and Leonard
II.
Atlanta, Emory University and the Department of Medicine
III.
History of the Division of Infectious Diseases and Subspecialty Training
Program in Infectious Diseases
IV.
Unique Aspects of the Emory Infectious Diseases Program
And Collaborative Ties
V.
Structure of Fellowship
A.
Inpatient Care Experience
B.
Ambulatory Care Experience
C.
Educational Programs
D.
Research
VI.
Opportunities for Research Training at CDC
VII. Accreditation
VIII. Application Procedure
IX.
Faculty Interest Table
APPENDICES
A.
Full-time Faculty
B.
Faculty Research and Publications
C.
Clinical (Volunteer) Faculty
D.
Associated and Adjunct Faculty
E.
Current Trainees
F.
Graduates
1
Page
2
3
3
4
6
7
8
9
11
17
18
18
19
23
25
100
101
101
103
Comment [WSA1]: Need to update
2
II.
ATLANTA, EMORY UNIVERSITY AND THE DEPARTMENT
OF MEDICINE
Metropolitan Atlanta, home to over 4.5 million people, is the commercial, industrial and
financial leader of the Southeast and was the host city for the 1996 Olympic Games.
Emory University was founded at Oxford, Georgia, in 1836 and moved to Atlanta in
1919. The campus, located fifteen minutes from downtown Atlanta, covers 550 acres of
forested hills and is home to 10,000 students. The national headquarters for the Centers
for Disease Control and Prevention (CDC) IS adjacent to the Emory University campus.
Emory University School of Medicine recently celebrated its 150th anniversary. The
School of Medicine founding dates back to 1854; and became part of Emory University
in 1915 following a series of mergers by forerunner Atlanta medical schools. The Emory
University School of Medicine is the cornerstone of Emory’s Robert W. Woodruff Health
Sciences Center. The clinics and hospitals of this center, with 2,975 inpatient beds and
2.2 million annual patient visits, create an exceptionally rich environment for 1147
residents and fellows, 455 medical students and 1,804 faculty to engage in teaching,
patient care and research activities.
The Chair of the Emory Department of Medicine is R. Wayne Alexander, MD, PhD. The
Department of Medicine is nationally recognized for excellence in teaching, basic and
clinical research, and the delivery of patient care. There are 520 full-time faculty, 206
house officers and 147 fellows in the Department of Medicine. The Emory internal
medicine program and the training program in infectious diseases are centered in four
hospital settings which provide a large and varied patient population: city-county (Grady
Memorial Hospital), tertiary referrals (Emory University Hospital), veterans (Atlanta VA
Medical Center) and community (Emory Crawford Long Hospital).
III.
HISTORY OF THE DIVISION OF INFECTIOUS DISEASES AND
SUBSPECIALTY TRAINING PROGRAM IN INFECTIOUS DISEASES
Dr. Paul Beeson, who later became Chair of Medicine at Emory and Yale, founded the
Infectious Disease Program at Emory. Dr. Beeson was recruited by Dr. Eugene Stead,
Chairman of the Department of Medicine in 1942. At that time, Dr. Beeson was the first
and only infectious disease physician in the southeastern United States. He studied and
trained at McGill University (M.D.), the University of Pennsylvania, the Rockefeller
Institute Hospital in New York, and the Peter Bent Brigham Hospital in Boston. Early in
his career his research focused on the treatment of pneumococcal pneumonia. In 1942,
Dr. Beeson moved to Atlanta to join the Emory faculty and directed the bacteriology
laboratory at Grady Memorial Hospital. While at Emory he wrote the sentinel paper on
transfusion-related hepatitis, and carried out research on sepsis, endotoxin-induced fever,
and endocarditis. In 1946 he became Chair of Medicine at Emory, a post he held until
1952.
Dr. Charles A. LeMaistre initiated the Infectious Diseases clinical program at Emory
University in 1954. In 1958, Dr. LeMaistre became the Chairman of the Department of
3
Preventive Medicine and Community Health, and Dr. Thomas F. Sellers, Jr., assumed
responsibility for the Infectious Diseases program.
Subsequent directors of the Division of Infectious Diseases have been W. Edmund Farrar,
MD; Jonas A. Shulman, MD; W. Lee Hand, MD; and David S. Stephens, MD. Dr.
Stephens, the current Director of the Division of Infectious Diseases, was appointed to
this post in 1992. Dr. Stephens also currently serves as Vice President for Research in
the Robert W. Woodruff Health Sciences Center (WHSC) of Emory University.
During the past decade under the leadership of Dr. Stephens, the Emory ID Division has
experienced unparalleled growth and development. There are currently fifty-four faculty
members in the Emory ID Division who, between Grady, VA, Emory and Crawford Long
campuses have garnered in excess of $20 million in research funding per year (the most
of any Division in the Department of Medicine).
The formal subspecialty training program in Infectious Diseases started in the late-1960s.
To date, 119 physicians have completed Infectious Diseases fellowship training in the
program. Over the past decade, ~80% of the fellows completing the Emory ID
fellowship training program have pursued careers in academic medicine or public health
and ~20% have gone into private practice. More than a third of these trainees have been
women (and currently more than half of the ID fellows are women); 14% are members of
an underrepresented minority group.
IV.
UNIQUE ASPECTS OF THE EMORY INFECTIOUS DISEASES
PROGRAM AND COLLABORATIVE TIES
The broad range of available clinical and research experiences, a diverse and
accomplished faculty, and the unique resources in the Emory and Atlanta community
create an unparalleled opportunity for training in infectious diseases research, teaching,
and patient care. Members of the Division have developed close collaborative ties with
the following Schools and Centers at Emory University and other institutions in Atlanta:
Centers for Disease Control and Prevention (CDC) - Many division members have
collaborative relationships with the CDC, leading to exciting basic and translational,
clinical and epidemiologic research projects. In addition, more than 50 CDC physicians
have clinical faculty appointments in the Division and participate in divisional clinical
and teaching activities.
Georgia Department of Human Resources (DHR)/Division of Public Health
Epidemiology and Prevention Branch - This state agency is responsible for public
health aspects of infectious disease problems in Georgia and Atlanta. The Emory
Division of Infectious Diseases and the Epidemiology and Prevention Branch of DHR
have developed several research ties including area-wide population-based surveillance
for agents of emerging infectious diseases and food-borne illness and projects related to
control of tuberculosis in hospitals, correctional facilities and in the community, as well
as tuberculosis-related epidemiologic studies.
4
The Carter Center - The Carter Center has a number of infectious disease-related
initiatives both on a local and international level. Involvement of the Division in the
activities of the Carter Center enhances our research capabilities and national exposure.
Rollins School of Public Health (RSPH) of Emory University - The Division of
Infectious Diseases plays an active role at the Rollins School of Public Health (RSPH) of
Emory University. The Dean of the RSPH is James Curran, MD, MPH, former Director
of the HIV/AIDS Program at CDC. Dr. Curran serves as the PI/Program Director for the
Emory Center for AIDS Research (CFAR). Emory ID Fellows may combine clinical
training in Infectious Diseases with the MPH degree through the RSPH or with the
MSCR (Masters of Science in Clinical Research) degree for those interested in a career in
clinical investigation as described below.
Global Health Research Training Activities -- In September of 2006 Emory University
established a Global Health Institute (GHI) under the leadership of Dr. Jeffrey Koplan,
former Director of the CDC and now Vice-President for Global Health at Emory. The
GHI has provided opportunities for fellows to be involved in international research
projects. The Emory Division of Infectious Diseases is the home of two NIH/Fogarty
funded international research training programs. They are the Emory-Georgia TB
Research Training Program (TB-RTP) and the Emory AIDS International Training and
Research Program (AITRP). These NIH-funded training grants support international
researchers to come to Emory for further training. The Emory AITRP and TB-RTP
fellows participate in divisional activities which provide an opportunity for interaction
between ID Fellows and international scholars. In addition, the Center for Global Safe
Water at the Rollins School of Public Health, led by Division of Infectious Diseases
faculty member Dr. James M. Hughes provides an opportunity for fellows to participate
in clinical and epidemiologic studies of water related diseases.
Global Health Institute of Emory University. The mission of the recently established
Emory Global Health Institute is to advance Emory University’s efforts to improve health
around the world. The Global Health Institute, directed by Dr. Jeffrey Koplan, former
Director of CDC, is a university-wide initiative that supports Emory faculty, students,
and alumni in their work to find solutions to critical global health problems. Emory has
demonstrated its commitment to Global Health through its $55 million investment in the
institute.
Emory Masters of Science in Clinical Research (MSCR) – As part of the Emory
Division of Infectious Diseases Fellowship Training Program, Emory ID fellows have the
opportunity to receive didactic and mentored clinical and translational research training
through the MSCR program (www.actsi.org/retcd and www.sph.emory.edu/mscr). The
specific aim and overall goal of the Emory MSCR program is to provide an outstanding
postgraduate education program for clinical investigators so that upon completion of this
program and receipt of the MSCR degree, they can more effectively conduct high-quality
clinical and translational research and compete successfully for research funding. The
MSCR program is now housed in the Atlanta Clinical and Translational Science Institute
5
[ACTSI] (NIH supported Emory CTSA). Dr. David Stephens, M.D. (Division Director,
Infectious Diseases) serves as PI of the ACTSI and Dr. Henry Blumberg (Program
Director, Division of Infectious Diseases) serves as the Program Director of the ACTSI
Research Education, Training and Career Development (RETCD) program which
includes the MSCR program and the KL2-Mentored Clinical Research Scholars Program.
The MSCR program is designed to help prepare participants for careers as clinical
research scientists. The program includes formal course work (analytic sciences
including statistical reasoning, decision analysis, probability theory, analytical
epidemiology, biostatistics and bioinformatics; thorough understanding of the principles
of evidence-based medicine, bioethics, clinical trials design, regulations involving human
subjects, scientific and grant writing, technology transfer, outcomes research, and the
responsible conduct of research) and a mentored thesis leading to the MSCR degree from
the Graduate School of Emory University.
Basic Science Departments of Emory University School of Medicine - Members of the
Division of Infectious Diseases have strong research and teaching ties with the
Department of Microbiology and Immunology, headed by Dr. Charles Moran well as the
Emory Vaccine Center headed by Dr. Rafi Ahmed. These ties include involvement in
graduate student training and teaching, and membership in graduate programs in
Immunology and Molecular Pathogenesis or Microbiology and Molecular Genetics.
Graduate level courses are available for our fellows in areas such as Immunology and
Prokaryotic Genetics.
Emory Vaccine Center – The Emory Vaccine Center represents one of the largest
academic vaccine centers in the world, and is renowned for its expertise in cellular
immunity and immune memory. This expertise leads to the creation of new technologies
for the prevention of emerging infectious diseases. Established in 1996 with support from
Emory University and the Georgia Research Alliance, the Emory Vaccine Center has 21
faculty members who study HIV/AIDS, tuberculosis, malaria, and other global infectious
disease threats.
The Hope Clinic – The Hope Clinic of the Emory Vaccine Center is the key vaccine
clinical trial site of the Emory University School of Medicine. The Hope Clinic offers an
innovative, community based, and scientifically grounded clinical trials program to
address the need for safe and effective vaccines to prevent major global infectious
diseases. The clinic is recognized for its excellent, innovative prevention studies, its high
impact public health agenda, and its active strategic partnerships and service to the
community. The Hope Clinic has been funded as a NIH/National Institute of Allergy and
Infectious Diseases (NIAID) Vaccine and Treatment Evaluation Unit (VTEU) and an
HIV Vaccine Trials Unit (HVTU).
V.
STRUCTURE OF FELLOWSHIP
There are three tracks available to ID Fellows in the Emory program. This includes a 2year clinical track, a three-year clinical investigator (or epidemiologic) track, and a 3-year
6
basic investigator track. A two-year program provides training and experience to acquire
board eligibility in Infectious Diseases. Most fellows in our program complete a third
year and on occasion, an optional fourth year to provide for additional training in clinical
investigation or basic science research in preparation for an academic career. The ID
fellowship includes 12 months of clinical rotations during a 2 year program and 13 to 15
months during 3 year or 4 year fellowships. The remainder of the fellowship is devoted
to research and research training activities. Research training is an essential component
of the Emory ID Training Program as discussed below in Section D.
As noted, there are outstanding opportunities for both clinical and research training. In
addition to hospital based consult services, fellows also have rotations and gain
experience in transplant infectious disease, clinical microbiology, outpatient infectious
diseases, pediatric infectious diseases, infection control and healthcare epidemiology, and
infectious disease pharmacology. An outpatient continuity clinic and rotations at
specialty clinics (e.g., STD, TB, Travel, Pediatric Immunology, and Transplant ID) are
part of the training program.
A. Inpatient Care Experience
The clinical infectious diseases training program utilizes four Emory-affiliated teaching
hospitals which provide opportunities to care for patients with a variety of infectious
diseases. The experiences at these hospitals are varied and complement each other. ID
fellows completing the Emory program pride themselves in “having seen it all”. Year 1
of the Emory ID fellowship is devoted to clinical training.
The ID consult team consists of the ID fellow and an ID attending. The number of
medical residents assigned to the team varies by hospital due to differences in consult
volume, but generally teams include one or two housestaff. Senior medical students may
also do rotations on the infectious diseases consult service. Clinical pharmacists
(PharmD) either round with the ID consult team or are readily available at each of the
four Emory-affiliated hospitals.
Grady Memorial Hospital - This large public urban hospital (~ 1000 beds) located in
downtown Atlanta serves as the source of care for a population of more than half a
million and receives 2,000 patient visits per day. Common infectious disease problems
encountered include tuberculosis, sexually transmitted infections, HIV/AIDS,
complications of injection drug use, orthopedic and trauma-related infections, diabeticrelated infections, pulmonary infections and tropical diseases (because of an increasing
number patients from Latin America, Southeast Asia and sub-Saharan Africa).
Specialized HIV care is provided on a separate ward, thus the hospital ID consult service
is not dominated by HIV care, but intensive experience with inpatient HIV-related
problems is acquired during a separate rotation. The general infectious diseases consult
team sees approximately 75-100 new consults per month and follows 10-20 patients at
any given time. On the HIV ward, the fellow assists the ID Attending with supervision of
a house staff team which cares for up to 35 inpatients. Grady Memorial Hospital is also
home to a NIH funded General Clinical Research Center (GCRC), one of the few public
hospitals in the nation to house such a center.
7
VA Medical Center (Atlanta) –This 173 bed hospital is a primary and tertiary care
facility (40-50 consults per month 10-20 patients at any given time) with an adjacent 100
bed nursing home unit.
Emory University Hospital - Emory Hospital, a tertiary care facility with 583 total beds,
deals with specialized and complicated problems and procedures. Areas of expertise and
interest include heart failure, primary pulmonary hypertension, coronary artery bypass
surgery, interventional cardiology, neurosurgical procedures, bone marrow transplantation,
and solid organ (kidney, kidney-pancreas, liver, heart, and lung) transplantation. At
present, 150 kidney, 10 kidney-pancreas, 25 heart, 80 liver and 30 lung transplants are
performed each year. Fellows rotate on the general ID consult service and also on a
separate ID Transplant Consult service at Emory University Hospital. All fellows also
spend one month on the clinical microbiology rotation at Emory Hospital during their first
year of training. Approximately 90-100 consults per month are seen on the General ID
Consult service and 50 consults per month on the ID Transplant Consult service.
Emory Crawford Long Hospital – Located in Midtown Atlanta, this university-owned
community teaching hospital with 500 beds is staffed by both private physicians and fulltime faculty of Emory University. Crawford Long Hospital provides primary and tertiary
care and has busy ID consult service (90-100 consults per month, 15-30 patients at any
given time). The hospital complex has recently undergone a $270 million renovation.
B. Ambulatory Care Experience
Throughout the fellowship, each trainee maintains a continuity outpatient clinic that
meets one-half day per week. Fellows are assigned a continuity clinic at one of three
sites (Grady Infectious Diseases/Ponce Center, the Emory Healthcare Infectious Diseases
Clinic, or the VAMC Infectious Diseases Clinic). Although these clinics differ somewhat
in their organization and in the patient population served, they all offer excellent
opportunities to see outpatient infectious diseases referrals (HIV-infected and HIVuninfected patients) and to follow a cohort of patients with HIV infection. A faculty
member is present to provide supervision at each setting.
Outpatient clinics and facilities utilized in the program include:
Continuity Clinic
The Ponce de Leon Center of Grady (Directed by Dr. Jeffrey Lennox) - The
Infectious Diseases Program (IDP) at the Ponce de Leon Center provides primary
care for over 4,500 HIV-infected adults and children and is a major site of clinical
research in HIV/AIDS. Drs. Aikens, Anderson, Armstrong, Broyles, del Rio,
DiazGranados, Gunthel, Lennox, Leonard, Mulligan, Palmore, Ofotokun, and
Nguyen provide the care and supervision at this center which is composed of six
interrelated outpatient clinics and is one of the finest outpatient facilities for
HIV/AIDS care in the country. General infectious disease outpatient consultations
are also provided at this site.
•
8
•
The Emory Healthcare Infectious Diseases Clinic (at Emory Crawford Long
Hospital; Directed by Dr. Molly Eaton) - Drs. Franco, Jacob, Kuhar, Lyon, Osborn,
Ribner, Rouphael, Steinberg, Talati, and Workowski provide primary care for HIV
infected persons (including the majority of HIV-infected hemophiliac patients in
Atlanta) and infectious disease consultation services for a broad referral area in the
southeastern United States. Approximately 1,000 HIV-infected patients are followed
at this clinic.
•
The Atlanta VA Medical Center (VAMC) Infectious Diseases Clinic This clinic is
directed by Dr. David Rimland, Chief of Infectious Diseases at the Atlanta VAMC.
Drs. Rimland, Moanna and others including several CDC colleagues provide care to
approximately 1,000 HIV-infected veterans.
Specialty Clinics – Emory ID fellows rotate through all of the following subspecialty
clinics.
•
Sexually Transmitted Disease (STD) Clinic – Fellows rotate through the Fulton
County STD clinic which is located directly across the street from Grady Memorial
Hospital. This urban STD clinic provides the opportunity to see a wide variety of
outpatient sexually transmitted infections.
•
Travel Well Clinic - (Directed by Drs. Carlos Franco and Phyllis Kozarsky). Travel
Well has approximately 3,000 visits per year, including pre-travel visits for advice,
vaccination etc., and post travel evaluations for illnesses acquired during travel. The
clinic also sees an increasing number of immigrants and refugees. The Travel Well
Clinic is located at Emory Crawford Long Hospital adjacent to the Emory
Healthcare Infectious Diseases Clinic. Because of the large number of international
corporations with headquarters in Atlanta (e.g., Coca-Cola, UPS, Home Depot, Delta
Airlines, and CNN), the large number of missionary organizations based in the
Southeast, and the large numbers of persons traveling with the CDC, Travel Well
provides services to persons who have visited a wide variety of locations.
•
Pediatric Immunology Clinic – This clinic directed by Lisa Kobrynski, M.D. in the
Department of Pediatrics provides fellows with the opportunity to see patients with
unusual non-HIV immunodeficiencies.
•
Tuberculosis Clinic at Fulton County Health Department (Division activities
directed by Dr. Susan Ray) -The Emory Division of Infectious Diseases provides
care for patients with tuberculosis in an arrangement with the Fulton County Health
Department which is located directly across the street from Grady Memorial
Hospital. Fellows rotate through the TB Clinic at Fulton County and have the
opportunity to also attend the HIV/TB clinics at the DeKalb County Health
Department.
•
Transplant ID Clinic – (Directed by Dr. Marshall Lyon). Fellows rotate through
the transplant ID clinic, based at Crawford Long Hospital, which provides outpatient
follow-up to those solid-organ and marrow transplant patients with infectious
9
complications.
C. Educational Programs
A wide array of conferences and educational programs are available in Atlanta including
at Emory and CDC. The Emory Division of Infectious Diseases sponsors several
conferences; these include:
•
Case of the Week - In this weekly clinical conference, fellows present two clinical
cases followed by a review of medical literature pertaining to specific questions
raised by the case. A third case is presented each week by a faculty member.
•
Infectious Diseases Seminar - This research conference is held on a weekly basis.
Members of the Emory ID Division, other faculty at Emory, or visitors from the
CDC or other institutions present research topics related to infectious diseases,
microbiology, or immunology. Each ID fellow presents at least once at Seminar
during the fellowship.
•
Journal Club - Journal club meets monthly at the home of a faculty member (drinks
and dinner provided by the faculty member!). Fellows and faculty discuss clinical
and basic research articles in detail. The content of the articles as well as aspects of
interpretation of medical literature is emphasized.
•
Citywide Infectious Diseases Case Conference - This dinner conference is held at
restaurants around Atlanta and replaces the regular case of the week conference
approximately once every 2 months. There are a variety of interesting presentations
including cases presented by infectious diseases practitioners in the community and
interesting reports or outbreaks presented by staff from the CDC. ID fellows also
have the opportunity to present cases at this conference. This conference facilitates
interaction with the outstanding clinical community in Atlanta as well as infectious
diseases physicians at CDC.
•
Basic Concepts of Infectious Diseases (“Didactic”) - This weekly lecture series
(directed by Drs. Molly Eaton and Melissa Osborn) serves to provide fellows with
information that might not be encountered during clinical rotations. The course
includes a general review of basic science methods, mechanisms of action and
resistance of antimicrobial agents, infectious disease syndromes, and infectious
agents. The course is on a two year schedule so that fellows entering the program at
different times receive a didactic review of important topics covered in the course
curriculum during their fellowship training.
•
Advanced Management of HIV/AIDS - This weekly lecture series directed by Dr.
Wendy Armstrong is primarily targeted to second and third year fellows. The course
runs from September to June and provides a full HIV curriculum including basic
science and clinical topics in a small group, often case-based and highly interactive
format.
10
A wide variety of conferences and presentations are also available outside the Division.
Weekly research seminars are sponsored by the Graduate Departments of Microbiology
and Immunology and monthly seminars by the Emory Vaccine Center. In addition,
weekly epidemiology seminars, monthly Infectious Diseases Grand Rounds, and frequent
special presentations are held at the CDC. Conferences and seminars are also sponsored
by the Department of Medicine and by each division within the department and at the
Rollins School of Public Health of Emory University. Of particular relevance to our
Division are the Center for AIDS Research (CFAR)-sponsored events including the
CFAR AIDS Soirée and the Vaccine Dinner Club meetings.
Additional conferences include the monthly Housestaff ID conference and Neuro-ID
conference and the bi-monthly Pulmonary ID conference. The Housestaff conference is
held at the end of each month and rotates between each hospital. A member, from each
consult team, usually the resident, presents an instructive case illustrating basic principles
of infectious diseases. The Neuro-ID conference is held at Grady Memorial Hospital on a
monthly basis. This is an interdisciplinary conference. Attendees include the Grady ID
consult team, the SIS team, the Neurology consult team, a neuroradiologist and the
neurosurgery residents and faculty at Grady. Selected interesting cases are reviewed with
a discussion of the diagnostic and management challenges.The Pulmonary ID conference
is held at Grady Memorial Hospital the second and fourth Thursday of each month. It is a
joint conference where members of the Grady ID consult team, SIS team, Pulmonary
consult service and MICU team, often with representatives from pathology as well,
discuss interesting current cases.
Support is provided for trainees to attend at least two scientific meetings (typically IDSA
or ICAAC and another conference of their choice) during their fellowship. Attendance at
additional meetings is encouraged and supported financially when feasible, especially for
those who are making presentations.
D. Research
Outstanding opportunities are available for research—basic, translational, clinical, or
epidemiologic—through the Emory University School of Medicine Division of Infectious
Diseases. The Emory Division of Infectious Diseases had more than $23 million in
research funding in fiscal year 2007, more than any other division in the Department of
Medicine. Additional outstanding opportunities for research are also available through
collaborators at the Emory Vaccine Center, the Emory Department of Microbiology and
Immunology, the Emory Rollins School of Public Health, and the CDC. During the past
year the Emory Division of Infectious Diseases faculty and fellows have recorded
approximately 247 publications - 153 in peer-reviewed journals, 31 book chapters, 3
books; in addition there were 70 abstracts presented at scientific meetings.
All trainees participate in a major clinical, epidemiologic, and/or laboratory research
project during their fellowship. After beginning the program, all fellows will identify a
faculty mentor under whose guidance they will carry out their research project. The
fellow-faculty mentor relationship is crucial to a successful research program. The
11
Emory ID program provides an environment suited to developing expertise in many
disciplines within infectious diseases. While some trainees designate a specific area of
interest prior to the start of the fellowship, this is not required. Clinical rotations are
scheduled in blocks (i.e., 1st year of training) so that extended periods are available for
concentrated research efforts (i.e., 2nd and 3rd years of training). Each November, all
first-year fellows participate in a research retreat designed to assist in their planning of
the upcoming research year. Division leaders present their experiences in a variety of
general research areas including: basic science, clinical and translational research,
healthcare epidemiology, clinician-educator, and global health. Additional topics
covered during the retreat are selection of a research mentor, publication expectations, the
MSCR program, and an introduction to training/career development grants.
To take advantage of the broad range of possible experiences, some fellows participate in
1 to 2 smaller research efforts in addition to their primary project which may be basic
laboratory research or clinical (or epidemiologic) research. Fellows have generated one
or more publications as a result of their research activities. When fellows choose to
conduct research under the guidance of an investigator from CDC or the Emory graduate
programs, a faculty member from the Division of Infectious Diseases is assigned as a comentor to assist with project choices and progress evaluation.
Two research tracks are available for trainees – a clinical investigator track (for fellows
interested in clinical, translational, or epidemiologic research) and a basic investigator
track. A third year and in some cases subsequent years of training are designed for
individuals with a goal of a career in academic infectious diseases emphasizing clinical,
translational, or basic investigation. The trainee spends these years largely in research
activities under the supervision of the faculty mentor. Funding support is provided
through a variety of sources (e.g., NIH training grants, CDC funded research, Divisional
funding, competitive fellowships, and VA Career Development Program support).
Understanding the basic science underlying infectious diseases and related disciplines is
encouraged throughout the fellowship. This is accomplished through trainee
presentations at research seminars, review at Journal Club of basic research articles and
attendance at basic research seminars in the Division of Infectious Diseases, the
Department of Medicine, the Department of Microbiology and Immunology and at the
CDC.
RESEARCH OPPORTUNITIES
a.
BASIC AND TRANSLATIONAL SCIENTIFIC RESEARCH - Basic
scientific research within the Division focuses on pathogenesis of infectious diseases
such as bacterial meningitis (Drs. Stephens, Farley, Satola, Tzeng, Weiss and Shafer
[adjunct faculty]) as well as basic and translational research in HIV, immunology,
vaccine development and/or virology (Drs. Galinksi, Garber, Blackwell, Moreno,
Grakoui and Radziewicz and Drs. Eric Hunter, Rafi Ahmed and Harriet Robinson
[Vaccine Center Investigators]). Major areas of investigation of bacterial pathogens
include analysis of mechanisms of attachment and invasion of Neisseria and
Haemophilus (including molecular investigation of synthesis and function of pili,
12
capsules and lipooligosaccharides, roll of toll receptors), studies of the molecular
mechanisms of antibiotic resistance (Drs. Stephens, McGowan), research into the role of
transposable elements and repetitive nucleotide sequences in microbial pathogenesis, and
agents associated with bioterrorism (Dr. Stephens). The pathogenesis group works
closely with the other investigators in the Emory Department of Microbiology and
Immunology and investigators at the CDC who focus on microbial pathogenesis. The
Division participates in graduate programs and research in microbiology and molecular
genetics, immunology and molecular pathogenesis, and population biology, ecology, and
evolution. Additional opportunities are available for basic research in toxin mediated
infections, intracellular pathogens, influenza, hemorrhagic fever viruses, zoonotic
pathogens, parasites and fungi.
The Emory Vaccine Center has been established at Emory University at the Yerkes
Primate Research Center. Dr. Rafi Ahmed serves at the, Director of the Vaccine Center.
The EVC currently has 24 faculty and 71 postdoctoral fellows who have attracted more
than $24 million in sponsored research funding. Primary program areas in basic science
and translational research currently include HIV/AIDS, tuberculosis, malaria, Hepatitis C
virus (HCV), cytomegalovirus, gamma-herpes viruses, influenza, and DNA and proteinconjugate vaccines. In addition, as discussed above, the Emory Vaccine Center has a unit
(The Hope Clinic directed by Emory ID faculty member Dr. Mark Mulligan) to conduct
clinical research, vaccine trials, and critical research on vaccine policies. The Emory
Vaccine Center provides many opportunities for basic and translational investigation of
HIV-related immunology, vaccine development and virology; these are a major focus of
investigation that involves our faculty (Drs. Garber, Grakoui, Radziewicz, Blackwell, and
others). Malaria research is also a major focus covering molecular, cellular and
immunophysiopathological aspects of this disease, as well as malaria vaccine
development and testing (Drs. Galinski and Moreno). Investigations of naturally
acquired immune responses in malaria endemic regions are also a priority. Further
vaccine related research addresses T-cell immunologic responses and antigen processing
(Drs. Ahmed, Galinski, and Robinson) as well as homeostasis of T-cells. A number of
additional opportunities for basic scientific research are available in the Graduate
Divisions of Microbiology and Immunology and through CDC. HIV translational
research is also a major focus of the ID Division and Emory Vaccine Center investigators
(Drs. Hunter, Radziewicz, Blackwell).
Clinical and Diagnostic Microbiology - Emory University Hospital and Grady
Memorial Hospital have outstanding resources in diagnostic and clinical microbiology.
Dr. Angela Caliendo Director of the Emory Healthcare Laboratories is a nationally
known leader in clinical microbiology and molecular diagnostics. Areas of focus have
included development and assessment of diagnostic tools based on nucleic acid detection,
optimization of laboratory procedures for diagnosis of mycobacterial infections, and
assessment of the accuracy of automated systems for detection of antimicrobial
resistance.
b.
CLINICAL RESEARCH - Major areas of focus for clinical research include
HIV/AIDS, sexually transmitted infections, tuberculosis, vaccine research, healthcare
13
epidemiology, emerging infectious diseases, global health, and bioterrorism. Clinical
research training opportunities are enhanced by the presence of a Clinical Interaction
Sites (previously called General Clinical Research Centers (GCRC) at the Emoryaffiliated hospitals. In addition, opportunities for clinical and translational research
training are enhanced by the presence of the NIH funded CTSA award (Atlanta Clinical
and Translational Science Institute [ACTSI] which was awarded to Emory University in
collaboration with Morehouse School of Medicine and the Georgia Institute of
Technology. A major component of the ACTSI is the Research Education, Training and
Career Development program which includes the Master of Science in Clinical Research
(MSCR) program described above.
A number of clinical and translational research studies are ongoing at the Infectious
Diseases Clinics on the campuses of Grady, Emory, Crawford Long and at the VA in
addition to hospital-based clinical research activities.
•
The Grady Infectious Diseases Program/Ponce de Leon Center follows more than
5,000 HIV-infected patients and is the site of the NIH-funded Emory HIV/AIDS
Clinical Trial Unit (EHCTU, directed by Dr. Lennox). Treatment trials for the AIDS
Clinical Trials Group at the Ponce center are directed by Dr. Del Rio, who also
oversees the HIV Prevention Trials Network (HPTN) studies at Ponce and at the
Hope Clinic. In addition, investigator initiated or pharmaceutical research at the
facility is currently addressing new antiretroviral agents, new combinations of
antiretrovirals, adherence issues, pharmacokinetics, and therapy for opportunistic
infections. The EHCTU also performs HIV Vaccine Trials Network studies at the
Hope Clinic, under the direction of Dr. Mulligan as outlined below.
•
The HIV program at the VA follows ~1000 patients in a primary care clinic staffed
primarily by CDC volunteers. In addition, 2-3 ID fellows have their continuity clinic
at the VA. All patients are included in a prospective cohort study- the HIV Atlanta
VA Cohort Study. The clinic is integrated with several clinical research endeavors,
including cohort studies and several epidemiologic studies of HIV and comorbid
conditions. Areas of interest include hepatitis co-infections, antiviral resistance,
pulmonary infections and MRSA. These studies are funded by VA, CDC, NIH and
the pharmaceutical industry.
•
The Hope Clinic of the Emory Vaccine Center is an international center of
excellence and leadership for clinical and translational research on vaccines and other
biomedical interventions targeting infectious diseases with public health importance.
The Hope Clinic serves as the clinical arm of the Emory Vaccine Center. It is located
in Decatur, approximately two miles from the Emory campus. Dr. Mulligan serves as
Executive Director. In addition, Drs. Edupuganti, del Rio, Workowski, and Rouphael
have active research projects at the site. Immediate disease targets for which
clinical/translational programs are ongoing include AIDS, anthrax, avian influenza,
malaria, mumps, pneumococcus, and yellow fever. Other projects include approaches
to improve vaccine immunogenicity through protein conjugation, adjuvants, and
DNA electroporation. In addition, the Hope Clinic has major commitments to:
14
mentoring and training of the next generation of vaccine investigators, particularly
Infectious Disease Fellows interested in clinical and translational research careers;
supporting basic science research on the immunology of human vaccination; and
community-based education, prevention, and research. The Hope Clinic is an NIHsponsored HIV Vaccines Trials Unit (HVTU) and one of eight national NIHsponsored Vaccine and Treatment Evaluation Unit (VTEUs), charged with vaccine
and treatment studies for all infectious diseases other than AIDS. Drs. Mulligan,
Keyserling and Spearman direct this large multi-site consortium of clinical and
translational research programs. A significant initial focus of the Emory VTEU is on
better H5N1 avian influenza vaccine regimens, a component of US national pandemic
influenza preparedness.
•
The Division (especially Drs. Workowski, Eaton, Stephens, del Rio, and Shafer) has
an expanding program in sexually transmitted infections, particularly Chlamydia,
Herpes simplex virus, Treponema pallidum, and Neisseria gonorrhoeae, and works
closely with the STD Prevention and Laboratory Programs at CDC and local health
departments. For example, the Division is home for one of the regional U.S.
laboratories for gonococcal antibiotic resistance testing as part of the CDC-funded
Gonococcal Isolate Surveillance Program (GISP). In addition, the role of social
networks in the transmission of sexually transmitted infections (STIs), HIV and
tuberculosis is being explored.
•
Tuberculosis is a major public health problem in Atlanta, an enormous global public
health problem, and an important focus of clinical research efforts as well as
laboratory based research efforts in the Division and at Emory. Examples include the
CDC funded Tuberculosis Epidemiological Studies Consortium grant to Dr.
Blumberg, the CDC-funded Tuberculosis Trials Consortium grant to Dr. Ray, and
tuberculosis control and prevention both in the institutional setting and community in
conjunction with the Georgia Division of Public Health and local health departments
(Drs. Blumberg, Ray, Leonard). In addition, Dr. Leonard serves as the TB Medical
Consultant to the Georgia Division of Public Health. Laboratory based projects
include molecular epidemiologic studies assessing transmission dynamics of M.
tuberculosis in Atlanta (Drs. Ray and Blumberg) as well as in the former Soviet
Republic of Georgia. International tuberculosis research training is an important
focus, and Dr. Blumberg serves as the PI for an NIH Fogarty Center supported
Emory-Georgia TB Research Training Program. Other ongoing interests include the
development and study of new diagnostic tests for latent tuberculosis infection (Drs.
Blumberg, Leonard, Talati and del Rio) and TB/HIV in low and middle income
countries (Zambia, Russian Federation, Georgia).
• General Infectious Diseases Epidemiology - The proximity of Emory University to
CDC has led to the development of numerous collaborations between the Division of
Infectious Diseases and investigators at CDC. The Georgia Emerging Infections
Program (Dr. Farley-principal investigator, and Drs. Stephens, Rimland, and Ray)
conducts population-based surveillance for infectious diseases occurring in the 20county Atlanta metropolitan area. This project has provided critical data concerning the
epidemiology of infections with Haemophilus influenzae, Listeria monocytogenes,
15
Neisseria meningitidis, Group A streptococci, Group B streptococci, penicillin-resistant
S. pneumoniae, vancomycin-resistant enterococci (VRE), Cryptococcus neoformans,
community acquired methicillin-resistant Staphylococcus aureus (MRSA), a variety of
food-borne diseases, Creutzfeldt-Jakob Disease, and offers countless opportunities for
additional research. The epidemiology of infections in patients with HIV/AIDS is
studied intensively throughout the Emory system. Recently completed studies have
addressed epidemiologic questions related to opportunistic pulmonary and intestinal
infections.
•
Supplemental training in infectious diseases epidemiology and clinical research is
available through the Rollins School of Public Health at Emory University (MPH in
Epidemiology or International Health) as well as the Emory Master of Science in
Clinical Research (MSCR) program. The MSCR Program provides didactic and
mentored clinical and translational research training for physicians interested in a
career in clinical investigation. This program is discussed in further detail above.
Additional opportunities are available at CDC and through the joint Emory-CDC ID
fellowship training activities.
•
Healthcare Epidemiology - Active healthcare epidemiology programs are in place at all
four hospitals in the Emory system. Fellows are encouraged to participate in general
infection control activities as well as outbreak investigations. Several techniques for
molecular typing of isolates are available (laboratories of Drs. Blumberg, Farley, Ray,
Satola, and Stephens). Research efforts have focused on the epidemiology of infections
with methicillin-resistant S. aureus (MRSA)—both healthcare associated and
community-acquired, C. difficile, M. tuberculosis, vancomycin-resistant enterococci
(VRE), Group B streptococci, fungi, influenza, and parvovirus B19. Recent studies
have also addressed the epidemiology of infections associated with intravascular
devices. Antibiotic utilization and antimicrobial resistance is another major area of
research interest of a number of faculty (Drs. Gaynes, Steinberg, Ribner, Ray, Jernigan,
Blumberg, Jacob and DiazGranados).
•
Bioterrorism Preparedness and Biodefense Research - Emory faculty (Drs. Stephens,
Hughes and others) in collaboration with CDC and local and state public health officials
are involved in bioterrorism preparedness, investigations, molecular epidemiology and
education. For example, Dr. Stephens serves as the Executive Director of the
Southeastern Center for Emerging Biologic Threats (SECEBT), an Emory based, multiinstitutional collaboration, administered out of the Woodruff Health Science Center,
which includes representatives from academic institutions, state health departments and
governmental and nonprofit organizations across the southeast. Dr. Stephens is also the
primary investigator for Emory in the Southeast Regional Center of Excellence for
Emerging Infections and Biodefense (SERCEB), the southeast region’s collaboration on
the NIH Regional Centers of Excellence grant. Over the next 5 years, investigators from
Emory University, Duke University, Vanderbilt University, the University of AlabamaBirmingham, the University of Florida, and other affiliate institutions will work together
to develop new vaccines, therapeutics, and diagnostics to better protect the nation
against potential bioterrorist threats.
•
Global Health and Travel Medicine -The Emory/Atlanta community has a strong
16
interest in infectious diseases in developing countries. Members of the faculty of the
Division of Infectious Diseases have established collaborations and perform studies in
Mexico, India, Ethiopia, Sudan, Rwanda, South Africa, Zambia, Thailand, the
Republic of Georgia, Vietnam, and Venezuela. Dr. Phyllis Kozarsky has developed
an outstanding international travel clinic at Emory Crawford Long Hospital. Dr.
Carlos Franco coordinates clinical and research efforts at the Travel Clinic. The
Travel Clinic is the site for several research studies (e.g., studies of efficacy of
malaria chemoprophylaxis and hepatitis A vaccine). Dr. Mary Galinski, who is an
affiliate scientist at Yerkes and the Emory Vaccine Center, joined the growing global
effort to eradicate malaria by helping to establish a dedicated malaria research
program which is currently conducting multiple trials aimed at assessing the safety
and immunogenicity of several potential vaccines. The Division is also home for a
NIH funded AIDS International Training and Research Program (AITRP) which
allows close collaborations with developing countries in AIDS research and open
overseas opportunities for our fellows (e.g., Mexico, the Republic of Georgia,
Zambia, Rwanda, and Vietnam). Division investigators are also supported by an NIH
funded Emory-Georgia Tuberculosis Research Training Program grant. In addition,
Dr. Keith Klugman serves as the Director of the Respiratory and Meningeal
Pathogens Research Unit in Johannesburg, South Africa. The Unit runs national
surveillance in South Africa for blood and CSF isolates of pneumococci,
meningococci, H. influenzae and Salmonella. Large vaccine and antibiotic clinical
trials are conducted in Soweto and the molecular laboratory in Johannesburg does
research on the molecular basis of resistance in these pathogens and tracks the
molecular epidemiology of the strains. Dr. Klugman is also the convener of the
Pneumococcal Molecular Epidemiology Network, which determines the
nomenclature of global clones of pneumococci. Dr. James M. Hughes is leading the
Center for Global Safe Water which is evaluating the impact of approaches to
introducing the Safe Water System into communities and schools in Nyanza Province
in Western Kenya in collaboration with the CDC, Rotary Atlanta and the Coca-Cola
Company.
Other Global Health Activities - Examples of ID Fellow Research Opportunities
•
CDC: Opportunities for research related to Global Health are also available
through the CDC. Recent trainees have participated in studies of the immunology
of schistosomiasis in Egypt, studies of the immunology of infections with
Trypanosoma cruzi in Brazil, and the impact and prevention of malaria in
pregnant women in Malawi.
•
Rwanda-Zambia HIV Research Group. Dr. Susan Allen is Principal
Investigator of the Rwanda-Zambia HIV Research Group. The RZHRG has
research sites in Kigali, Rwanda; and the cities of Lusaka, Ndola, and Kitwe,
Zambia. The RZHRG follows one of the largest cohorts of HIV discordant
couples in the world and conducts research on the biology of transmission as well
as clinical trials of behavioural and biomedical interventions to prevent HIV
transmission. Recent trainees have participated in projects with the RZHRG
involving observational research which spans policy, socio-demographic,
behavioral, clinical, and laboratory aspects of HIV and related conditions
17
including syphilis. The project sites have participated in a phase III trial of
acyclovir in HIV+/HSV-2+ individuals in discordant couples to assess impact on
transmission of HIV, and are preparing for vaginal microbicide trials as well. In
addition, the sites support TB/HIV related research focusing on the development
of new diagnostic tests for TB and on tuberculosis vaccine trials.
•
Global Health Institute. In 2006 and as a result of a University-wide Strategic
Planing process, Emory University made a major commitment and investment to
global health activities at the institution through the establishment of the Global
Health Institute (GHI) which is directed by Dr. Jeffrey Koplan, former Director of
the CDC and now Vice President for Global Health at Emory University. The
$55 million investment by the University to enhance and expand global health
related activities plus additional funding through the Gates Foundation provides
even further activities for fellows to become engaged in public health and
research activities in the international arena. The Emory GHI has already funded
important projects in Mexico, South Africa, India, Georgia and Zambia in which
faculty and fellows of the division are currently involved.
Bioethics Training – All fellows receive training in human subject protection and ethics.
These courses are conducted by the Emory Institutional Review Board (IRB) and the
Emory Center for Ethics.
VI. Opportunities for Research Training at CDC
The combined Emory-CDC ID fellowship program offers three years of clinical and
research training leading to eligibility for board certification in infectious diseases. The
program is designed for physicians with training in internal medicine who wish to pursue
a career in academic infectious diseases and/or public health. Two tracks are offered one in epidemiology and the other in basic laboratory research in infectious diseases.
The epidemiology track includes a three year fellowship in epidemiology and clinical
infectious diseases, which includes 12-15 months of clinical infectious diseases training
and a block of 21-24 months of research in years 2 and 3 of fellowship training. All
clinical rotations are held in the Emory-affiliated teaching hospitals. The emphasis of
research in this track would be on joint CDC-Emory projects with an overall goal of
linking prevention strategies to active clinical problems. Such studies might include
population based, cohort or case-control studies or might have a molecular epidemiologic
laboratory component. There is also an opportunity to pursue an MPH or MSCR degree
during the third year of training.
The Emory-CDC basic science laboratory research track consists of a three year
fellowship in basic laboratory research and clinical infectious diseases which would
include 12 months of clinical infectious diseases training in year one and 24 months of
basic laboratory research in a CDC laboratory (years 2 and 3). The laboratory research
would be conducted under an established investigator with a joint Emory faculty
appointment. An emphasis would be on laboratory projects of joint CDC/Emory interest.
18
VII.
ACCREDITATION
The Emory Division of Infectious Diseases Fellowship Training Program has full
accreditation by the American Board of Internal Medicine [ABIM] (last review in 2001)
and the Accreditation Council for Graduate Medical Education (ACGME). The most
recent ACGME review took place in September 2003. The Emory Division of Infectious
Diseases received a full 5-year accreditation, effective January 30, 2004. The ACGME
“commended the [Emory ID] program for its demonstrated substantial compliance with
the Essentials of Accredited Residencies in Graduate Medical Education without
citation”.
VIII. APPLICATION PROCEDURE
Applications to the Emory ID Fellowship Training Program should be submitted through
the Electronic Residency Application Service (ERAS). More information about ERAS
and how to apply is available at their web site (www.aamc.org/eras).
Applications for Emory ID fellowship positions beginning July 1, 2010, should be
submitted no later than March 31, 2009; we encourage applicants to submit applications
by January 31, 2009. Selected candidates are interviewed between January and May.
Candidates are invited for full-day visits generally on Wednesdays. The Emory Division
of Infectious Diseases participates in the National Residency Matching Program
(NRMP). More information about the match is available at www.nrmp.org.
Applicants wishing to further explore specific areas of interest are encouraged to contact
the appropriate division members, the Program Director ([email protected]),
Associate Program Director ([email protected]) or the Emory ID Division Education
Office at 404.616.3600.
19
INFECTIOUS DISEASES FACULTY: RESEARCH INTERESTS
Aikens
Anderson
Edward
Albert
HIV
Healthcare Disparities
HIV
Antiretroviral Therapy
NeuroAIDS
Armstrong
Wendy
HIV
Fever of Unknown Origin
Blackwell
Jerry
Vaccine Development
Blumberg
Broyles
Caliendo
Chancey
delRio
Henry
Laura
Angela
Scott
Carlos
Tuberculosis
transplantation
Gene Therapy &
Immunotherapy
Hospital & Molecular
Epidemiology
HIV
Streptococcal Infections
Healthcare Disparities
Clinical Microbiology
Molecular Diagnostics
HIV
Antimicrobial Resistance
Streptococcus pneumoniae
Access to Care
Substance abuse and HIV
International research
DiazGranados
Eaton
Edupuganti
Farley
Franco
Carlos
Molly
Srilatha
Monica
Carlos
Antimicrobial utilization
Antimicrobial resistance
Hospital Epidemiology
HIV
Syphilis
Medical Education
HIV vaccine research
Vaccine clinical studies
H.influenzae Pathogenesis
Emerging Infectious Diseases
International Health
Vaccines
Frew
Galinski
Garber
Paula
Mary
David
Travel Medicine
Infectious Disease
Prevention Research
Malaria Pathogenesis
Clinical Trials
Vaccine Development
HIV
Gaynes
Robert
Gould
Carolyn
Grakoui
Gunthel
Arash
Cliff
Hughes
James
Jacob
Jernigan
Jurado
Jesse
John
Rafael
Klugman
Kozarsky
Keith
Phyllis
HIV
AIDS Vaccine Research
Antibiotic Resistance &
Utilization
Healthcare-associated
infections
Hepatitis C Virus
Pathogenesis
Antibiotic Resistance &
Utilization
HIV
Emerging Infectious
Diseases
Related Oncology
Waterborne Diseases
Healthcare epidemiology
MRSA
Health Care Epidemiology
Bioterrorism
antiretroviral
therapy
Clinical Research Training
International
HIV/AIDS
Formatted: Not Highlight
MVA
poxvirus
C. difficile-associated disease
long-term acute
care hospitals
Viral Immunology
Evaluating Public Health
Policy
Antibiotic Resistance and
utilization
Housestaff Education
vaccines for bacterial
diseases
Streptococcus pneumonia
Travel Medicine
Tropical Medicine
Kuhar
Lennox
Leonard
David
Jeffrey
Michael
HIV drug resistance
Lyon
McGowan
Moanna
Marshall
John
Abeer
Moreno
Alberto
Mulligan
Nguyen
Mark
Minh
HIV Clinical trials
Pneumococcal diseases
Antibiotic
Resistance
outpatient parenteral
antimicrobial administration
outcomes
anti-retroviral therapy
HIV
adherence
resistance
Tuberculosis
HIV
Public Health
Transplant
Infectious Diseases
Fungal Infections
Medical Education
Fungal
Pathogenesis
Antibiotic Resistance
Microbiology & Epidemiology
Public Health Aspects of ID
HIV Pathogenesis
Malaria Vaccine
Development
Malaria Pathogenesis
vaccines
clinical trials
experimental animal models
translational human
immunology
HIV in Minority Women
Elderly with HIV
20
preclinical trials
HIV/AIDS
INFECTIOUS DISEASES FACULTY: RESEARCH INTERESTS
Ofotokun
Osborn
PrattPalmore
Radziewicz
Ray
Rengarajan
Igho
Melissa
HIV
Antiretroviral Pharmacokinetics &
Pharmacogenomics
Hepatitis B
HCV co infection
Melody
Henry
HIV in women
Susan
Jyothi
Immune Reconstitution
HIV Infection
Stem Cell Transplantation
Tuberculosis
Pneumococcal Vaccine
Interventions
HCV Coinfection
Emerging
Infectious
Diseases
Tuberculosis
host-pathogen interactions
bacterial pathogenesis
host immunity
Bioterrorism
Antibiotic Resistance and
Utilization
HIV
MRSA infections
nosocomial infections
hepatitis
Vaccines
Clinical trials
Molecular Pathogenesis
Healthcare Assoc
Infections
Gene Regulation
Antibiotic Resistance & Utilization
Bacterial Pathogenesis
Bacterial Meningitis Pathogens
Bacterial Vaccines
Innate Immunity
Infections in the Elderly
MRSA
Healthcare Epidemiology
Ribner
Rimland
Rouphael
Satola
Bruce
David
Nadine
Sarah
Srinivasan
Steinberg
Stephens
Stone
Arjun
James (Jay)
David
Nimalie
Talati
Naasha
Tuberculosis
TB/HIV Coinfection
Tzeng
Yih-Ling
Bacterial Pathogenesis
Meningococcal Signal
Transduction
Infectious Diseases
Bacterial Gene
Regulation
Workowski
Zughaier
Kimberly
Susu
Sexually transmitted
diseases
Hepatitis C
HIV/AIDS
Vaginal
microbicides
Innate immunity
TLR4
capsular polysaccharide
endotoxin
Antimicrobial Resistance
21
A.
FULL-TIME FACULTY:
David S. Stephens, MD
Stephen W. Schwarzmann Distinguished
Professor of Medicine, Professor of Microbiology and Immunology
Professor of Epidemiology
Department of Medicine,
Director, Division of Infectious Diseases
Vice President for Research, WHSC
Emory University
Monica M. Farley, MD
Professor of Medicine
Adjunct, Associate Professor of Microbiology and Immunology
Associate Director, Division of Infectious Diseases
Director, Georgia Emerging Infections Program
Wendy S. Armstrong, MD
Associate Professor of Medicine
Program Director, Division of Infectious Disease
Associate Medical Director, Infectious Disease Program, Ponce de Leon Center
Michael K. Leonard, Jr., MD
Associate Program Director, Division of Infectious Disease
Medical Director, Georgia DHR TB Program
Edward Aikens, MD
Senior Associate of Medicine
Albert L. Anderson, MD,
MHS
Assistant Professor of Medicine
Jerry Blackwell, PhD
Associate Scientist, Center for AIDS Research
Henry M. Blumberg, MD
Professor of Epidemiology, Rollins School of Public Health
Program Director, ACTSI Research Education and Clinical Research
Programs
Hospital Epidemiologist, Grady Memorial Hospital
Laura Broyles, MD
Angela Caliendo, MD, PhD
Professor of Pathology and Laboratory Medicine
Vice Chair, Clinical Pathology
Director, Emory Medical Laboratories
Medical Director, Microbiology Laboratory
Medical Director, Molecular Diagnostics Laboratory
Director, Medical Microbiology Fellowship
Scott Chancey, PhD
Senior Research Associate
22
Training
Carlos del Rio, MD
Vice-Chair for Grady Affairs and Chief of the Emory Medical Service, Grady
Memorial Hospital
Program Director of the Internal Medicine Residency Program
Director for Clinical Sciences and International Research, Emory Center for
AIDS Research (CFAR)
Director of Emory AIDS International Training & Research Program
Carlos DiazGranados, MD
Assistant Hospital Epidemiologist, Grady Memorial Hospital
Molly E. Eaton, MD
Clinic Director, Emory Crawford Long Infectious Disease Clinic
Srilatha Edupuganti, MD,
MPH
Medical Director, The Hope Clinic
Carlos Franco, MD, MPH
Co-Director, Travel Well, International Travelers Medical Clinic
Paula Frew, PhD, MPH
Assistant Professor of Medicine, Division of Infectious Diseases
Assistant Professor of Behavioral Sciences and Health Education, Rollins School
of Public Health
Director of Health Communications and Applied Community Research - The
Hope Clinic of the Emory Vaccine Research Center
Mary Galinski, PhD
Affiliate Scientist, Emory Vaccine Center
Yerkes National Primate Research Center
David Garber, PhD
Robert Gaynes, MD
Adjunct Professor of Epidemiology, Rollins School of Public Health
Hospital Epidemiologist VAMC
Assistant to Director, Division of Healthcare Quality Promotion, CDC
Carolyn V. Gould, MD, MS
Medical Epidemiologist, Response Team., Division of Healthcare Quality
Promotion Centers for Disease Control and Prevention
Arash Grakoui, PhD
Clifford J. Gunthel, MD
James Hughes, MD
Professor of Medicine and Public Health
Senior Scientific Advisor for Infectious Diseases, International Association of
National Public Health Institutes (IANPHI)
Senior Advisor, Center for Global Safe Water, School of Public Health
Director, Program in Global Infectious Diseases
Director, Southeastern Center for Emerging Biological Threats
Jesse Jacob, MD
Associate Hospital Epidemiologist, Crawford-Long Hospital
John A. Jernigan, MD, MS
23
Deputy Chief, Prevention and Response Branch
Division of Healthcare Quality Promotion, CDC
Rafael L. Jurado, MD
Assistant Chief of Medicine, VAMC
Keith P. Klugman, MD
William H Foege Chair of Global Health, Rollins School of Public Health.
Director of Respiratory and Meningeal Pathogens Research Unit of
MRC/NICD/Wits, Johannesburg, South Africa
Phyllis E. Kozarsky, MD
Adjunct Assistant Professor of International Health
Director of Travel Well, International Travelers Medical Clinic at Crawford Long
Hospital
Expert Consultant, Division of Global Migration and Quarantine, Centers for
Disease Control and Prevention
David Kuhar, MD
Instructor of Medicine
Jeffrey L. Lennox, MD
Medical Director, HIV/AIDS Programs, Ponce de Leon Center
Emory Chief of Service, Grady Health Systems
G. Marshall Lyon, III, MD
Director, Transplant Infectious Disease Program
John E. McGowan Jr., MD
Director, MD/MPH Programs, Emory University School of Medicine
and Rollins School of Public Health
Abeer A. Moanna, MD
Alberto Moreno, MD
Assistant Research Professor of Medicine
Assistant Research Professor, Emory Vaccine Center
Mark Mulligan, MD
Executive Director, The Hope Clinic of the Emory Vaccine Center
Co-Director, Clinical and Translational Research Core, CFAR
Assoc Director for Clinical Trials, The Emory Vaccine Center
Minh Ly Thi Nguyen, MD
Ighovwerha Ofotokun, MD
Melissa K. Osborn, MD
Melody Pratt Palmore, MD
Director, Women’s Clinic, Ponce de Leon Center
Henry T. Radziewicz, MD
Susan M. Ray, MD
24
Associate Hospital Epidemiologist, Grady Memorial Hospital
Jyothi Rengarajan, PhD
Bruce S. Ribner, MD, MPH
Hospital Epidemiologist, Emory University Hospital
David Rimland, MD
Chief, Infectious Diseases, VA Medical Center
Director, HIV/AIDS Program VA Medical Center
Nadine G. Rouphael, MD
Instructor in Medicine, Division of Infectious Disease
Co-PI, Vaccine Treatment Evaluation Unit (VTEU)
Sarah Satola, PhD
Jonas A. Shulman, MD
Senior Advisor to the Dean for Curriculum Development
Arjun Srinivasan, MD
Team Leader, Response Team, Division of Healthcare Quality Promotion CDC
James P. Steinberg, MD
Chief Medical Officer, Emory Crawford Long Hospital
Hospital Epidemiologist, Emory Crawford Long Hospital
Nimalie Stone, MD
Director of Antimicrobial Infections and Wesley Woods Center Epidemiologist
Naasha Talati, MD
Instructor, Division of Infectious Disease
Yih-Ling Tzeng, PhD
David Weiss, PhD
Kimberly A. Workowski,
MD
Susu Zughaier, PhD
Chief Guidelines Unit, Epidemiology and Surveillance Branch,
Division of STD Prevention, CDC
25
Formatted: English (U.S.)
B.
FACULTY RESEARCH AND PUBLICATIONS
David S. Stephens, MD
Education:
Medical School:
Internal Medicine Residency:
Fellowship:
Current Appointment:
Bowman Gray School of Medicine, Wake Forest
University
Vanderbilt University Hospitals
Vanderbilt University Hospitals
Stephen W. Schwarzmann Distinguished
Professor of Medicine,
Professor of Microbiology and Immunology
Professor of Epidemiology
Director, Division of Infectious Diseases
Vice President for Research
Woodruff Health Sciences Center
Emory University
Research and other Academic Interests:
Genetic determinants of bacterial pathogenesis
Pathogenesis and epidemiology of Neisseria meningitidis, Haemophilus influenzae and other
agents of bacterial meningitis
• Molecular mechanisms of attachment, colonization and invasion of human mucosal surfaces
by pathogenic bacteria
• Conjugative transposons and role of transposons in bacterial virulence
• Bacterial vaccines
• Innate Immunity
•
•
Selected Recent Publications:
1.
Kahler CM, Lyons-Schindler S, Choudhury B, Glushka J, Carlson RW, Stephens DS. Oacetylation of the terminal N-acetylglucosamine of the lipooligosaccharide inner core in Neisseria
meningitidis: influence of inner core structure and assembly. J Biol Chem 2006; 281:19939-48.
2.
Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Stephens DS.
Neisseria meningitidis group B correlates of protection and assay standardization – International
Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine
2006; 24:5093-107.
3.
Zimmer SM, Stephens DS. Serogroup B meningococcal vaccines. Curr Opin Invest Drugs 2006;
7:733-9.
4.
Gazmararian JA, Orenstein W, Wortley P, Buehler J, Elon L, Koplan J, Schild L, Dixon T,
Stephens DS. Preventing influenza: vaccine system and practices in the Southeast. Pub Health
Rep 2006; 121:684-94.
5.
Dunning Hotopp JC, Grifantini R, Kumar N, Tzeng Y-L, Fouts D, Frigimelica E, Draghi M,
Guiliani MM, Rappuoli R, Stephens DS, Grandi G, Tettelin H. Comparative genomics of
Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen specific genes.
Microbiology 2006; 152:3733-49.
26
6.
Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31:3-14.
7.
Tzeng Y-L, Zhou X, Bao S, Zhao S, Noble C, Stephens DS. Autoregulation of the MisR/MisS
two-component signal transduction system in Neisseria meningitidis. J Bacteriol 2006; 188:505565.
8.
Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P,
Norville KJ, Barr JR, Zaki SR, Patel JB, Reagan SP, Pirkle JL, Treadwell TA, Messonnier NR,
Rotz LD, Meyer RF, Stephens DS. A case of naturally acquired inhalation anthrax: clinical care
and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007;
44:968-71.
9.
Zughaier S, Steeghs L, van der Ley P, Stephens DS. TLR4-dependent adjuvant activity of
Neisseria meningitidis lipid A. Vaccine 2007; 25:4401-9.
10.
Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcemia and
Neisseria meningitidis. Lancet 2007; 369:2196-210.
11.
Zimmer SM, Zughaier SM, Tzeng Y-L, Wang G, Stephens DS. Human MD-2 discriminates
between lipid A structures. Glycobiology 2007; 17:847-56.
12.
Alonso JM, Gilmet G, Nassif X, Plotkin SA, Ramsay M, Siegrist C-A, Stephens DS, Teyssou R,
Vogel U. Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March
2005. Vaccine 2007 25:4125-9.
13.
Haber M, Barkley A, Baughman W, Orenstein W, Stephens DS. Herd immunity and
pneumococcal conjugate vaccines: a predictive impact model. Vaccine 2007; 5390-8.
14.
Kessler AT, Stephens DS, Somani J. Laboratory–acquired serogroup A meningococcal
meningitis. J Occup Health 2007; 49:399-401.
15.
Zughaier SM, Lindner B, Howe J, Garidel P, Koch MHJ, Brandenburg K, Stephens DS.
Physiochemical characterization and biological activity of lipooligosaccharides and lipid A from
Neisseria meningitidis. J Endotox Res 2007; 13:343-57.
16.
Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier M, Bilukha O, Zhang X,
Stephens DS, Rosenstein N, and the Active Bacterial Core Surveillance (ABCs) Team.
Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the
United States. Clin Infect Dis 2008; 46:1-13.
17.
Stephens DS. Vaccines for the unvaccinated: protecting the herd (Invited Commentary). J Infect
Dis 2008; 197:643-5.
18.
Tzeng Y-L, Kahler CM, Zhang X, Stephens DS. The MisRS two-component regulon in Neisseria
meningitidis. Infect Immun 2008; 76:704-16.
19.
Choudhury B, Kahler CM, Datta A, Stephens DS, Carlson RW. The structure of the L9
immunotype lipooligosaccharide from Neisseria meningitidis NMB Z2491. Carbohydr Res (In
Press).
20.
Zimmer SM, Liu J, Clayton JL, Stephens DS, Snyder JP. Paclitaxel binding to human and murine
MD-2. J Biol Chem 2008 (In Press).
27
Monica M. Farley, MD
Education:
Medical School:
Fellowship:
University of Missouri
Emory University School of Medicine
Adjunct, Associate Professor of Microbiology and
Immunology
Staff Physician, VA Medical Center, Atlanta
Director, Georgia Emerging Infections Program
Associate Director, Division of Infectious
Diseases
My major laboratory research interests concern mucosal pathogenesis of Haemophilus influenzae.
Experiments have focused on the mechanisms of attachment, colonization and invasion of human
nasopharyngeal mucosa by H. influenzae. Current research involves a examination of the role of
pili (a specific bacterial surface component) in mucosal attachment and pathogenesis and the
characterization of capsule-specific genes.
My clinical research interest is in population-based surveillance and epidemiology of invasive
bacterial pathogens including (H. influenzae, N. meningitidis, groups A and B Streptococcus and
S. pneumoniae), and related vaccine effectiveness studies. I am the Principal Investigator for the
CDC-funded Georgia Emerging Infections Program.
1.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak
PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline in invasive
pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl
J Med 2003; 348:1737-46.
2.
Satola SW, Schirmer PL, Farley MM. Complete sequence of the cap locus of Haemophilus
influenzae serotype b and nonencapsulated b capsule-negative variants. Infect Immun 2003;
71:3639-44.
3.
Satola SW, Schirmer PL, Farley MM. Genetic analysis of the capsule locus of Haemophilus
influenzae serotype f. Infect Immun 2003; 71:7202-7.
4.
Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J,
Farley MM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus
pneumoniae infections. JAMA 2004; 29:2197-203.
5.
Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Gay K, Jackson D, Orenstein WA,
Arnold K, Schuchat A, Farley MM. Incidence of macrolide resistance in Streptococcus
pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based
assessment. Lancet 2005; 365:855-63.
6.
Fridkin SK, Hageman J, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K,
Harrison LH, Lynfield R, Farley MM, for the Active Bacterial Core Surveillance Program of the
Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in
three communities. N Engl J Med 2005; 352:1436-44
28
7.
Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner
W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG. Changing epidemiology of
invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate
vaccine. JAMA 2005; 294:2043-51.
8.
Kapogiannis BG, Satola S, Keyserling HL, Farley MM. Invasive infections with Haemophilus
influenzae type a containing an IS1016-bexA deletion: possible association with virulence. Clin
Infect Dis 2005; 41:e 97-103.
9.
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Cieslak PR, Harrison LH,
Bennett NM, Farley MM, Facklam RR, Jorgensen J, Besser J, Zell ER, Schuchat A, Whitney CG.
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus
pneumoniae. N Engl J Med 2006; 354(14):1522-4.
10.
Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR,
Harrison LH, Reingold AL, Hadler JL, Farley MM, Anderson BJ, Schaffner W. Invasive
pneumococcal disease among infants before and after introduction of pneumococcal conjugate
vaccine. JAMA 2006; 295(14):1668-74.
11.
Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A, Gershman
KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Zell ER, Jorgensen JH, Beall B, Schuchat
A. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal
disease. Lancet 2006; 368:1495-1502.
12.
Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive
pneumococcal disease in metropolitan Atlanta after introduction of a 7-valent pneumococcal
conjugate vaccine. Clin Infect Dis 2007; 44: 1569-76.
13.
Satola SW, Collins JT, Napier R, Farley MM. Capsule gene analysis of invasive Haemophilus
influenzae: accuracy of serotyping and prevalence of IS1016 among nontypeable isolates. J Clin
Microbiol 2007; 45:3230-3238.
14.
O’Loughlin RE, Roberson A, Barrett NL, Craig A, Cieslak PR, Farley MM, Gershman K,
Harrison L, Lynfield R, Reingold A, Spina N, Albanese B, Beall B, Van Beneden C for the ABCs
team. The epidemiology of invasive group A streptococcus in the United States, 2000-2004 and
the potential impact of a vaccine. Clin Infect Dis 2007; 45(7): 853-62.
15.
Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A,
Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. Incidence of pneumococcal disease
due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era
of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54.
16.
Adamkiewicz TV, Silk B, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM.
Effectiveness of the seven-valent pneumococcal conjugate vaccine in children with sickle cell
disease in the first decade of life. Pediatrics 2008; 121(3):562-9.
17.
Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman
K, Reingold A, Farley MM, et al. Population snapshot of emergent Streptococcus pneumoniae
serotype 19A in the United States, 2005. J Infect Dis 2008; 197:1016-27.
18.
Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner
W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell, ER, Schuchat A, Schrag SJ.
Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA,
2008;299:2056-65.
29
19.
Hsu HE, Shutt KA, Moore MR, Beall B, Bennett NM, Craig AS, Farley MM, Jorgensen JH,
Lexau CA, Petit S, Reingold A, Thomas A, Whitney CG, Harrison LH. Impact of pneumococcal
conjugate vaccine on pneumococcal meningitis in the United States, 1998-2005. (in press, NEJM).
20.
Satola SW, Napier B, Farley MM. Association of IS1016 with the hia adhesion gene and biotype
V and I in invasive nontypeable Haemophilus influenzae. (in press, Infect Immun).
Wendy S. Armstrong, MD
Education:
Medical School:
Chief Residency:
Fellowship:
Harvard Medical School
University of Michigan Medical Center
Program Director, Division of Infectious Disease
Associate Medical Director, Infectious Disease
Program, Grady Health Systems
My research interests are clinical and translational in HIV-infected patients and include 1)
opportunistic infections in HIV-infected patients, primarily sulfa resistance in Pneumocystis
jirovecii 2) HIV-associated fever of unknown origin, 3) solid organ and bone marrow
transplantation in HIV-infected patients and 4) clinical trials pursuing treatment strategies in HIV
with emphasis on salvage therapies and drug resistance.
Selected Publications:
1.
Boulis NM, Armstrong WS, Chandler WF and Orringer MB. Epidural abscess: a delayed
complication of esophageal stenting for benign stricture. Ann Thor Surg 1999;68(2): 568-70.
2.
Armstrong WS, Meshnick S and Kazanjian P. Pneumocystis carinii mutations associated with
sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes and Infection
2000;2:61-67.
3.
Kazanjian P, Armstrong WS, Hossler PA, Burman W, Richardson J, Lee C-H, Crane L, Katz J
and Meshnick SR. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone
prophylaxis exposure in AIDS patients. J Infect Dis 2000;182:551-7. (co-first author)
4.
Armstrong WS and Kazanjian P. Use of cytokines in HIV-infected patients: colony-stimulating
factors, erythropoietin and interleukin-2. Clin Infect Dis 2001; 32:766-73.
5.
Kazanjian P, Armstrong WS, Hossler PA, Huang L, Beard CB, Crane L, Duchin J, Burman W,
Richardson J, Navin TR, and Meshnick SR. Pneumocystis carinii cytochrome b mutations are
associated with atovoquone exposure in AIDS patients. J Infect Dis 2001; 183:819-22.
6.
Cinti SK, Armstrong WS, and Kauffman CA. Recurrence of increased intracranial pressure with
antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses 2001;44:497-501.
30
7.
Armstrong WS, Calabrese L and Taege A. HIV update 2002: Delaying treatment to curb rising
resistance. Cleve Clin J Med 2002;69:995-9.
8.
Armstrong WS, Bashour CA, Smedira N, Heupler F, Hoeltge G, Mawhorter SD, Sudheendra V
and Gordon SM. A case of fatal West Nile virus meningoencephalitis associated with receipt of
blood transfusions following open heart surgery. Ann Thor Surg 2003;76:605-7.
9.
Malani, PN, Dyke DBS, Pagani FD, Armstrong WS and Chenoweth CE. Successful treatment of
vancomycin-resistant Enterococcus faecium mediastinitis associated with left ventricular assist
devices. Ann Thor Surg 2003;76:1719.
10.
Kazanjian P, Fisk D, Armstrong WS, Shulin Q, Liwei H, Ke Z, and Meshnick S. Increase in
prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia in
the US and China. J Infect Dis 2004; 189:1684.
11.
Armstrong WS, Calabrese L, and Taege AJ. HIV Update 2005: Origins, issues, prospects and
complications. Cleve Clin J Med 2005;72:73-78.
12.
Taege AJ and Armstrong WS. Highly resistant HIV: At least a wake-up call. Cleve Clin J Med
2005;72:285-286.
13.
Castillo JR and Armstrong WS. Fever of unknown origin in adults. Infect Med 2006;23:6-15.
14.
Armstrong WS, Taege AJ. HIV testing for all: the new standard of care. Cleve Clin J Med
2007;74:297-301.
Selected Book Chapters:
1.
Armstrong W and Kazanjian P. Fever of unknown origin in the general population and in HIVinfected persons. In: Cohen J, Powderly WG eds. Infectious Diseases, 2e. London: Mosby, 2004,
pp.871-880.
2.
Section editor (Part 6, Infectious Diseases) and author, Chapters 48-58; “Approach to Fever,”
“Approach to Microbiology,” “Fever and Rash,” “Fever of Unknown Origin,” “Skin and Soft
Tissue Infections,” “Acute Rheumatic Fever,” “Infective Endocarditis,” “CD4 Counts and
Complications of HIV Infection,” “Pulmonary Disease in HIV-Infected Patients,”
“Gastrointestinal manifestations of HIV disease,” “Neurologic Manifestations of HIV disease.” In:
Saint S, Frances C eds. Saint-Frances Guide to Inpatient Medicine, 2nd ed. Philadelphia:
Lippincott, Williams and Wilkins, 2004, pp263-315.
3.
Armstrong WS, Tungsiripat M. HIV for the Primary Care Physician. In: Carey WD ed. Current
Clinical Medicine, Elsevier, in press.
Michael K. Leonard, Jr., MD
Education:
Medical School:
Internship:
Residency:
Fellowship:
East Carolina University School of Medicine
University of Tennessee Hospitals
Vanderbilt University School of Medicine
Associate Program Director, Division of Infectious Disease
31
Staff Physician, Grady Memorial Hospital
Medical Director, GA DHR TB Program
Research and Other Academic Interests:
My research is focused on the epidemiology of tuberculosis in HIV-infected patients; mortality
associated with tuberculosis; hepatotoxicity related to co-infection of tuberculosis and hepatitis C;
access to care for inner-city patients with HIV. I am also an investigator with the CDC TB
Epidemiologic Studies Consortium (TBESC). In Tbilisi, Republic of Georgia, I work with the
National TB Program and National Centers for Disease Control on drug resistant TB surveillance.
Also in Tbilisi I serve as an infection control consultant at the Central Republican Hospital and
am working on developing a hospital acquired infection surveillance program there. Other
interests include medical education and history of medicine.
1.
Petrillo T, Fortenberry J, Stockwell J, Leonard MK. Respiratory failure caused by tuberculous
pneumonia requiring extracorporeal membrane oxygenation. Journal of Perfusion 2001; 16: 525529.
2.
Franco-Paredes C, Leonard MK, Jurado R, Blumberg HM, Smith R. Tuberculosis of the
pancreas: report of two cases and review of the literature. American Journal of the Medical
Sciences 2002; 323 (1): 54-58.
3.
Leonard MK, Larsen N, Dreschler H, et al. Increased survival of persons with tuberculosis and
HIV 1991-2000. Clinical Infectious Diseases 2002; 34:1002-7.
4.
Leonard MK, Murrow J, Jurado R, and Gaynes R. Salmonella Meningitis in Adults infected with
HIV: Case Report and review of the literature. Am J Med Sci 2002; 323 (5): 266-268.
5.
Marshall GS, Jacobs RF, Schutze GE, Paxton H, Buckingham SC, DeVincenzo, JP, Jackson MA,
San Joaquin VH, Standaert SM, Woods CR, Tick-Borne Infections in Children Study (TICS)
Group (M Leonard). Ehrlichia chaffeensis seroprevalence among children in the Southeast and
Southcentral regions of the United States. Arch Pediatr Adolesc Med 2002; 156:166-170.
6.
Wolf J, Blumberg HM, Leonard MK*. Laryngeal Histoplasmosis: case report and review of the
literature. American Journal of the Medical Sciences 2004; 327 (3):160-162.
7.
Leonard MK, Wang YW, Del Rio C, Blumberg HM. How many sputums are necessary to
diagnose pulmonary tuberculosis? Am J Infect Control 2005; 33:58-61.
8.
Leonard MK, Egan K, Parrott P, White N, Del Rio C, Blumberg HM. Increased efficiency in
evaluating patients with suspected tuberculosis by use of a dedicated airborne infection isolation
unit. Am J Infect Control 2006; 34:69-72.
9.
Leonard MK, Kraft CK, Corpe RL. A man with syncopal episodes and abnormal chest
radiograph findings. Clin Iinf Dis 2006; 42 1755, 1800-02.
10.
Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis disease and
latent tuberculosis infection. JAMA 2005; 293:2776-2784.
11.
Mehrabi M, Leonard MK. Mucocutaneous cryptococcus. Journal of Oral and Maxillofacial
Surgery 2005; 63:1543-1549.
12.
Franco Paredes C, Diaz Borjon A, Barragan M, Leonard MK. The Ever Expanding Association
32
between Tuberculosis and Rheumatologic diseases. Am J Med 2006; 119:470-477.
13.
Rubin ZA, Leonard MK*, Martin GS. Brief report: TB Sepsis and Activated Protein C. Am J
Medical Sciences 2006; 332: 48-50.
14.
Kourbatova EV, Leonard MK*, Del Rio C, Blumberg HM. Letter to the ed. How many sputums
are necessary to diagnose pulmonary tuberculosis? Am J Infect Control 2006; 34: 328-329.
15.
Kourbatova EV, BE.Borodulin, EA Borodulina, MK Leonard*, C del Rio, and HM Blumberg.
Risk factors for mortality among patients with newly diagnosed tuberculosis in a large industrial
Russian Center. International J Tuberc Lung Dis 2006; 10: 1-7.
16.
Kourbatova EV, Leonard MK*, Kraft CK, Romo J, Del Rio C, Blumberg HM Risk Factors for
Extrapulmonary Tuberculosis mortality at an academic inner city hospital. European Journal of
Epidemiology 2006; 21: 715-721.
17.
C Hamilton, T Sterling, H Blumberg, MK Leonard, J McAuley, D Schlossberg, G Huitt
Extensively Drug-resistant Tuberculosis: Are We Learning from History or Repeating It? Clin
Infect Dis 2007; 45:338-42.
18.
Mirtskhulava V, Kempker R, Shields KL, Leonard MK, Tsertsvadze T, del Rio C, Salakaia A,
Blumberg HM. Prevalence and risk factors for latent tuberculosis infection among health care
workers in Georgia. Int J Tuberc Lung Dis 2008; 12:513–519
19.
Low C, Macharashvili N, Kourbatova E, Walker K, Leonard M. Hospital Acquired Blood-Stream
Infections among Intensive Care Unit (ICU) Patients in Tbilisi, Georgia. Eur J Epidemiol. 2008;23
(6):441-2.
20.
Jacob J, Kozarsky P, Dismukes R, Leonard M, Franco-Paredes C, Tellez I.
Five year experience with Type 1 and Type 2 reactions in Hansens disease at a US travel clinic.
Am J Trop Med and Hygeine 2008; 79(3): 452-454.
Edward L. Aikens, MD
Education:
Medical School:
Residency:
Temple University School of Medicine
General Internal/HIV medicine. Benign/malignant Hematologic Disorders in the HIV infected
individuals. Health care disparities in the African American community.
Albert M.L. Anderson, MD, MHS
Education:
Medical School:
Graduate School:
Residency:
Fellowship:
University of North Carolina at Chapel Hill
Duke University
Duke University
Duke University
33
Assistant Professor in Medicine
I am interested in HIV clinical research, specifically immunologic outcomes in patients on
antiretroviral therapy as well as central nervous system involvement of HIV and other infectious
diseases.
1.
Anderson AM, Varkey JB, Petti CA, Liddle RA, Frothingham R, Woods CW. Non-O1 Vibrio
cholerae septicemia: case report, discussion of literature, and relevance to bioterrorism. Diagn
Microbiol Infect Dis 2004 August;49(4):295-7.
2.
Anderson AM, Cabell CH, Sexton DJ. Aortic coarctation endarteritis in an adult: case report with
cardiovascular magnetic resonance imaging findings and review of the literature. Clin Infect Dis
2005 February 15;40(4):e28-e31.
3.
Turner JW, Pien BC, Ardoin SA, Anderson AM, Shieh WJ, Zaki SR, Bhatnagar J, Guarner J,
Howell DN, Woods CW. A man with chest pain and glomerulonephritis. Lancet 2005 June
11;365(9476):2062.
4.
Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV1 infection. Expert Rev Anti Infect Ther 2005 December;3(6):871-83.
5.
Anderson AM, Bartlett JA. Changing antiretroviral therapy in the setting of virologic relapse:
review of the current literature. Curr HIV/AIDS Rep 2006 May;3(2):79-85.
6.
Szczech LA, Anderson AM, Ramers C, Engeman J, Ellis M, Butterly D, Howell DN. The
uncertain significance of anti-glomerular basement membrane antibody among HIV-infected
persons with kidney disease. Am J Kidney Dis. 2006 Oct; 48(4):e55-9.
7.
Anderson AM, Kosinski AS, Bartlett JA. Decreasing CD4+ T-cell count during suppressed or
low-level viraemia in patients with HIV infection. Antiviral Therapy. 2007; 12(7):1041-8.
8.
Anderson AM, Lennox JL. Antiretroviral therapy: When to start and which drugs to use. Current
Infectious Disease Reports. 2008 July; 10(4): 332-339.
9.
Anderson AM, Lennox JL. Abacavir/lamivudine fixed dose combination in the treatment of HIV
infection. Future HIV therapy 2009 (in press).
Jerry L. Blackwell, PhD
Education:
Undergraduate:
PhD:
Postdoctoral Training:
University of Geogia
Georgia State University
University of Alabama
Associate Scientist, Center for AIDS Research
Research Interests:
34
My research interests are in the areas of vaccine development, gene therapy and immune
modulation. My lab's HIV vaccine efforts are focused towards developing better vaccine vectors
for delivering novel antigens with the rationale that this combination may effectively protect from
an HIV-1 infection. In addition, many of the adenovirus-vectored vaccines that we use for
infectious diseases can be modified for use in gene therapy applications for malignancies, which
is another area of investigation in my lab. Finally, I am interested in understanding ways to
modulate and improve cellular and humoral vaccine-induced immune responses.
1.
Blackwell, J.L. and M.A. Brinton, Translation elongation factor-1 alpha interacts with the 3' stemloop region of West Nile virus genomic RNA. J Virol, 1997. 71(9): p. 6433-44.
2.
Blackwell, J.L., C.R. Miller, J.T. Douglas, H. Li, P.N. Reynolds, W.R. Carroll, G.E. Peters, T.V.
Strong, and D.T. Curiel, Retargeting to EGFR enhances adenovirus infection efficiency of
squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, 1999. 125(8): p. 856-63.
3.
Kasono, K., J.L. Blackwell, J.T. Douglas, I. Dmitriev, T.V. Strong, P. Reynolds, D.A. Kropf,
W.R. Carroll, G.E. Peters, R.P. Bucy, D.T. Curiel, and V. Krasnykh, Selective gene delivery to
head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res, 1999. 5(9):
p. 2571-9.
4.
Blackwell, J.L., H. Li, J. Gomez-Navarro, I. Dmitriev, V. Krasnykh, C.A. Richter, D.R. Shaw,
R.D. Alvarez, D.T. Curiel, and T.V. Strong, Using a tropism-modified adenoviral vector to
circumvent inhibitory factors in ascites fluid. Hum Gene Ther, 2000. 11(12): p. 1657-69.
5.
Haviv, Y.S., J.L. Blackwell, H. Li, M. Wang, X. Lei, and D.T. Curiel, Heat shock and heat shock
protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res, 2001. 61(23): p.
8361-5.
6.
Haviv, Y.S. and J. Blackwell, Transcriptional regulation in cancer gene therapy. Isr Med Assoc J,
2001. 3(7): p. 517-22.
7.
Li, H., Y.S. Haviv, C.A. Derdeyn, J. Lam, C. Coolidge, E. Hunter, D.T. Curiel, and J.L.
Blackwell, Human immunodeficiency virus type 1-mediated syncytium formation is compatible
with adenovirus replication and facilitates efficient dispersion of viral gene products and de novosynthesized virus particles. Hum Gene Ther, 2001. 12(18): p. 2159-2169.
8.
Wesseling, J.G., M. Yamamoto, Y. Adachi, P.J. Bosma, M. van Wijland, J.L. Blackwell, H. Li,
P.N. Reynolds, I. Dmitriev, S.M. Vickers, K. Huibregtse, and D.T. Curiel, Midkine and
cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic
carcinoma. Cancer Gene Ther, 2001. 8(12): p. 990-6.
9.
Wesseling, J.G., P.J. Bosma, V. Krasnykh, E.A. Kashentseva, J.L. Blackwell, P.N. Reynolds, H.
Li, M. Parameshwar, S.M. Vickers, E.M. Jaffee, K. Huibregtse, D.T. Curiel, and I. Dmitriev,
Improved gene transfer efficiency to primary and established human pancreatic carcinoma target
cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther,
2001. 8(13): p. 969-76.
10.
Haviv, Y.S., J.L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito,
X. Lei, A. Hemminki, D. Carey, and D.T. Curiel, Adenoviral gene therapy for renal cancer
requires retargeting to alternative cellular receptors. Cancer Res, 2002. 62(15).
11.
Pereboev, A.V., C.K. Asiedu, Y. Kawakami, S.S. Dong, J.L. Blackwell, E.A. Kashentseva, P.L.
Triozzi, W.A. Aldrich, D.T. Curiel, J.M. Thomas, and I.P. Dmitriev, Coxsackievirus-adenovirus
receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic
35
cells. Gene Ther, 2002. 9(17): p. 1189-93.
12.
Kawakami, Y., H. Li, J. Lam, V. Krasnykh, D.T. Curiel, and J.L. Blackwell, Substitution of the
Adenovirus Serotype 5 Knob with a Serotype 3 Knob Enhances Multiple Steps in Virus
Replication. Cancer Res, 2003. 63(6): p. 1262-9.
13.
Lam, J.T., G.J. Bauerschmitz, A. Kanerva, S.D. Barker, J.M. Straughn, M. Wang, M.N. Barnes,
J.L. Blackwell, G.P. Siegal, R.D. Alvarez, D.T. Curiel, and A. Hemminki, Replication of an
integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer
Gene Ther, 2003. 10(5): p. 377-87.
14.
Pereboev, A.V., J.M. Nagle, M.A. Shakhmatov, Q.L. Matthews, Y. Kawakami, D.T. Curiel, and
J.L. Blackwell, Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated
with a novel adapter molecule. Mol Ther, 2004. 9(5): p. 712-20.
15.
Johnson, R.W., B. Li, S. Sunay, R.H. Moore, J. Mulenga, E. Hunter, S. Allen, J.L. Blackwell, and
C.A. Derdeyn, Real-time PCR quantitation of subtype C HIV DNA in a Zambian discordant
couple cohort. AIDS Res Hum Retroviruses, 2006. 22(5): p. 438-44.
16.
Li, B., J.M. Decker, R.W. Johnson, F. Bibollet-Ruche, X. Wei, J. Mulenga, S. Allen, E. Hunter,
B.H. Hahn, G.M. Shaw, J.L. Blackwell, and C.A. Derdeyn, Evidence for potent autologous
neutralizing antibody titers and compact envelopes in early infection with subtype C human
immunodeficiency virus type 1. J Virol, 2006. 80(11): p. 5211-8.
17.
Davis, W.G., J.L. Blackwell, P.Y. Shi, and M.A. Brinton, Interaction between the Cellular Protein
eEF1A and the 3'-Terminal Stem-Loop of West Nile Virus Genomic RNA Facilitates Viral MinusStrand RNA Synthesis. J Virol, 2007. 81(18): p. 10172-87.
18.
Lam, J.T., A. Hemminki, A. Kanerva, K.B. Lee, J.L. Blackwell, R. Desmond, G.P. Siegal, and
D.T. Curiel, A three-dimensional assay for measurement of viral-induced oncolysis. Cancer Gene
Ther, 2007.
19.
Rong, R., F. Bibollet-Ruche, J. Mulenga, S. Allen, J.L. Blackwell, and C.A. Derdeyn, Role of
V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to
autologous neutralization during clade C infection. J Virol, 2007. 81(3): p. 1350-9.
20.
Rong, R., S. Gnanakaran, J.M. Decker, F. Bibollet-Ruche, J. Taylor, J.N. Sfakianos, J.L. Mokili,
M. Muldoon, J. Mulenga, S. Allen, B.H. Hahn, G.M. Shaw, J.L. Blackwell, B.T. Korber, E.
Hunter, and C.A. Derdeyn, Unique mutational patterns in the envelope alpha 2 amphipathic helix
and acquisition of length in gp120 hypervariable domains are associated with resistance to
autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol, 2007.
81(11): p. 5658-68.
Henry M. Blumberg, MD
Education:
Medical School:
Chief Resident:
ID Fellowship:
Current Appointments:
Emory Crawford Long Hospital
Professor of Medicine, Emory University School of
Medicine
36
Professor of Epidemiology, Rollins School of Public
Health
Director, Clinical and Translational Research Training
Programs, Atlanta Clinical and Translational Science
Institute, Woodruff Health Sciences Center, Emory
University
Hospital Epidemiologist, Grady Memorial Hospital
Research interests include healthcare and molecular epidemiology (especially investigations
focused on nosocomial and community acquired methicillin-resistant Staphylococcus aureus
[MRSA] and emerging multidrug resistant organisms); tuberculosis (nosocomial and community
control, molecular and clinical epidemiology, new diagnostics, tuberculosis-nutrition related
interactions, international research including that in the former Soviet Republic of Georgia); and
clinical and translational research training.
Blumberg HM, Watkins DL, Berschling JD, Antle A, Moore PP, White N, Hunter M, Green B,
1.
Ray SM, McGowan JE Jr. Preventing the nosocomial transmission of tuberculosis. Ann Intern
Med 1995; 122: 658-663.
2.
Camins BC, Bock N, Watkins DL, Blumberg HM. Acceptance of isoniazid therapy by health care
workers after tuberculin skin test conversion. JAMA 1996; 275:1013-1015.
3.
Blumberg HM, White N, Parrott P, Gordon W, Hunter M, Ray S. False-positive tuberculin skin
test results among health care workers. JAMA 2000; 283:2793.
4.
Weinstock DM, Hahn O, Wittkamp M, Sepkowitz KA, Khechinashvili G, Blumberg HM. Risk
for tuberculosis infection among internally displaced persons in the Republic of Georgia. Int J
Tuberc Lung Dis 2001; 5:164-169.
5.
Blumberg HM, Jarvis WR, Soucie M, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto
MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP and the NEMIS Study Group. Risk Factors
for Candida Bloodstream Infections in Surgical Intensive Care Units: the NEMIS Prospective
Multicenter Study. Clin Infect Dis 2001; 33:177-186.
6.
Larsen NM, Biddle CL, Sotir MJ, White N, Parrott P, Blumberg HM. Risk of tuberculin skin test
conversion among health care workers: occupational versus community exposure and infection.
Clin Infect Dis 2002; 35:796–801.
7.
Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD,
Kawamura LM, Hopewell PC and the Short-Course Rifampin and Pyrazinamide for Tuberculosis
Infection (SCRIPT) Study Investigators. Short-course rifampin and pyrazinamide compared with
isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med
2002;137:640-7.
8.
Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease
Control and Prevention/Infectious Diseases Society of America. Treatment of Tuberculosis. Am
J Respir Crit Care Med 2003; 167:603-662. [co-Chair of Writing Committee].
9.
Hidron AI, Kourbatova EV, Halvosa JS, Terrell BJ, Blumberg HM, King MD. Risk Factors for
colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an
urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005;
37
41:159-66.
10.
Leonard MK, Osterholt D, Kourbatova EV, del Rio C, Wang W, Blumberg HM. How many
sputum specimens are necessary to diagnose pulmonary tuberculosis? Am J Infect Control 2005;
33:58-61.
11.
Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent
tuberculosis infection. JAMA 2005; 293:2776-2784.
12.
Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, Blumberg HM. Emergence of
community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) USA 300 clone
as a cause of healthcare-associated infections among patients with prosthetic joint infections. Am J
Infect Control 2005;33:385-91.
13.
Leonard MK, Egan KB, Kourbatova E, White N, Parrott P, del Rio C, Blumberg HM. Increased
efficiency in evaluating patients with suspected tuberculosis by the use of a dedicated respiratory
isolation unit. Am J Infect Control 2006; 34:69-72.
14.
Seybold U, Kourbtova EV, Johnson JG, Halvosa S, Wang WF, King MD, Ray SM, Blumberg
HM. Emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA)
USA300 genotype as a major cause of healthcare associated blood stream infections. Clin Infect
Dis 2006; 42:647-56.
15.
King MD, Terrell BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of
community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the
predominant cause of S. aureus skin and soft tissue infections. Ann Intern Med 2006; 144:309-17.
16.
Richards DC, Mikiashvili T, Parris JJ, Kourbatova EV, Wilson JC, Shubladze N, Tsertvadze T,
Khechinashvili G, del Rio C, Blumberg HM. High prevalence of hepatitis C virus but not HIV
co-infection among patients with tuberculosis in Georgia. Int J Tuberc Lung Dis 2006 ; 10:396401.
17.
Camins BC, Farley MM, Jernigan JJ, Ray SM, Steinberg JP, Blumberg HM. A population-based
investigation of invasive vancomycin-resistant Enterococcus infection in metropolitan Atlanta,
Georgia, and predictors of mortality. Infect Control Hosp Epidemiol 2007;28:98
18.
Mirtskhulava V, Kempker R, Shields KL, Leonard MK, Tsertsvadze T, Del Rio C, Salakaia A,
Blumberg HM. Prevalence and risk factors for latent tuberculosis infection among health care
workers in Georgia. Int J Tuberc Lung Dis 2008; 12:513-519.
19.
Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM,
Salakaia A. Prevalence and risk factors for multidrug-resistant tuberculosis in Georgia: A
population-based study. Int J Tuberc Lung Dis 2008; in press.
20.
Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze N, Kutateladze T,
Khechinashvili G, del Rio C, Salakaia A, Blumberg HM. High prevalence of multidrug-resistant
tuberculosis in Georgia. Int J Infect Dis 2008; in press.
Laura N. Broyles, MD
Education:
Medical school:
38
Internal medicine residency:
Fellowship:
Barnes-Jewish Hospital, Washington University School of
Medicine.
Officer – Centers for Disease Control and Prevention;
Division of HIV/AIDS Prevention
Emory University School of Medicine.
Current appointment:
Epidemic Intelligence Service
Research and other academic interests:
HIV clinical care, especially in indigent and underserved patient populations; beta-hemolytic
streptococci; delivery of HIV care in international resource-limited settings
Selected publications:
1.
Dewan PK, Fry AM, Laserson K, Tierney BC, Quinn CP, Hayslett JA, Broyles LN, Shane A,
Winthrop KL, Walks I, Siegel L, Hales T, Semenova VA, Romero-Steiner S, Elie C, Khabbaz R,
Khan AS, Hajjeh RA, Schuchat A. Inhalational anthrax outbreak among postal workers,
Washington, D.C., 2001. Emerg Infect Dis 2002 Oct; 8 (10): 1066-72.
2.
Broyles, LN. “Specific Precautions for HIV-infected Travelers” in Health Information for
International Travel, 2003-2004. Atlanta, Georgia: U.S. Department of Health and Human
Services, Public Health Service, CDC.
3.
Santibanez SS, Abdul-Quader AS, Broyles LN, Gusseynova N, Sofronova R. Expansion of
outreach through government AIDS centers is needed to prevent the spread of HIV in Russia.
Drugs: Education, Prevention and Policy, 2005 Feb;12(1):71-74.
4.
Greenberg AE, Tappero J, Choopanya K, van Griensven F, Martin M, Santibanez S, Molotilov V,
Hader S, Broyles LN. CDC international HIV prevention research activities among injection drug
users in Thailand and Russia. J Urban Health. 2005 Sep; 82(3 Suppl 4):iv24-iv33.
5.
Broyles LN, Van Beneden C, Beall B, Facklam R, Shewmaker PL, Malpiedi P, Daily P, Reingold
A, Farley MM. Population-based study of invasive disease caused by beta-hemolytic streptococci
of groups other than A and B. Submitted - Clinical Infectious Diseases.
Angela M. Caliendo, MD, PhD
Education:
Medical School:
Residency:
Fellowship:
PhD:
Case Western Reserve University School of Medicine
Brigham and Women’s Hospital
Massachusetts General Hospital
Case Western Reserve University School of Medicine
Vice Chair, Clinical Pathology
Director, Emory Medical Laboratories
Medical Director, Molecular Diagnostics Laboratory
Medical Director, Microbiology Laboratory
Director, Medical Microbiology Fellowship
39
- Studies of HIV in the female genital tract
In collaboration with Dr. Susan Cu-Uvin at Brown University, we are evaluating HIV-1 RNA
burden and the development of antiretroviral resistance in the plasma and cervical secretions of
HIV-1 seropositive women. The goal of these studies is to determine how viral load levels and
resistance profiles differ in the female genital tract and plasma compartments. This work has
implications for both vertical and heterosexual transmission of HIV-1.
- Development and evaluation of molecular testing for Infectious Diseases
My research laboratory has been actively involved in the development and clinical evaluation of
molecular tests for the diagnosis and monitoring of infectious diseases. These studies focus on
both the analytical and clinical performance of the tests.
- Co-Director of Virology and Drug Discovery Core for the Emory Center for AIDS Research
(CFAR)
The preclinical and clinical virology laboratories provide support to investigators studying HIV
by providing a range of molecular testing for the detection and monitoring of SIV, HIV-1, HIV-2,
CMV, HCV, and sexually transmitted diseases. This testing supports investigators at Emory as
well as those associated with other CFAR centers across the United States. The Core is also
involved with training investigators in molecular methods.
1.
Caliendo AM, Schuurman R, Yen-Lieberman B, Spector SA, Andersen J, Manjiry R,
Crumpacker C, Lurain N, and Erice A, for the CMV Working Group Complications of HIV
Disease RAC, AIDS Clinical Trials Group (ACTG). Comparison of quantitative and qualitative
PCR assays for CMV DNA in plasma. J Clin Microb 2001; 39:1334-38.
2.
Caliendo AM, St. George K, Allega J, Bullotta AC, Gilbane L, and Rinaldo CR. Distinguishing
cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol.
2002; 40:1581-1586.
3.
Humar A, Dumar, D, Boivin, G, and Caliendo A. Cytomegalovirus (CMV) viral load kinetics to
predict recurrent disease in solid organ transplant patients with CMV disease. J Infect Dis 2002;
186(6):829-833.
4.
Caliendo A, Yen-Lieberman B, Baptista J, Andersen J, Crumpacker C, Schuurman R, Spector S,
Bremer J, and Lurain N. Comparison of molecular tests for detection and quantification of cellassociated cytomegalovirus DNA. J Clin Microbiol 2003; 41:3509-3513.
5.
De Pasquale MP, Leigh Brown AJ, Cu-Uvin S, Allega-Ingersoll J, Caliendo AM, Sutton L,
Donahue S, and D'Aquila RT. Differences in HIV-1 pol sequences from female genital tract and
blood during antiretroviral therapy. JAIDS. 2003; 34(1):37-44.
6.
Natividad-Villanueva GU, Santiago E, Manalastas RM, Jr. Brown HW, Ingersoll J, Caliendo AM,
Mayer KH, and Cu-Uvin S. Human immunodeficiency virus in plasma and cervicovaginal
secretions in Filipino women. Int J STD AIDS 2003; 14(12):826-9.
7.
Hill C, Green A, Ingersoll J, Easley K, Nolte F, and Caliendo AM. Assessment of agreement
between the AMPLICOR HIV-1 MONITOR test version 1.0 and 1.5. J Clin Microbiol 2004;
42(1):286-289.
8.
Kessler AT, Kourtis AP, and Caliendo AM. Vascular graft infection due to Pasteurella
multocida. Infection 2004; 32(2):122-123.
40
9.
Barbeau JM, Goforth J, Caliendo AM, and Nolte FS. Performance characteristics of a
quantitative, TaqMan Hepatitis C virus RNA analyte specific reagent. J Clin Microbiol 2004;
42(8):3739-3746.
10.
Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweka F, Nadler PI, Sattler
F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo AM, Pollard RB. A phase
II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anticytomegalovirus antibody (MLS-109) in combination with standard therapy versus standard
therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res
2004; 64:103-111.
11.
Caliendo AM, Ingersoll J, Green AM, Nolte FS, Easley KA. Comparison of the sensitivity and
viral load values between the AMPLICOR HIV-1 MONITOR version 1.0 and 1.5 tests. Journal of
Clinical Microbiology. 2004. 42 (11):5392-5393.
12.
Caliendo AM, Jordan JA, Green, AM, Ingersoll J, Wingood GM, and DiClemente RJ. Real-Time
PCR Provides Improved Detection of Trichomonas vaginalis Infection Compared to Culture
Using Self-Collected Vaginal Swabs. Infectious Diseases in Obstetrics and Gynecology.
2005;13:145-150.
13.
Roback JD, Caliendo AM, Newman JL, Sgan S, Saakadze N, Gillespie TW, Lane TA, Kurtzberg
J, and Hillyer CD. Comparison of CMV PCR and serology for screening umbilical cord blood
components. Transfusion. 2005;45:172-1728.
14.
Cu-Uvin S, Snyder B, Harwell JI, Hogan J, Chibwesha C, Hanley D, Ingersoll J, Kurpewski J,
Mayer KH, and Caliendo AM. Association between paired plasma and cervicovaginal lavage
fluid HIV-1 RNA levels during 36 months. J Acquired Immun Def Syndr 2006;42:584-7.
15.
Hill CE, Harris SB, Culler EE, Zimring JC, Nolte FS, and Caliendo AM. Comparison of a
laboratory-developed real-time PCR assay with a LightCycler commercial assay for the
quantification of Epstein Barr Virus DNA. American Journal of Clinical Pathology
2006;125:665-671.
16.
Caliendo AM, Valsamakis A, Zhou Y, Yen-Lieberman B, Andersen J, Young S, FerreiraGonzalez A, Tsongalis GJ, Pyles R, Bremer JW, and Lurain, NS. Multi-Laboratory Comparison
of Hepatitis C Viral Load Assays. J Clin Micro 2006;44:1726-1732.
17.
Kraft CS, Ramirez G, Caliendo AM. Human Immunodeficiency Virus 1 Viral Load Testing in
Developing Countries. Point of Care 2006;5:186-191.
18.
Crosby R, Voisin D, Salazar LF, DiClemente RJ, Yarber WL, and Caliendo AM. Family
influences and biologically confirmed sexually transmitted infections among detained adolescents.
American Journal of Orthopsychiatry 2006;76:389-94.
19.
Caliendo AM, Ingersoll J, Fox-Canale AM, Pargman S, Bythwood T, Hayden MK, Bremer JW,
Lurain NS. Evaluation of real-time PCR laboratory developed tests using analyte specific reagents
(ASRs) for the quantification of cytomegalovirus. J Clin Micro 2007; 45:1723-1727.
20.
Crosby R, Salazar LF, DiClemente RJ, Yarber WL, Caliendo AM, Staples-Horne M. Condom
misuse among adjudicated girls: association with laboratory confirmed chlamydia and gonorrhea.
Journal of Pediatric and Adolescent Gynecology. In press.
Scott Chancey, PhD
41
Education:
BS:
MS:
PhD:
Auburn University
Auburn University
University of Arizona
Senior Research Associate
Antibiotic resistance mechanisms in Streptococcus pneumoniae.
1.
Petnicki-Ocwieja T, Schneider DJ, Tam VC, Chancey ST, Shan L, Jamir Y, Schechter LM, Janes
MD, Buell CR, Tang X, Collmer A, Alfano JR. Genomewide identification of proteins secreted by the
Hrp type III protein secretion system of Pseudomonas syringae pv. tomato DC3000. Proc Natl Acad
Sci U S A May 28; 99(11):7652-7.
2.
Pierson, L.S. III, Wood, D.W., Pierson, E.A., and Chancey, ST. Homoserine lactone-mediated gene
regulation in plant-associated bacteria. Annu. Rev. Phytopathol. 1998. 36:207-225.
3.
Pierson, L.S. III., Wood, D.W., Pierson, E.A., and Chancey, ST. N-acyl-homoserine lactonemediated gene regulation in biological control by fluorescent pseudomonads: current knowledge and
future work. Eur. J. Plant Pathol. 1998. 104:1-9.
4.
Chancey ST, Wood DW, Pierson LS 3rd. Two-component transcriptional regulation of N-acylhomoserene lactone production in Pseudomonas aureofaciens. Appl Environ Microbiol. Jun 1999;
65(6):2294-9
5.
Chancey ST, Wood DW, Pierson EA, Pierson LS 3rd. Survival of GacS/GacA mutants of the
biological control bacterium Pseudomonas aureofaciens 30-84 in the wheat rhizosphere. Appl Environ
Microbiol. 2002 Jul; 68(7):3308-14.
6.
Guo M, Chancey ST, Tian F, Ge Z, Jamir Y, Alfano JR. Pseudomonas syringae type III chaperones
ShcO1, ShcS1, and ShcS2 facilitate translocation of their cognate effectors and can substitute for each
other in the secretion of HopO1-1. J Bacteriol. 2005 Jun; 187(12):4257-69.
Carlos del Rio, MD
Education:
Medical School:
Residency:
Chief Resident:
Fellowship:
Universidad La Salle, Mexico City, Mexico
Crawford Long Hospital of Emory University
Vice Chair for Grady Affairs and Chief of the Emory Medical
Service at Grady Memorial Hospital
42
Program Director, J. Willis Hurst Internal Medicine Residency
Program
Director for Clinical Sciences and International Research, Emory
Center for AIDS Research
Director of the Emory AIDS International Training and Research
Program.
My research focuses on access to care and barriers to care among HIV-infected persons in
the United States as well as healthcare resource utilization by HIV-infected patients. I also
do epidemiologic research on opportunistic infections and HIV/AIDS-associated risk
behaviors as well as adherence and the impact of therapy on behavior. I am an investigator
for the ACTG, HVTN and HPTN. Finally, I am also interested in the spectrum and impact
of AIDS in developing countries and issues related to access to care in resource poor
settings.
1.
del Rio C, Franco-Paredes C, Duffus W, et al. Routinely Recommended HIV Testing at an Urban
Urgent-Care Clinic - Atlanta, GA 2000. MMWR 2001; 50(25): 538-541.
2.
Navin TR, Beard CB, Hung L, del Rio C, Lee S, Pieniazek NJ, Carter JL, Lee T, Hightower A,
Rimland D. Effect of Mutations in the Pneumocystis carinii dihydropteroate synthase gene do not
affect outcome of P. carinii pneumonia in HIV-infected patients. Lancet 2001; 358: 545-549.
3.
Del Rio C, Sepúlveda J. AIDS in Mexico: lessons learned and implications for developing countries
AIDS 2002; 16:1445-1457.
4.
Duffus WA, Baragan M, Metsch L, Krawczyk CS, Loughlin AM, Gardner LI, Anderson-Mahoney
P, Dickinson G, del Rio C. Effect of Physician Specialty on Counseling Practices and Medical
Referral Patterns for Physicians Caring for Disadvantaged HIV-infected Populations. Clin Infect
Dis 2003; 36:1577-84.
5.
Tobin M, Blass M, del Rio C, Havlosa S, Blumberg H, Horsburgh CR. Hospital water as a source
of Mycobacterium avium complex (MAC) isolates in respiratory specimens. J Infect Dis 2004;
189:98-104.
6.
Blair A, Corbie-Smith G, Thomas S, Mohanan S, del Rio C. Understanding the Patients
Perspective on Rapid and Routine HIV Testing in an Inner-City Urgent Care Center. AIDS
Education and Prevention 2004; 16(2):101-114.
7.
Metsch LR, Pereyra M, del Rio C, Gardner L, Duffus W, Dickinson G, Kerndt P, AndersonMahoney P, Strathdee S, Greenberg A. The Delivery of HIV Prevention Counseling by Physicians
at HIV Medical Care Settings in Four US Cities. Am J Publ Health 2004; 94:1186-1192.
8.
Gardner LI, Metsch LR, Anderson-Mahoey P, Laughlin AL, del Rio C, Strathdee S, Samsom SL,
Siegal HA, Greenberg AE, Holmberg SD. Efficacy of a case management intervention to link
recently diagnosed HIV-infected person to care. AIDS 2005; 19: 423-431.
9.
Stvilia K, Tsertsvadze T, Sharvadze L, Aladashvili M, del Rio C, Kuniholm MH, Nelson KE.
Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A populationbased study of the adult population of Tbilisi, Republic of Georgia. J Urban Health 2006; 83 (2):
289 – 298.
43
10.
Shapatava E, Nelson KE, Tsersvadze T, del Rio C. Risk Behaviors and the Transmission of HIV,
Hepatitis B and Hepatitis C among Injecting Drug Users in Georgia. Drug and Alcohol
Depedence 2006; 82 (suppl 1): S35 – S38.
11.
Hutchinson AB, Farnham PG Dean HD, Ekwueme DU, del Rio C, Kamimoto L, Kellerman SE.
The Economic Burden of HIV in the US in the Era of Highly Active Antiretroviral Therapy:
Evidence of Continuing Racial and Ethnic Differences. JAIDS 2006; 43: 451 – 457.
12.
Markosyan KM, Babikian T, DiClemente RJ, Hirsch JS, Grigoryan S, del Rio C. Correlates of
HIV Risk and Preventive Behaviors in Armenian Female Sex Workers. AIDS and Behavior 2007;
11(2): 325 – 34.
13.
Anthony MN, Gardner L, Marks G, Anderson-Mahoney P, Metsch L, Valverde E, del Rio C,
Loughlin A. Factors associated with use of HIV primary care among persons recently diagnosed
with HIV: Examination of variables from the behavioral model of health-care utilization. AIDS
Care 2007; 19(2): 195-202.
14.
Priddy FH, Pilcher CD, Moore RH, Tambe P, Park MN, Fiscus SA, Feinberg MB, del Rio C.
Detection of acute HIV in an urban HIV counseling and testing population in the United States.
JAIDS 2007; 44(2): 196 - 202.
15.
Brewer T, Zhao W, Pereira M, del Rio C, Loughlin A, Anderson-Mahoney P, Gardner L. Metsch
L: ARTAS Study Group. Initiating HIV Care: Attitudes and Perceptions of HIV Positive Crack
Cocaine Users. AIDS and Behavior 2007; 11(6): 879-904. [Epub ahead of print Feb 13th, 2007]
16.
del Rio C, Hall G, Hook EW, Holmes KK, Whittington WLH, Judson FN, et al. Update to
CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer
Recommended for Treatment of Gonococcal Infections. MMWR 2007; 56(14): 333 – 336.
17.
Hirsch JS, Meneses S, Thompson B, Negroni M, Plancarte B, del Rio C. The inevitability of
Infidelity: Sexual Reputation, Social Geographies, and Marital HIV Risk in Rural Mexico. Am J
Publ Health 2007; 97 (6): 986 – 96
18.
Gardner LI, Marks G, Metsch LR, Loughlin AM, O’DanielsC, del Rio C, Anderson-Mahoney P,
Wilkinson JD. Psychological and Behavioral correlates of entering care for HIV infection: The
Antiretroviral Treatment Access Study (ARTAS). AIDS Patient Care and STD 2007; 21 (6): 41825.
19.
Wang SA, Harvey AB, Conner SM, Zaidi AA, Knapp JS, Whittington WLH, del Rio C, Judson
FN, Holmes KK. Trends in antimicrobial resistance for Neisseria gonorrheae in the United
States, 1988 – 2003: the increasing spread of fluoroquinolone-resistance. Ann Intern Med 2007;
147: 81-88.
20.
Metsch L, Pereyra M, Messinger S, del Rio C, Strathdee SA, Anderson-Mahoney P, Rudy E,
Marks G, Gardner L. Reduction of HIV transmission Risk behaviors among HIV infected persons
who are successfully linked to care. Clin Infect Dis 2008; 47:577-584.
Carlos DiazGranados, MD
Education:
Medical School:
Residency:
Colegio Mayor de Nuestra Señora del Rosario-Hospital de San
Jose
University of Miami – Jackson Memorial Hospital
44
Chief Resident:
Fellowship:
Master of Science:
University of Miami – Jackson Memorial Hospital
Emory University School of Arts and Sciences
Assistant Hospital Epidemiologist and Director of Antibiotic
Utilization, Grady Memorial Health System
Interests: 1) Antimicrobial utilization. 2) Antimicrobial resistance. 3) Hospital Epidemiology. 4)
International HIV/AIDS. 5) Tropical infectious diseases.
Current studies: 1) Impact of an Antimicrobial utilization physician as a component of an
interdisciplinary team on clinical and ecologic outcomes of critically ill patients. 2) Non-ID
clinical pharmacist active participation in antimicrobial stewardship. 3) Predictors of imipenemrequiring organisms, piperacillin/tazobactam-requiring organisms, and imipenem-resistant
organisms in patients with suspected gram-negative infections. 4) HIV resistance in Colombia. 5)
Retrospective cohort study on treatment of bacteremia caused by ESBL producing
enterobacteriaceae. 6) Prevalence of MRSA in military and competitive sports personnel in
Bogota, Colombia.
1.
DiazGranados CA, Bisno AL. Clues to Early Diagnosis of Necrotizing Fasciitis. Infections in
Medicine 2001;18:198-206.
2.
DiazGranados CA, Franco C, Steinberg JP. A long-suffering patient with new abdominal pain.
Clin Infect Dis 2002; 34(9):1213-4, 1267-8.
3.
Franco-Paredes C, Bellehemeur T, Merchant A, Sanghi P, DiazGranados C, Rimland D. Aseptic
meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a
patient with AIDS. AIDS 2002; 16(7):1045-9.
4.
Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, Pham SM, Zaki
S, Lanciotti RS, Lance-Parker SE, DiazGranados CA, Winquist AG, Perlino CA, Wiersma S,
Hillyer KL, Goodman JL, Marfin AA, Chamberland ME, Petersen LR, and the West Nile Virus in
Transplant Recipients Investigation Team. Transmission of West Nile Virus from an Organ Donor
to Four Transplant Recipients. N Engl J Med 2003; 348:2196-203.
5.
DiazGranados CA, Jernigan JA. Impact of Vancomicin Resistance on Mortality Among
Neutropenic Patients with Enterococcal Blood Stream Infections. J Infect Dis 2005;191:588-95 .
6.
DiazGranados CA, Zimmer S, Klein M, Jernigan JA. Comparison of Mortality Associated with
Vancomycin-Resistant and Vancomycin-Susceptible Enterococcal Bloodstream Infections: a
meta-analysis. Clin Infect Dis 2005; 41:327-33.
7.
DiazGranados CA, Jernigan JA. Vancomycin-Resistant Enterococcal Bloodstream Infection–
Related Mortality: Focus on the Lack of Appropriate Therapy. [Reply] Clin Infect Dis
2006;42:1203-5.
45
8.
Valderrama A, Del Castillo J, DiazGranados CA, Ortega JC, Guio G, Hernandez JI, Molano E.
Deep Vein Thrombosis in Chronically Bedridden Elderly Individuals. J Am Geriatr Soc
2006;54(5):866-7.
9.
Olaya P, DiazGranados CA. Correlation and concordance of three HIV viral load techniques
available in Colombia [Spanish]. Biomedica 2006;26:302-8.
10. Miranda AD, Rodriguez R, Novoa DM, Rojas D, Pachon A, DiazGranados CA. Utility of
endocervical curettage in women with low-grade squamous intraepithelial lesions or atypical
squamous cells of unknown significance on Pap smear. J Low Genit Tract Dis 2006; 10(3):14650.
11. DiazGranados CA, Silva A, Bermudez A, Roncancio D, Diruggiero P, Mantilla M. Rate and
Predictors of Optimal Virologic Response to Antiretroviral Therapy in Colombia. Int J Infect Dis
2007 Nov;11(6):531-5
12. Whitaker JA, Jacob JT, Little JV, DiazGranados CA. Cytomegalovirus cystitis with bladder wall
dehiscence in a patient with AIDS. AIDS 2008;22:795-6.
13. DiazGranados CA, Cardo DM, McGowan JE Jr. Antimicrobial Resistance: International Control
Strategies, with a Focus on Limited Resource Settings. Int J Antimicrob Agents 2008;32(1):1-9
14. DiazGranados CA, Martinez A, Deaza C, Valderrama S. An outbreak of Candida spp.
bloodstream infection in a tertiary care center in Bogotá, Colombia. Braz J Infect Dis 2008 (in
press).
15. Contreras GA, DiazGranados CA, Cortes L, Reyes J, Vanegas S, Panesso D, Rincón S, Díaz L,
Prada G, Murray BE, Arias CA. Nosocomial Outbreak of Enteroccocus gallinarum: Untaming of
Rare Species of Enterococci. J Hosp Infect 2008 (in press).
Formatted: Highlight
Molly E. Eaton, MD
Education:
Medical School:
Residency:
Fellowship:
Washington University School of Medicine
Clinic Director, Emory Crawford Long Infectious Disease Clinic
Clinical manifestations, diagnosis, and response to therapy of syphilis, especially in HIV coinfected patients. Antiretroviral clinical trials in HIV-infected persons. I participate in the NIHsponsored AIDS Clinical Trials Group.
1.
Eaton ME, Cohen MT, et al. Ciprofloxacin treatment of typhus (letter). JAMA 1989; 262:772-73.
46
2.
Shlim DR, Schwartz EL, Eaton ME, et al. The effect of oral and parenteral typhoid vaccination
on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in
Nepal. Arch Intern Med 1990; 150:349-51.
3.
Shlim DR, Cohen MT, Eaton ME, et al. An alga-like organism associated with an outbreak of
prolonged diarrhea among foreigners in Nepal. Am J Trop Med Hyg 1991; 45:383-89.
4.
Eaton M and Kozarsky P. Use of Mefloquine for Malarial Chemoprophylaxis in its first year of
availability in the United States. (letter) Clinical Infectious Diseases 1993; 16: 185.
5.
Gordon S, Eaton M, Thompson S, et al. Response of symptomatic neurosyphilis to high-dose
intravenous penicillin G in persons infected with the human immunodeficiency virus. N Engl J
Med 1994; 331:1469-73.
6.
Eaton M, Padhye A, Steinberg J, et al. Osteomyelitis of the sternum caused by Apophysomyces
elegans. J Clin Microbiol 1994:2827-88.
7.
Shlim DR, Schwartz E, Eaton M. Clinical Importance of Salmonella paratyphi A infection to
enteric fever in Nepal. Journal of Travel Medicine 1995; 2(3):165-168.
8.
Marra CM, MD1,2, Maxwell CL, MD1, Smith SL, BS1, Lukehart SA, PhD2, Rompalo AM,
MD3, Eaton M, MD4, Stoner BP, MD, PhD5, Augenbraun M, MD6, Barker DE, MD7, Corbett
JJ, MD8, Zajackowski M, MD9, Raines C, CRNP, MSN3, Nerad J, MD7, Kee R, MD9, Barnett
SH3. Cerebrospinal Fluid Abnormalities in Patients with Syphilis: Association with Clinical and
Laboratory Features. J Infect Dis 2004; 189(3):96-376.
9.
Marra CM, Maxwell CL, Tantalo L, Eaton M, Rompalo AM, Raines C, Stoner BP, Corbett JJ,
Augenbraun M, Zajackowski M, Kee R, Lukehart SA. Normalization of cerebrospinal fluid
abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004;
38(7):1001-1006.
Other Publications/Book Chapters
1.
Eaton M, Steinberg J. Sepsis Syndrome. In: Hurst W, ed.
2.
McLellan S, Eaton M, Stephens D. Pasteurella multocida. In: Schlossberg D, ed. Current
Therapy of Infectious Disease. Mosby-Year Book, Inc,1996.
Srilatha Edupuganti, MD, MPH
Education:
Medical School:
MPH:
Residency:
Fellowship:
LSU School of Medicine, New Orleans, LA
UNC-Chapel Hill School of Public Health
University of Texas Southwestern Medical School, Dallas, TX
Infectious Diseases, Emory University School of Medicine and
UNC-Chapel School of Medicine
Sri Edupuganti, MD, MPH joined Emory University in September 2006 as an Assistant Professor
of Medicine. She is the Medical Director of the Hope Clinic of the Emory Vaccine Center which
is dedicated to clinical vaccine research. Her main interests are performing vaccine trials for HIV
vaccines, non-HIV vaccines including yellow fever vaccines, avian flu vaccines and others. She is
47
also interested in translational research pertaining to vaccine immunology. Prior to her
appointment at Emory, she was a faculty member at UNC-Chapel Hill for 6 years where she
conducted several phase I Merck HIV vaccine trials.
1.
Edupuganti S, Svec F, Bao W, Srinivasan SR, Berenson GS. Thyroid function in children with
different lipoprotein profiles: observation in a biracial (black/white) population – the Bogalusa
Heart Study. Am J Med Sci 1997; 313: 80-4.
2.
Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, and Stephens
DS. Capsule switching of Neisseria meningitidis. PNAS 1997; 94: 271-6.
3.
Swartley JS, Liu LJ, Miller YK, Martin LE, Edupuganti S, Stephens DS. Characterization of the
gene cassette required for biosynthesis of the (alpha-6)-linked N-acetyl-D-mannosamine-1phosphate capsule of serogroup A Neisseria meningitidis. J Bacteriol 1998;180:1533-9.
4.
Edupuganti S, Weber D, Hudgens M and Poole C. Cytotoxic T-lymphocyte responses to
canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of
published studies. HIV Clinical Trials 2004; 5:259-268.
5.
Joseph D. Miller, Robbert G. van der Most, Rama Akondy, John T. Glidewell, Sophia Albott,
David Masopust, Kaja Murali-Krishna, Patryce L. Mahar, Srilatha Edupuganti, Susan Lalor,
Stephanie Germon, Carlos Del Rio, Mark Mulligan, Silvija I. Staprans, John D. Altman, Mark B.
Feinberg, and Rafi Ahmed. Using the smallpox and yellow fever vaccines to study human
effector and memory CD8 T cell responses to acute viral infection. Immunity 28(5):710-22,May
2008.
6.
Edupuganti S, Sena A, Cohen M. Sexually Transmitted Diseases. In: Bryan CS, ed. Infectious
Diseases in Primary Care. W.B. Saunders; 2002. p. 371-399.
7.
Swygard H, Edupuganti S, Cohen M, Sena A. Approach to sexually transmitted diseases. In:
UptoDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2004.
Carlos E. Franco, MD, MPH
Education:
Medical School:
Graduate School:
Residency:
Fellowship:
La Salle University School of Medicine
Emory University, School of Public Health
Infectious Diseases, Emory University
Co- Director, Travel Well, International Travelers Medical
Clinic
I am interested in travel and tropical medicine as well as vaccine research.
1.
Franco-Paredes C, Rouphael N, Méndez J, Folch E, Rodríguez-Morales AJ, Santos JI, Hurst JW.
Cardiac manifestations of parasitic infections. Part 2: Parasitic myocardial disease. Clin Cardiol.
2007 May;30(5):218-22.
48
2.
Cardiac manifestations of parasitic infections part 3: pericardial and miscellaneous
cardiopulmonary manifestations. Clin Cardiol. 2007 Jun;30(6):277-80.
3.
Franco-Paredes C, Von A, Hidron A, Rodríguez-Morales AJ, Tellez I, Barragán M, Jones D,
Náquira CG, Mendez J. Chagas disease: an impediment in achieving the Millennium Development
Goals in Latin America. BMC Int Health Hum Rights. 2007 Aug 28;7:7.
4.
Franco-Paredes C, Dismukes R, Nicolls D, Hidron A, Workowski K, Rodriguez-Morales A,
Wilson M, Jones D, Manyang P, Kozarsky P.Persistent and untreated tropical infectious diseases
among sudanese refugees in the United States. Am J Trop Med Hyg. 2007 Oct;77(4):633-5.
5.
Osorio J, Carvajal C, Sussman O, Buitrago R, Franco-Paredes C. Acute liver failure due to
dengue virus infection. Int J Infect Dis. 2008 Jul;12(4):444-5
6.
Franco-Paredes C, Lammoglia L, Hernández I, Santos-Preciado JI.Epidemiology and outcomes
of bacterial meningitis in Mexican children: 10-year experience (1993-2003). Int J Infect Dis.
2008 Jul;12(4):380-6.
7.
Rodríguez-Morales AJ, Sánchez E, Arria M, Vargas M, Piccolo C, Colina R, Franco-Paredes C.
Haemoglobin and haematocrit: the threefold conversion is also non valid for assessing anoaemia
in Plasmodium vivax malaria-endemic settings.Malar J. 2007 Dec 17;6:166.
8.
Jacob JT, Franco-Paredes C. The stigmatization of leprosy in India and its impact on future
approaches to elimination and control. PLoS Negl Trop Dis. 2008 Jan 30;2(1):e113.
9.
Tellez I, Barragán M, Franco-Paredes C, Petraro P, Nelson K, Del Rio C. Pneumocystis jiroveci
pneumonia in patients with AIDS in the inner city: a persistent and deadly opportunistic infection.
Am J Med Sci. 2008 Mar;335(3):192-7.
10.
Rodriguez-Morales AJ, Benitez JA, Tellez I, Franco-Paredes C. Chagas disease screening among
Latin American immigrants in non-endemic settings.Travel Med Infect Dis. 2008 May;6(3):162-3.
11.
Talati NJ, Rouphael N, Kuppalli K, Franco-Paredes C. Spectrum of CNS disease caused by
rapidly growing mycobacteria.Lancet Infect Dis. 2008 Jun;8(6):390-8.
11.
Jacob JT, Kozarsky P, Dismukes R, Bynoe V, Margoles L, Leonard M, Tellez I, Franco-Paredes
C. Five-year experience with type 1 and type 2 reactions in Hansen disease at a US travel clinic.
Am J Trop Med Hyg. 2008 Sep;79(3):452-4.
Paula Frew, PhD, MPH
Education:
Graduate School:
Undergraduate:
PhD - University of Georgia, College of Public Health
MPH - Emory University, Rollins School of Public Health
MA - San Diego State University
BA - University of California at San Diego (Thurgood Marshall
College)
Assistant Professor of Behavioral Sciences and Health
Education, Rollins School of Public Health
49
Director of Health Communications and Applied Community
Research - The Hope Clinic of the Emory Vaccine Research
Center
Engaging communities in clinical research and promoting the adoption of new infectious disease
"prevention technologies" particularly among those who may be disproportionately affected by
disease in the community is a scientific and ethical imperative. Consequently, issues impacting
infectious disease prevention research and future immunization and product uptake among
women and minorities are a centerpiece of my current efforts. The facilitators and barriers in the
acceptance of clinical research, as well as future challenges to mass immunization among priority
populations (e.g., women and minorities at risk for HIV/STI infection) continue to be explored
for a variety of pandemic concerns. This vibrant "participatory action research" agenda also
extends to the development and evaluation of novel evidence-based HIV/AIDS "indigenous
interventions" to address sociocultural and epidemiologic determinants of risk in community
settings.
1.
Frew P & Bernhardt JM. Photojournalism in health education: ‘Hope for Humanity: The Quest
for an AIDS Vaccine,’ Health Educ & Behavior 2003; 30(3):261-262.
2.
Frew P & Bernhardt JM. Focusing on HIV/AIDS in Africa, Am J Public Health 2003;
93(11):1809.
3.
Crosby RA, Holtgrave DR, Bryant L, Frew PM. Correlates of negative intent to receive an AIDS
vaccine: An exploratory study, Intl J STDs & AIDS 2004; 15:552-557.
4.
Crosby RA, Holtgrave DR, Bryant L, Frew PM. Factors associated with the acceptance of an
AIDS Vaccine: An exploratory study, Preventive Med 2004; 39:804-808.
5.
Frew PM. ‘Real People, Real Progress’: Improving HIV vaccine awareness & knowledge through
integrated community education. Health Educ & Behavior 2005; 32(1):8-9.
6.
Salazar LF, Holtgrave D, Crosby RA, Frew PM, Peterson JL. Issues related to gay and bisexual
men’s acceptance of a future AIDS vaccine, Intl J STDs & AIDS 2005; 16(8): 546-548.
7.
Frew PM & Bernhardt JM. Using the web to translate health communication research to practice:
The HealthComm Key. Public Health Reports 2005; 120(5): 576-578.
8.
Priddy FH, Cheng AC, Salazar LF, Frew PM. Racial and ethnic differences in knowledge and
willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Intl
J STDs & AIDS 2006; 17(2): 99-102.
9.
Frew PM, Archibald ME, Martinez N, del Rio C, Mulligan MJ (2008). Promoting HIV vaccine
research in African American communities: Does the theory of reasoned action explain potential
outcomes of involvement? Challenge: A Journal of Research on African American Men 2008;
13(1): 61-97.
10.
Frew PM, del Rio C, Clifton S, Archibald ME, Hormes JT, Mulligan MJ. Factors influencing
HIV vaccine community engagement in the urban South, J Comm Health 2008; 33(4): 259-269.
50
11.
Frew PM, Crosby RA, Salazar LF, Gallinot L, Bryant LO, Holtgrave DR. Minority women’s
acceptance of an HIV/AIDS vaccine. J Natl Med Assn 2008; 100(7): 802-813.
12.
Frew PM, Macias W, Chan K, Harding AC. In ‘Step’ with HIV Vaccines? A content analysis of
recruitment campaigns for an international HIV vaccine clinical trial, J Health & Mass Comm
2008; in press.
13.
Shuster J, Sterk C, Frew PM, del Rio C. The Cultural and Community-level Acceptance of
Antiretroviral Therapy (ART) in a South African Village: Implications for Traditional Healers. J
Comm Health, in press.
Mary R. Galinski, PhD
Education:
PhD:
Post-Doctoral:
New York University School of Medicine
New York University School of Medicine
Affiliate Scientist, Emory Vaccine Center
Molecular Parasitology focusing on Malaria/Plasmodium: Research addresses molecular, cellular
and immunological questions on malaria parasitism in humans and non-human primates, which
are relevant for the development, testing and application of effective malaria vaccines and/or
drugs. Clinically focused research is carried out in endemic regions of Brazil and with vaccine
development partners.
Advocacy, Public Awareness and Education on Malaria: Service activities focus on the global
picture of malaria through involvement in several international initiatives and Malaria Foundation
International (www.malaria.org) programs to facilitate the development and implementation of
solutions to the health, economic and social problems caused by malaria.
1.
Al-Khedery, B, Barnwell, J.W. and Galinski, M.R. Antigenic variation in malaria: a 3’ genomic
alteration associated with the expression of a Plasmodium knowlesi variant antigen. Molecular
Cell 1999. 3:131-141.
2.
Galinski, M.R., Corredor-Medina, C., Povoa, M., Crosby, J., Ingravallo, P. and Barnwell, J.W.
Plasmodium vivax merozoite surface protein-3: coiled-coil motifs within an alanine-rich central
domain. Molec. Biochem. Parasitol. 1999. 101:131-147.
3.
Al-Khedery, B., Barnwell, J.W. and Galinski, M.R. Stage-specific expression of 14-3-3 in
asexual blood-stage Plasmodium. Molec. Biochem. Parasitol. 1999. 102: 117-130.
4.
Bruce MC, Donnelly CA, Alpers MP, Galinski MR, Barnwell JW, Walliker D, Day KP.
Molecular epidemiological evidence defines the nature of cross-species interactions between
malaria parasites in humans. Science 2000; 287:845-848.
51
5.
Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, Alpers M, Walliker D, Day
KP. Genetic diversity and dynamics of P. falciparum and P. vivax populations in multiply
infected children with asymptomatic malaria infections in Papua New Guinea. Parasitology 2000;
121:257-272.
6.
Etchegorry MG, Matthys F, Galinski MR, White NJ, Nosten F. Malaria epidemic in Burundi.
Lancet 2001; 357(9261):1046-1047.
7.
Galinski MR, Ingravallo P, Corredor-Medina C, Al-Khedery B, Povoa M, Barnwell JW.
Plasmodium vivax merozoite surface protein-3β and -3γ share structural similarities with P. vivax
MSP-3α and define a new gene family. Molec Biochem Parasitol 2001; 115:41-53.
8.
Rayner J, Vargas-Serrato E, Huber C, Galinski MR, Barnwell JW. A Plasmodium falciparum
homologue of PvRBP1 defines a trypsin resistant erythrocyte invasion pathway. J Exp Med 2001;
194 (11):1571-81.
9.
Vargas EL, Barnwell JW, Ingravallo P, Perler FB, Galinski MR. Merozoite surface protein of
Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P
.falciparum. Molec Biochem Parasitol 2000; 120(1):41-52.
10.
Vargas-Serrato E, Corredor V, Galinski MR. Phylogenetic analysis of csp and msp-9 gene
sequences demonstrates the close relationship of Plasmodium coatneyi to Plasmodium knowlesi.
Infection, Genetics and Evolution 2003; 3(1):67-73.
11.
Oliveira-Ferreira J, Vargas-Serrato E, Barnwell JW, Moreno A, Galinski MR. Immunogenecity
of Plasmodium vivax Merozoite Surface Protein-9 recombinant proteins expressed in E.
coli.Vaccine 2003; 7(22):2023-30.
12.
Rayner, J.C., Tran, T.M., Corredor, V., Huber, C.S., Barnwell, J.W. and Galinski, M.R. 2004.
Diversity within Reticulocyte Binding Like (RBL) gene family members differs dramatically in P.
falciparum and P vivax. Amer. J. Trop Med Hyg. 72(6): 666-74.
13.
Korir, C.C., Galinski, M.R. Proteomic Studies of P. knowlesi SICA Variant Antigens
Demonstrate their Relationship with P. falciparum EMP1. Infection, Genetics and Evolution.
2005. 6:75-79.
14.
Galinski, M.R., Dluzewski, A.R. and Barnwell. J.W. Malaria Merozoites and Invasion of
Erythrocytes. In: Molecular Approaches to Malaria. 2005. I.W. Sherman. ed. ASM Press, N.Y.
Pgs 113-168. ISBN # 1-55581-330-5.
15.
Tran, T.M., Oliveira-Ferreira J., Moreno, A., Santos, F., Yazdani, S.S., Chitnis, C.E., Altman,
J.D., Meyer, E. V-S, Barnwell, J.W., and Galinski, M.R. Comparison of IgG reactivities to
Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Amer. J. Trop
Med Hyg 2005. 73:244-255.
16.
Caro-Aguilar, I., Lapp, S., Pohl, J. Galinski, M.R. and Moreno, A. Polymeric linear peptide
chimeras that contain malaria universal T cell epitopes are efficient delivery system for subunit
vaccines. Microbes & Infection. 2005. 7:1324-37.
17.
Okenu, D.M., Meyer, E. V-S., Puckett, T., Barnwell, J.W. and Galinski, M.R. The Reticulocyte
Binding Proteins of Plasmodium cynomolgi: a model system for studies of P. vivax. Molec.
Biochem. Parasitol 2005. 143(1):116-20.
52
18.
Pfahler, J.M., Galinski, M.R., Barnwell. J.W. and Lanzer M. Transient transfection of
Plasmodium vivax blood-stage parasites. Mol Biochem Parasitol. 2006. 149:99-101.
19.
Moreno, A., Garcia, A., Cabrera-Mora, M., Strobert, E and Galinski, M.R. Case report:
Disseminated intravascular coagulation complicated by peripheral gangrene in a rhesus macaque
(Macaca mulatta) experimentally infected with Plasmodium coatneyi. Am J Trop Med Hyg. 2007.
76:648-54.
David A. Garber, PhD
Education:
Graduate School:
Harvard University
PhD, Microbiology & Molecular Genetics
Post-Doctoral Training: Emory University
Molecular virology and immunology of poxviruses focusing on the development of Modified Vaccinia
Ankara (MVA)-based vaccines against HIV/AIDS.
Publications:
1.
Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene Transfer into
Mammalian Central Nervous System Using Herpes Virus Vectors: Extended Expression of
Bacterial lacZ in Neurons Using the Neuron-Specific Enolase Promoter. Human Gene Therapy
1992;3:487-499.
2.
Breakefield XO, Hang Q, Andersen JK, Kramer MF, Bebrin WR, Davar G, Vos B,
Garber DA, DiFiglia M, Coen DM. Gene Transfer into the Nervous System using
Recombinant Herpes Virus Vectors. Gene Transfer and Therapy in the Nervous System 1992;
Gage, F.H.; Christen, Y., editors. Springer-Verlag, Berlin.
3.
Garber DA, Beverley SM, Coen DM. Demonstration of Circularization of Herpes
Simplex Virus DNA Following Infection Using Pulsed Field Gel Electrophoresis. Virology 1993;
197:459-462.
4.
Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM,
Kosz-Vnenchak M, Knipe DM, Breakefield XO, Isacson O. Comparative Efficacy of
Expression of Genes Delivered to Mouse Sensory Neurons with Herpes Virus Vectors. J
Comp Neurol 1994; 339:3-11.
5.
Garber DA, Schaffer PA, Knipe DM. A LAT-Associated Function Reduces
Productive-Cycle Gene Expression during Acute Infection of Murine Sensory Neurons with
Herpes Simplex Virus Type 1. J Virol 1997; 71(8):5885-5893.
6.
Chen S-H, Garber DA, Schaffer PA, Knipe DM, Coen DC. Persistent Elevated
Expression of Cytokine Transcripts in Ganglia Latently Infected with Herpes Simplex Virus in the
Absence of Viral Replication or Reactivation. Virology 2000; 278(1):207-16.
7.
Chen S-H, Lee LY, Garber DA, Schaffer PA, Knipe DM, Coen, DM. Neither
LAT nor Open Reading Frame P Mutations Increase Expression of Spliced or Intron-Containing
ICP0 Transcripts in Mouse Ganglia Latently Infected with Herpes Simplex Virus. J Virol 2002;
76(10):4764-4772.
53
8.
Garber DA, Feinberg MB. AIDS Vaccine Development: The Long and Winding Road. AIDS
Reviews 2003; 5:131-139.
9.
Garber DA, Silvestri G, Barry A, Fedanov A, Kozyr N, McClure H, Montefiori DC,
Larsen CP, Altman JD, Staprans SI, Feinberg MB. Blockade of T Cell Costimulation
Reveals Interrelated Actions of CD4+ and CD8+ T Cells in Control of SIV Replication. J
Clin Invest 2004; 113(6):836-845.
10.
Regoes RR, Antia R, Garber DA, Silvestri G, Feinberg MB, Staprans SI. Roles of
Target Cells and Virus-Specific Cellular Immunity in Primary Simian Immunodeficiency Virus
Infection. J Virol 2004; 78(9):4866-4875.
11.
Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions,no
easy answers. Lancet Infectious Diseases 2004; 4:397-413.
12.
Silvestri, G., Fedanov, A., Germon, S.,Kozyr, N., Kaiser, W.J.,Garber, D.A., McClure,
H.,Feinberg, M.B., Staprans, S.I. Divergent Host Responses During Primary Simian
Immunodeficiency Virus SIVsm infection of Natural Sooty Mangabey and Nonnatural Rhesus
Macaque Hosts. J Virol 2005;79:4043-54.
13.
Chavan, R.; Marfatia, K.A.,An, I.C.,Garber, D.A., Feinberg, M.B. Expression of CCL20 and
GM-CSF, but not Flt3-L, from Modified Vaccinia Ankara Enhances Antiviral Cellular and
Humoral Immune Responses. J Virol 2006. 80(15):7676-87.
14.
Chahroudi, A., Garber, D.A., Reeves, P., Liu, L., Kalman, D.,Feinberg, M.B. Differences and
Similarities in Viral Life Cycle Progression and Host Cell Physiology after Infection of Human
Dendritic Cells with Modified Vaccinia Virus Ankara and Vaccinia Virus. J Virol. 2006.
80(17):8469-8481.
15.
Garber, D.A., Feinberg, M.B. Probing the possibilities for T-cell-based AIDS Vaccines. Current
Opinion in HIV and AIDS. 2006. 1:314-22.
16.
Tatsis, N.,Lin, S.-W., Harris-McCoy, K.,Garber, D.A., Feinberg, M.B.,Ertl, H.C.J. Multiple
Immunizations with Adenovirus and MVA Vectors Improve CD8+ T Cell Functionality and
Mucosal Homing. Virology. 2007 Oct 10;367(1):156-67.
17.
Mandl, J.N., Regoes, R.,Garber, D.A.,Feinberg, M.B. Estimating the Effectiveness of SIVspecific CD8 T Cells from the Dynamics of Viral Immune Escape. J Virol. 2007
Nov;81(21):11982-91.
Robert P. Gaynes, MD
Education:
Medical School:
Residency:
EIS Officer:
Fellowship:
University of Chicago Pritzker School of Medicine
Michael Reese Hospital
Centers for Disease Control
University of Chicago
Adjunct Professor of Epidemiology, Rollins School of Public
Health;
Hospital Epidemiologist, VAMC;
54
Assistant to Director, Division of Healthcare Quality Promotion,
Centers for Disease Control
Using the latest technology in the computerized patient record system and clinical decision
support, to develop a computerized surveillance on antimicrobial use, nosocomial infections,
potential risk factors, pathogens and their antimicrobial susceptibility patterns in Atlanta VAMC.
This will aid in the development of efficient preventions strategies and guidelines to reduce the
risk of nosocomial infections and antimicrobial resistance in acute or chronic health-care settings.
Examining antimicrobial choice in a multihospital study to determine intervention(s) most
effective in optimizing antimicrobial use.
Selected Publications
1.
Trick W, Edwards J, Fridkin S, Gaynes R, Hajjeh R. Temporal trends in fungal bloodstream
infection rates in the United States. Clin Infect Dis 2002; 35:627-630.
2.
Fridkin,SK, Lawton R, Edwards JR, Tenover FC, McGowan JE Jr, Gaynes RP. Monitoring
Antimicrobial Use and Resistance: Comparison with a National Benchmark on Reducing
Vancomycin Use and Vancomycin-Resistant Enterococci. Emerg Infect Dis 2002; 8:702-7.
3.
Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton R, Gaynes RP, McGowan, JE Jr.
Temporal Changes in Prevalence of Antimicrobial Resistance in 23 U.S. Hospitals . Emerg Infect
Dis; 8:697-701.
4.
Leonard MK, Murrow JR, Jurado R, Gaynes R. Salmonella meningitis in adults infected with
HIV: case report and review of the literature. Am J Med Sci 2002; 323(5):266-8
5.
Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired
candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect
Dis 2002; 35(5):627-30.
6.
Gaynes R. Health care--associated bloodstream infections: a change in thinking. Ann Intern Med
2002; 137(10):850-1.
7.
Platt R, Kleiman K, Thompson K, Dokholyan RS, Livingston JM, Bergman A, Mason, JH, Horan
TC, Gaynes RP, Solomon S, Sands KE. Assessing surgical site infections through automated
health plan data: comparison across health plans and hospitals of risks following coronary artery
bypass surgery. Emerg Infect Dis 2002; 8:2-39.
8.
Steward CD, Mohammed JM, Swenson JM, Stocker SA, Williams PP, Gaynes RP, McGowan Jr
JE Jr, Tenover FC. Antimicrobial Susceptibility Testing of Carbapenems: Multicenter Validity
Testing and Accuracy Levels of Five Antimicrobial Test Methods for Detecting Resistance in
Enterobacteriaceae and Pseudomonas aeruginosa Isolates. J Clin Microbiol 2003; 41(1):351-8.
9.
Richards C, Edwards J, Culver D, Emori TG, Tolson J, Gaynes R. The Impact of Laparoscopy on
Surgical Site Infections Following Cholecystectomy. Ann Surg 2003; 237(3):358-62.
10.
Hageman JC, Fridkin SK, Mohammed JM, Steward CD, Gaynes RP, Tenover FC. Antimicrobial
Proficiency Testing of National Nosocomial Infections Surveillance System Hospital Laboratories
Infect Control Hosp Epidemiol 2003; 24:356-361.
11.
Sands KE, Yokoe DS, Hooper DC, Tully JL, Horan TC, Gaynes RP, Solomon SL, Platt R.
Detection of postoperative surgical-site infections: comparison of health plan-based surveillance
with hospital-based programs. Infect Control Hosp Epidemiol 2003; 10:741-3.
55
12.
Alonso-Echanove J, Edwards JR, Richards MJ, Brennan P, Venezia RA, Keen J, Ashline V,
Kirkland K, Chou E, Hupert M, Veeder AV, Speas J, Kaye J, Sharma K, Martin A, Moroz VD,
Gaynes RP. Effect of nurse staffing and antimicrobial-impregnated central venous catheters on
the risk for bloodstream infections in intensive care units. Infect Control Hosp Epidemiol 2003;
24(12):916-25.
13.
Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM 2nd, Killgore G, Tenover FC.
Outbreak of Clostridium difficile infection in a long-term care facility: association with
gatifloxacin use. Clin Infect Dis 2004; 38(5):640-5.
14.
Gaynes R, Edwards J, and the National Nosocomial Infections Surveillance System. Overview of
Gram-Negative Nosocomial Infections. Clin Infect Dis. 2005 Sep 15;41(6):848-54
15.
Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the
epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in intensive care units in
U.S. hospitals: 1992-2003. Clin Infect Dis 2006;4:389-91.
16.
Antoine TL, Curtis AB, Blumberg HM, DeSilva K, Fransua M, Gould CV, King M,. Kraman
AA, Pack J, Ribner B, Seybold U, Steinberg JP, Wells JB, Sinkowitz-Cochran RL, Cardo D,
Jernigan JA, Gaynes RP. Knowledge, attitudes, and behaviors about piperacillin/tazobactam
prescribing practices: Results from a multi-center study. Infect Control Hosp Epidemiol
2006;27:1274-7.
17.
Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM.
Estimating Healthcare-Associated Infections and Deaths in U.S. Hospitals, 2002. Public Health
Reports 2007;122:1-13.
18.
Stone N, Lewis D, Richards, C, Tenover FC, McGowan J, Johnson T, Gaynes RP. Importance of
Bacterial Burden among Methicillin-Resistant Staphylococcus aureus Carriers in a Long-Term
Care Facility. Infect Control Hosp Epidemiol 2008; 29:143–148
19.
Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated Risk Factors
for Clostridium difficle Infection. Clin Infect Dis 2008;46:S19-31.
20.
Klevens M, Edwards JE, Gaynes RP. The Impact of Antimicrobial Resistant Healthcareassociated Infections on Mortality in the United States. Clin Infect Dis 2008;47:927-30.
Carolyn V. Gould, MD, MS
Education:
Medical School:
University of Pennsylvania School of Medicine
Residency:
Hospital of the University of Pennsylvania
Clinical/Postdoctoral Fellowship:
Hospital of the University of Pennsylvania
Masters of Science in Clinical Research: Rollins Sch. of Public Health, Emory University
Medical Epidemiologist, Response Team
Division of Healthcare Quality Promotion, Centers for Disease
Control and Prevention
LCDR, USPHS
56
Research and Academic Interests:
My primary interest is in prevention of healthcare-associated infections and antibiotic
resistance. My current activities and research primarily involve responding to healthcareassociated infectious disease outbreaks and prevention and control of C. difficile infections. I
am also leading the revision of HICPAC's Guideline for Prevention of Catheter-associated
Urinary Tract Infections.
1.
Gould CV, Fishman NO, Nachamkin I, Lautenbach E. Chloramphenicol resistance in
vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use? Infection
Control and Hospital Epidemiology 2004; 25:138-145.
2.
Antoine TL, Curtis AB, Blumberg HM, DeSilva K, Fransu M, Gould CV, King M, Kraman AA,
Pack J, Ribner B, Seybold U, Steinberg JP, Wells JB, Sinkowitz-Cochran RL, Cardo D, Jernigan
JA, Gaynes RP. Knowledge, attitudes, and behaviors regarding piperacillin-tazobactam
prescribing practices: results from a multicenter study. Infection Control and Hospital
Epidemiology 2006; 27:1274-1277.
3.
Gould CV, Steinberg JP. Antibiotic resistance in long-term acute care hospitals (LTACHs): the
perfect storm. Infection Control and Hospital Epidemiology 2006;27:920-925.
4.
Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated
with haemophagocytic syndrome. Lancet Infect Dis 2007; 7:814–22.
5.
Gould CV, Sniegowski PD, Shchepetov M, Metlay JP, Weiser JN. Identifying mutator
phenotypes among fluoroquinolone-resistant strains of Streptococcus pneumoniae using
fluctuation analysis. Antimicrob Agents Chemother 2007;51:3225-3229.
6.
Gould CV. Pathogenesis and epidemiology of C. difficile infection. In: APIC Guide to
Elimination of Clostridium difficile Transmission in Healthcare Settings, 2008.
7.
Gould CV, McDonald LC. Clostridium difficile colitis: bench to bedside review. Crit Care
2008;12:203.
8.
Hidron AI, Schuetz AN, Nolte FS, Gould CV, Osborn MK. Daptomycin resistance in
Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 2008; 61: 1394-96.
9.
Blossom DB, Kallen AJ, Elward A, Perkins KM, Jaeger JL, Kurkjian KM, Schillie SF, Shehab N,
Ketterer D, Jones M, Gould CV, Turabelidze G, Nasr M, Dal Pan GJ, Kozlowski S, Austen KF,
Srinivasan A, Arduino MJ, Patel PR MD, Sasisekharan R. National outbreak of adverse reactions
associated with contaminated heparin. N Engl J Med 2008, in press
Other Publications/Book Chapters:
1.
Gould CV, Steinberg JP. Bacterial Cell Wall Inhibitors. In: Minneman K, Wecker L, Lucchesi B.
(eds). Brody’s Human Pharmacology. 4th edition. Philadelphia. Elsevier
2.
Gould CV, Maslow J. Epidemiologic Typing Systems. In: Lautenbach E, Woeltje K eds.
Practical Handbook for Hospital Epidemiologists, 2nd Edition. Slack Inc, 2004.
3.
Gould CV, Lautenbach E. Meningitis and Encephalitis. Evidence Based Infectious Diseases, Loeb
M, Smaill F, Smieja M. (eds.). British Medical Journal, 2004.
Arash Grakoui, PhD
57
Education:
Graduate School:
Fellowship:
Washington University in St. Louis
The Rockefeller University
Hepatitis C virus (HCV) infection chronicity and its detrimental long-term sequelae now comprise the
leading indication for liver transplantation in the United States. There are currently nearly 4 million
HCV carriers in the U.S., an estimated 170 million people worldwide, and in the next few years the
number of annual U.S. deaths from HCV-induced liver cancer may surpass deaths caused by HIV.
The paradoxical observation that HCV establishes a persistent infection despite the presence of
humoral and cellular immune responses has provided the impetus to rigorously explore the host
response to HCV. Our laboratory aims first to understand the role of the immune response in
combating hepatitis C virus infection and second, to elucidate methods of augmenting the natural
immune response to prevent HCV-associated liver disease and cancer.
1.
Grakoui, A., R. Levis, R. Raju, H. V. Huang, and C. M. Rice. A cis-acting mutation in the
Sindbis virus junction region which affects subgenomic RNA synthesis. J Virol. 1989. 63:5216.
2.
Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. Expression and
identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993. 67:1385.
3.
Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993.
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinasedependent polyprotein cleavage sites. J Virol 1993. 67:2832.
4.
Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993. A second
hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A. 1993. 90:10583.
5.
Grakoui, A., L. F. VanDyk, S. F. Dowdy, and P. M. Allen. Molecular basis for the lack of T cell
proliferation induced by an altered peptide ligand. Int Immunol. 1998. 10:969.
6.
Grakoui, A., D. L. Donermeyer, O. Kanagawa, K. M. Murphy, and P. M. Allen. 1999. TCRindependent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell
polarization. J Immunol 1999. 162:1923.
7.
Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin.
The immunological synapse: a molecular machine controlling T cell activation. Science 1999.
285:221.
8.
Grakoui, A., N. H. Shoukry, D. J. Woollard, J. H. Han, H. L. Hanson, J. Ghrayeb, K. K. Murthy,
C. M. Rice, and C. M. Walker. HCV persistence and immune evasion in the absence of memory T
cell help. Science. 2003. 302:659.
9.
Grakoui, A., E.J. Wherry, H.L. Hanson, C.M. Walker, and R. Ahmed. Turning on the off switch:
Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. Hepatology.
2006. 45: 468-472
10.
Radziewicz, H., C.C. Ibegbu, M.L. Fernandez, K.A. Workowski, K. Obideen, M. Wehbi, H.L.
Hanson, D. Steinberg, J.P., Masopust, E.J. Wherry, J.D. Altman, B.T. Rouse, G.J. Freeman, R.
58
Ahmed and Grakoui, A. Liver infiltrating lymphocytes in chronic human HCV infection display
an exhausted phenotype with high PD-1 and low CD127 expression. J Virol. 2007. 81: 2545.
11.
Mateu, G., R. O. Donis, T. Wakita, J. Bukh, and A. Grakoui. Intragenotypic JFH1 based
recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell
death. Virology 2008; 376:397-407.
12.
Radziewicz, H., C. C. Ibegbu, H. Hon, M. K. Osborn, K. Obideen, M. Wehbi, G. J. Freeman, J. L.
Lennox, K. A. Workowski, H. L. Hanson, and A. Grakoui.. Impaired HCV specific effector
CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and
in the liver during the chronic phase of infection. J Virol doi 2008;10.1128/JVI.01075-08
13.
Uebelhoer, L., J. H. Han, B. Callendret, G. Mateu, N. H. Shoukry, H. L. Hanson, C. M. Rice, C.
M. Walker, and A. Grakoui. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked
to maintenance of viral fitness. PLoS Pathog 2008; 4:e1000143
Clifford Gunthel, MD
Education:
Medical School:
Internship and Residency:
Chief Resident:
Fellowship:
Emory University Affiliated Hospitals
Crawford Long Hospital, Atlanta, GA
Infectious Diseases, Emory University School of
Medicine; Hematology-Oncology, University of
California,
San Francisco
The pathogenesis and clinical management of HIV-associated malignancies. With special interest in
the epidemiology and biology of human herpes virus 8 as it relates to Kaposi’s sarcoma and primary
effusion lymphomas. Also with interest in the clinical management of AIDS-associated high-grade
lymphomas.
1.
Walker BF, Gunthel CJ, Bryan JA, Watts NB, Clark RV: Disseminated cryptococcosis in an
apparently normal host presenting s primary adrenal insufficiency: Diagnosis by fine needle aspiration.
Am J Med 1989; 86(6):715-717.
2.
Gunthel CJ, Ng V, McGrath M, Herndier B, Shiramizu B: Association of Epstein-Barr virus types 1
and 2 with acquired immunodeficiency syndrome-related central nervous system lymphomas. Blood
1994; 83:618.
3.
Gunthel CJ and Northfelt DW: Common cancers not associated with immunodeficiency in persons
with HIV infection: epidemiology, clinical features, and therapy. Oncology 1994; 8(7):59-64.
4.
Gunthel CJ, Ng VL, McGrath MS, Herndier BG: Clonal origin of multicentric primary central
nervous (CNS) AIDS-related lymphomas. Blood (supp) 1994; 84(10):2413.
5.
Ng VL, Dimaid JM, Hurt MH, Gunthel CJ, Lyerly HK, McGrath MS: Pathogenesis of transplant59
associated B-cell lymphomas differ from those associated with AIDS. Blood (supp) 1994;
84(10):2428.
6.
Gunthel CJ and Perlino CA. Abdominal Pyogenic Abscess. Medicine for the Practicing
Physician. J. Willis Hurst (ed). Appleton & Lange 1996, p. 350-352.
7.
Gunthel CJ and Perlino CA. Appendicitis. Medicine for the Practicing Physician. J. Willis
Hurst (ed). Appleton & Lange 1996, p. 352-354.
8.
Gunthel CJ and del Rio C. Human T-cell Lymphotrophic virus type 1 infections. Medicine for
the Practicing Physician. J. Willis Hurst (ed). Appleton & Lange 1996, p. 514-517.
Cole JL, Marzec UM, Gunthel CJ, Karpatkin S. Waller EK, Sundell JB, Lennox, JL, Nichol IL,
Harker LA. Ineffective platelet production in HIV-infected: Blood (supp) 1997; 90(10):1422.
9.
10.
Kelly GD, Ensoli B, Gunthel CJ, Offerman MK: Purified Tat induces inflammatory response
genes in Kaposi’s sarcoma cell. AIDS 1998; 12(14):1753-1761.
11.
Meng YX, Spira TJ, Bhat GJ, Birch C, Druce J, Edlin BR, Edwards R, Gunthel C, Newton R,
Stamey FR, Wood C, Pellett PE: Individuals from North America, Australasia, and Africa are
infected with four different genotypes of human herpesvirus 8. Virology 1999; 261:106-119
12.
Cannon, MJ, Dollard, SC, Black, J, Edlin, B, Hogan, S, Hannah, C, Jaffe, H, Offermann, M, Spira,
T, Pellett, PE, Gunthel, C: Risk factors for Kaposi's sarcoma in men seropositive for both human
herpesvirus 8 and human immunodeficiency virus . AIDS 2003; 17:215-222.
13.
Laney AS, Dollard SC, Jaffe HW, Offerman MK, Spira TJ, Gunthel CJ, Pellett PE, Cannon MJ:
Two-month repeated measures study of human herpesvirus 8 (HHV-8) DNA in HHV-8 and HIVseropositive men with or without Kaposi’s sarcoma. AIDS 2004; 18(13):1819-26.
14.
Laney AS. Cannon MJ. Jaffe HW. Offermann MK. Ou CY. Radford KW. Patel MM. Spira TJ.
Gunthel CJ. Pellett PE. Dollard SC. Human herpesvirus 8 presence and viral load are associated
with the progression of AIDS-associated Kaposi's sarcoma. AIDS 2007; 21(12):1541-5.
James Hughes, MD
Education:
Medical School:
Residency:
Fellowship:
Stanford University School of Medicine
University of Washington
University of Virginia, Division of Infectious Diseases
Professor of Medicine and Public Health
Director, Program in Global Infectious Diseases, School of
Medicine
Director, Southeastern Center for Emerging Biologic Threats,
School of Medicine
Senior Scientific Advisor for Infectious Diseases, International
Association of National Public Health Institutes (IANPHI)
Senior Advisor, Center for Global Safe Water, Rollins School of
Public Health
60
Identifying factors contributing to the emergence and reemergence of infectious diseases, with a
focus on vectorborne and zoonotic diseases, water-related diseases, and antimicrobial resistance;
evaluating policies and practices for preventing, rapidly detecting, and responding to infectious
diseases; and assessing approaches to strengthening global capacity to address microbial threats.
1.
Hughes JM, La Montagne JR. The challenges posed by emerging infectious diseases. ASM News
1994;60:248-250.
2.
McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in
the United States. JAMA 1995;273:214-219.
3.
Schwartz DA, Bryan RT, Hughes JM. Pathology and emerging infections—Quo vadimus? Am J
Pathol 1995;147:1525-1533.
4.
Tenover FC, Hughes JM. The challenges of emerging infectious diseases: Development and spread of
multiply-resistant bacterial pathogens. JAMA 1996;275:300-304.
5.
Berkelman RL, Pinner RW, Hughes JM. Addressing emerging microbial threats in the United States.
JAMA 1996;275:315-317.
6.
Hughes JM, Tenover FC. Approaches to limiting emergence of antimicrobial resistance in bacteria in
human populations. Clin Infect Dis 1997;24(Suppl 1):S131-135.
7.
Binder S, Levitt AM, Sacks JJ, Hughes JM. Emerging infectious diseases: Public health issues for the
21st century. Science 1999;284:1311-1313.
8.
Hughes JM. Confronting emerging infectious diseases: The importance of partnerships between
clinical medicine and public health. Academic Medicine 2001;76:1086-1088.
9.
Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL,
Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin, SK, Sejvar, Shepard CW, McConnell
M, Guarner J, Shieh W-J, Malecki JM, Gerberding JL, Hughes JM, Perkins BA, and members of the
Anthrax Bioterrorism Investigation Team. Bioterrorism-related inhalational anthrax: The first 10 cases
reported in the United States. Emerg Inf Dis 2001;7:933-944.
10.
Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential
biological terrorism agents. Emerg Infect Dis 2002;8:225-230.
11.
Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM,
Gerberding J, Hauer J, Hughes JM, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat
K, for the Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: Updated
recommendations for management. JAMA 2002;287:2236-2252.
12.
Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM,
Meyerhoff A, O’Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Hamburg M, Hauer J,
Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM,
Russell P, Tonat K, for the Working Group on Civilian Biodefense. Hemorrhagic fever viruses as
biological weapons: Medical and public health management. JAMA 2002;287:2391-2405.
13.
Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M,
Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR,
Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh
W-J, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K,
61
Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes JM, Fleming D, Koplan JP, Gerberding JL, and
the National Anthrax Epidemiologic Investigation Team. Investigation of bioterrorism-related anthrax,
United States, 2001: Epidemiologic findings. Emerg Infect Dis 2002;8:1019-1110.
14.
McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and
adolescents. JAMA 2002;287:3096-3102.
15.
McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescriptions in ambulatory care settings,
United States, 1992-2000. Emerg Infect Dis 2003;9:432-437.
16.
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim
Wilina, Rollin P, Dowell SF, Ling A-E, Humphrey CD, Shieh W-J, Guarner J, Paddock C, Rota P,
Fields B, DeRisi J, Yang J-Y, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ, and the
SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N
Engl J Med 2003;348:1953-1966.
17.
Pinner RW, Rebmann CA, Schuchat A, Hughes JM. Disease surveillance and the academic, clinical,
and public health communities. Emerg Infect Dis 2003;9:781-787.
18.
Hughes, JM, Koplan KP. Saving lives through global safe water. Emerg Infect Dis 2005. 11:1636-7.
19.
Rodier G, Greenspan AL, Hughes, JM, Heymann DL. The promise of global health security: revised
International Health Regulations and strengthened public health institutes. Emerg Infect Dis 2007;
13:1447-1452.
20.
Barry M, Hughes JM. Talking dirty – the politics of clean water and sanitation. New Engl J Med
2008; 359:784-787.
Jesse T. Jacob, MD
Education:
Medical School:
Fellowship:
University of South Florida
Cleveland Clinic Foundation
Co-Director, Antimicrobial Assistance Program and
Associate Hospital Epidemiologist, Emory
Crawford Long Hospital
Guest Researcher, Division of Healthcare Quality
Promotion, CDC
My clinical research interest is in healthcare associated infections especially nosocomial
bacteremias and device-associated infections such as central line-associated bloodstream
infections and ventilator-associated pneumonias. I am also interested in prevention of infections
with multidrug resistant organisms such as MRSA. One current project is a case-control study to
assess the risk factors, particularly prior healthcare exposure, for community-onset MRSA
bacteremia. Another study plans to investigate the effect of a multi-component intervention in
reducing S. aureus bloodstream infections in hemodialysis patients.
62
1.
Rose DZ, Kedia N, Jacob JT, Tomford JW. A 48-year-old man with acute, 'knife-like' rectal
pain. Cleveland Clinic Journal of Medicine 2006, 73(11):1028-9.
2.
Jacob JT. Infectious diseases (chapter). Rolston DK and Nielsen C, editors. Rapid Review for
USMLE Step 3. New York: Mosby, 2007.
3.
Jacob JT, Franco-Paredes C. The stigmatization of leprosy in India and its impact on future
approaches to elimination and control. PLoS Neglected Tropical Diseases 2008; 2(1):e113.
4.
Whitaker JA, Jacob JT, Little JV, DiazGranados CA. Cytomegalovirus cystitis with bladder wall
dehiscence in a patient with AIDS. AIDS 2008;22(6):795-6.
5.
Jacob JT, Nguyen ML, Ray SM. Male genital tuberculosis. Lancet Infectious Diseases 2008;
8(5):335-342.
6.
Jacob JT, Kozarsky P, Dismukes R, Bynoe V, Margoles L, Leonard M, Tellez I, Franco-Paredes
C. Five-Year Experience with Type 1 and Type 2 Reactions in Hansen’s Disease at a US Travel
Clinic. Journal of the American Society for Tropical Medicine and Hygiene 2008;79(3):452-4.
7.
Franco-Paredes C, Hidron A, Jacob JT, Nicolls D, Kuhar D, Caliendo A. Transplantation and
Tropical Diseases. Lancet Infectious Diseases 2008; (in press).
8.
Jacob JT, Mehta AK, Leonard MK. Acute forms of tuberculosis. American Journal of Medicine
2009;(in press).
John Jernigan, MD, MS
Education:
Medical School:
Graduate School:
Residency:
Chief Resident:
Fellowship:
University of Virginia
Vanderbilt University Department of Medicine
St. Thomas Hospital, Vanderbilt University
Department of Medicine
University of Virginia
Deputy Chief, Prevention and Response Branch
Commander, US Public Health Service Commissioned Corps
Epidemiology of nosocomial infections with and emphasis on the epidemiology of antibiotic resistant gram-positive pathogens such as methicillin-resistant Staphylococcus aureus and
vancomycin-resistant enterococci, including molecular epidemiologic studies; bioterrorismrelated anthrax, Severe Acute Respiratory Syndrome (SARS)
1.
Jernigan JA, Siegman-Igra Y, Guerrant RC, Farr BM. A randomized crossover study of
disposable thermometers for prevention of Clostridium difficile and other nosocomial infections.
Infect Control Hospital Epidemiol 1998; 19:494-99.
63
2.
Keuhnart MJ, Jernigan JA, Pullen A, Rimland D, Jarvis W. Association of mucositis severity and
vancomycin-resistant enterococcal bloodstream infection in hospitalized patients with cancer.
Infect Control Hospital Epidemiol 1999; 20:660-63.
3.
Jernigan JA, Farr BM. The incubation period and sources of exposure for cutaneous
Mycobacterium marinum infection: case report and review of the literature. Clin Infect Dis 2000;
31(2):439-43.
4.
Lee WG. Jernigan JA. Rasheed JK. Anderson GJ. Tenover FC. Possible horizontal transfer of the
vanB2 gene among genetically diverse strains of vancomycin-resistant Enterococcus faecium in a
Korean hospital. J Clin Microbiol 2001; 39(3):1165-8.
5.
Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first
10 cases reported in the United States. Emerg Infect Dis 2001; 7:933--44.
6.
Barakat LMD, Quentzel HA, Jernigan JA, et.al. Fatal Inhalational Anthrax in a 94-Year-Old
Connecticut Woman. JAMA 2002; 287:863-868.
7.
Muto CA. Jernigan JA. Ostrowsky BE. Richet HM. Jarvis WR. Boyce JM. Farr BM. SHEA
guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus
aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
8.
Jernigan JA, Pullen AL, Flowers L, Bell M, Jarvis W. Prevalence of and risk factors for
colonization with methicillin resistant Staphylococcus aureus at the time of hospital admission.
Infect Control Hosp Epidemiol 2003; 409-14.
9.
Jernigan JA, Pullen AL, Flowers L, Bell M, Jarvis W. Prevalence of and risk factors for
colonization with methicillin resistant Staphylococcus aureus in an outpatient populaton. Infect
Control Hosp Epidemiol 2003; 445-50.
10.
Jernigan JA, Low D, Helfand R. An approach to the early recognition of the severe acute
respiratory syndrome: combining clinical and epidemiologic features. Emerg Infect Dis 2004;
10:327-333
11.
Whitener CJ, Park SY, Browne FA, Parent LJ, Julian K, Bozdogan B, Applebaum PC, Chaitram J,
Weigel L, Jernigan JA, Tenover FC, Fridkin SK. Vancomycin-Resistant Staphylococcus aureus
in the Absence of Vancomycin Exposure Clin Infect Dis 2004; 38(8):1049-55.
12.
Jernigan JA. Is the Burden of Staphylococcus aureus Among Patients With Surgical-Site
Infections Growing? Infect Control Hosp Epidemiol 2004;25:457-60.
13.
Jernigan JA, Helfand RF, Parashar UD. Accurate Clincal Prediction Of Severe Acute Respiratory
Distress Syndrome: Are we there yet? Ann Intern Med 2004;141:406-7
14.
DiazGranados C, Jernigan JA. Impact of Vancomycin Resistance on Mortality Among
Neutropenic Patients with Enterococcal Blood Stream Infections. J Infect Dis 2005;191:588-95
15.
Fridkin SK. Hageman JC. Morrison M. Sanza LT. Como-Sabetti K. Jernigan JA. Harriman K.
Harrison LH. Lynfield R. Farley MM. Active Bacterial Core Surveillance Program of the
Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in
three communities. N Eng J Med. 2005; 352:1436-44
16.
DiazGranados C, Zimmer SM, Klein M, Jernigan JA. Comparison of Mortality Associated with
Vancomycin-Resistant and Vancomycin-Susceptible Enterococcal Bloodstream Infections: A
Meta-analysis. Clin Infect Dis 2005; 41:327 33.
64
17.
Huang SS, Rifas-Shiman SL, Pottinger JM, Herwaldt LA, Zembower TR, Noskin GA, Cosgrove
SE, Perl TM, Curtis AB, Tokars JL, Diekema DJ, Jernigan JA, Hinrichsen VL, Yokoe DS, Platt
R. Improving Assessment of Vancomycin-Resistant Enterococci by Routine Screening. J Infect
Dis 2007;195:339-46.
18.
Huang SS, Rifas-Shiman SL, , Warren DK, Clim MW, Wong ES, Cosgrove SE Perl TM,
Pottinger JM Herwaldt LA, Jernigan JA, Tokars JL, Diekema DJ, Hinrichsen VL, Yokoe DS,
Platt R. Improving MRSA Surveillance and Reporting in ICUs. J Infect Dis 2007;195:330-8.
19.
Dedrick RE. Sinkowitz-Cochran RL. Cunningham C. Muder RR. Perreiah P. Cardo DM.
Jernigan JA. Hand hygiene practices after brief encounters with patients: an important
opportunity for prevention. Infect Control Hosp Epidemiol 2007;28(3):341-5.
20.
Muder RM, Cunningham C, McCray E, Squier C, Perreiah P, Jain R, Sinkowitz-Cochran R
Jernigan JA. Implementation of an Industrial Systems-Engineering Approach to Reduce the
Incidence of Methicillin-Resistant Staphylococcus aureus Infection. Infect Control Hosp
Epidemiol 2008;29:702-708.
Rafael L. Jurado, MD
Education:
Medical School:
Residency:
Fellowship:
Universidad de Guayaquil School of Medicine
Assistant Chief of Medicine, VA Medical Center
Staff Physician, Grady Memorial and VA Hospitals
1.
Jurado RL. Iron, infections and the Anemia of inflammation. Clin Infect Dis 1997; 25:888-95.
2.
Jurado RL. Prevencion de infecciones en pacientes inmunodeprimidos. Oncologia 1977; 7:15966.
3.
Jurado RL. Reacciones febriles post-transfusionales. Oncologia 1077; 7:171-76.
4.
Varela N, Bognar M, Agudelo C, Jurado RL. Salycilate toxicity in the older patient. J of Clin
Rheum 1998; 4:1-5.
5.
Jurado RL and Klein S. Infective endocarditis associated with fiberoptic bronchoscopy in an
individual with mitral valve prolapse. Clin Infect Dis 1998; 26:768-9.
6.
Jurado RL , MD, and Del Rio C, MD Nassar G, MD, Jose Navarrete, MD and Pimentel JL. The
low anion gap. Southern Medical Journal 1998; 91:624-630.
7.
Orsetti K, Carpenter S and Jurado R. Cavitary Rhodococcus equi pneumonia in a patient with
gastrectomy. Infect Dis Clin Pract 1998; 7:243-244.
8.
Jurado RL, and Mattix H,. The decreased BUN-creatinine ratio. Accepted for publication in Arch
Intern Med 1998; 158:2509-2511.
65
9.
Jurado RL and Ribeiro M. Is the systemic inflammatory reaction involved in vascular access
thrombosis? S Med J 1996; 92:877-881.
10.
Mansour C, Marathe A, Barnett B and Jurado RL. Recurrent bacteremias associated with TIPSS.
Infect Dis Clin Pract 1999; 8:346-347.
11.
Jurado RL and Franco-Paredes C. Fibrocavitary Pulmonary disease in Ankylosing Spondilitis.
Clin Infec Dis 2001; 32:1062.
12.
Jurado RL. Why we should not order an erythrocyte sedimentation rate? Clin Infec Dis 2001;
33:548-549.
13.
Franco C, MD; Evans, J, MD and Jurado RL. Streptococcus pneumoniae meningitis causing
central Diabetes insipidus. Arch Intern Med 2001; 161:1114-1115.
14.
Jurado RL and Franco-Paredes C. Aspiration pneumonia, a misnomer. Clin Infec Dis 2001;
33:1612-1613.
15.
Franco-Paredes C, Blumberg H, Smith R, Jurado RL. Tuberculosis of the pancreas. Report of
two cases and review of the literature. Am J Med Sci 2002; 323(1):54-58.
16.
Jurado RL Non-bleeding clotting. The role of the Coagulation system in the Systemic
inflammatory reaction. Infect Dis Clin Pract 2001; 10:415-420.
17.
Jurado RL. Comments [to above article]. Infect Dis Clin Pract 2001; 10:420-421.
18.
Franco-Paredes C, Del Rio C, Jurado RL. The Gram stain of the urine. Infect Dis Clin Pract.
2002; 11(9): 561-563.
19.
Carlos Franco-Paredes, Juan C Calle, Jurado RL. Night sweats revisited. Infect Dis Clin Pract
2002; 11: 291-293.
20.
Alexander T. Kessler, MD, A. P. Kourtis MD, PhD, R. Jurado, MD. Lymphoepithelial cyst of the
parotid in HIV infection. Clin Infec Dis.
Keith P. Klugman, MD
Education:
Medical School:
PhD:
Residency:
Fellowship:
University of the Witwatersrand, South Africa
University of the Witwatersrand, South Africa
Johannesburg Hospital, South Africa
Rockefeller University, New York, New York
William H Foege Chair of Global Health,
Rollins School of Public Health.
Director of Respiratory and Meningeal Pathogens Research Unit
of MRC/NICD/Wits, Johannesburg, South Africa
Pneumococcal diseases; epidemiology of antibiotic resistance in pneumococci; vaccines for
bacterial diseases; bacterial/viral interaction in infectious diseases.
Selected publications:
66
1.
McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, Hakenbeck R, Hryniewicz W,
Lefevre JC, Tomasz A, Klugman KP. Nomenclature of major antibiotic - resistant clones of
Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J
Clin Microbiol; 39: 2565 – 2571. Highlighted (2001) in Current Topics of ASM News; 67: 435 –
436 and Journal Highlights of ASM News; 67: 465.
2.
Paterson DL, Ko W–C, von Gottberg A, Casellas AM, Mulazimoglu L, Klugman KP, Bonomo
RA, Rice LB, McCormack JG, Yu VL. Outcome of cephalosporin treatment for serious infections
due to apparently susceptible organisms producing extended - spectrum beta – lactamases:
implications for the clinical microbiology laboratory. J Clin Microbiol 2002.; 39: 2206 – 2212.
3.
Klugman KP. Efficacy of pneumococcal conjugate vaccines and their impact on carriage and
antimicrobial resistance. Lancet Infect Dis 2001; 1: 85 – 91. (Review)
4.
Nicol M, Huebner R, Mothupi R, Kähyty H, Mbelle N, Khomo E, Klugman KP. Haemophilus
influenzae type b conjugate vaccine diluted tenfold in diphtheria – tetanus – whole cell pertussis: a
randomised trial. Pediatr Infect Dis J 2001.; 21: 138 - 141.
5.
Madhi SA, Petersen K, Khoosal M, Huebner RE, Mbelle N, Mothupi R, Saloojee H, Crewe –
Brown H, Klugman KP. Reduced effectiveness of Haemophilus influenzae type b conjugate
vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection.
Pediatric Infect Dis J 2002.; 21: 315 – 321.
6.
Feikin DR, Klugman KP. Historical changes in the pneumococcal serogroup distribution:
implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002.; 35: 547 – 555.
7.
Klugman KP. Bacteriologic evidence of antibiotic failure in pneumococcal lower respiratory tract
infections. Eur Respir J 2002.; 20 Suppl 36: 3s – 8s. (Review)
8.
Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, for the Vaccine
Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those
without HIV infection. New Engl J Med 2003; 349: 1341 - 1348.
9.
Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman
DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP for the International Pneumococcal
Study Group. An international prospective study of pneumococcal bacteraemia: correlation with in
vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230 –
237.
10.
Klugman KP, Greenwood BM. Pneumococcal diseases. In Oxford Textbook of Medicine - 4th
Edition, Warrell DA, Cox TM, Firth JD (Eds.), Oxford University Press 2003, Oxford, UK, pp
461–470. (Invited review)
11.
Paterson DL, Ko W-C, von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L,
Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, Mc Cormack JG, Yu VL.
International prospective study of Klebsiella pneumoniae bacteremia: implications of extendedspectrum ß-lactamase production in nosocomial infections. Annals Intern Med 2004; 140:26-32.
12.
Buie KA, Klugman KP , von Gottberg A, Perovic O, Karstaedt A, Crewe – Brown HH, Madhi
SA, Feldman C. Gender as a risk factor for both antibiotic resistance and infection with pediatric
serogroups in HIV- infected and -uninfected adults with pneumococcal bacteremia. J Infect Dis
2004; 189:1996-2000.
13.
Madhi S, Klugman KP, The Vaccine Trialist Group. A role for the pneumococcus in viral
pneumonia. Nature Med 2004; 10: 811-3.
67
14.
Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM,
Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC. International
Pneumococcal Study Group Combination antibiotic therapy lowers mortality in severely ill
patients with pneumococcal bacteremia. Amer J Resp Crit Care Med 2004; 170: 440 – 444.
15.
Hausdorff WP, Feikin DR, Klugman KP . Epidemiological differences among pneumococcal
serotypes. Lancet Infect Dis 2005; 5: 83 – 93. (Review)
16.
Madhi SA, Heera JR, Kuwanda L, Klugman KP. Use of procalcitonin and C-reactive protein to
evaluate vaccine efficacy against pneumonia. PLOS Med 2005; 2: 147 - 151.
17.
Madhi SA, Kuwanda L, Cutland C, Klugman KP . The impact of a 9-valent pneumococcal
conjugate vaccine on the public health burden of pneumonia in HIV infected and -uninfected
children. Clin Infect Dis 2005; 40: 1511 – 1518.
18.
Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Pablos-Mendez A,
Klugman KP. Antibacterial resistance in developing countries. Part I: recent trends and current
status. Lancet Infect Dis 2005; 5: 481 - 493. (Review)
19.
Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Pablos-Mendez A,
Laxminarayan R. Antibacterial resistance in developing countries. Part II: strategies for containment.
Lancet Infect Dis 2005; 5: 568 - 580. (Review)
20.
Klugman KP, Madhi SA. Pneumococcal vaccines and flu preparedness. Science 2007; 316: 49 – 50.
Phyllis E. Kozarsky, MD
Education:
Medical School:
Residency:
Fellowship:
Albert Einstein College of Medicine
Albert Einstein College of Medicine and Bronx Municipal
Hospital Center
Adjunct Assistant Professor of International Health
Director of Travel Well, International Travelers Medical Clinic
at Crawford Long Hospital
Staff Physician, Crawford Long & Emory Hospitals
Expert Consultant, Division of Global Migration and Quarantine,
Centers for Disease Control and Prevention
Current research efforts have primarily focused on issues in clinical tropical medicine and
traveler’s health, and include: several short-term studies performed by those in training: For
example, epidemiologic studies of travelers and post-travel evaluations, and analyses using data
from the GeoSentinel surveillance system (through a cooperative agreement with CDC).
1.
Keystone JS, Kozarsky PE, Freedman DO. Internet and computer-based resources for medical
practitioners. Clin Infect Dis 2001; 32:757-765.
68
2.
Martin M, Weld LH, Tsai TF. et al. Advanced age as a risk factor for illness temporarily
associated with yellow fever vaccination. Emerg Infect Dis 2001; 7:945-951.
3.
Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis and treatment
of anthrax. Emerg Infect Dis 2002; 8:222-225.
4.
Bettinger J, Kozarsky PE. Defining short and long term travel. J Trav Med 2002; 9:111-112
5.
Kozarsky PE, Keystone JS. Body of knowledge for the practice of travel medicine. J Trav Med
2002; 9:112.
6.
Leder K, Sundararajan V, Weld L, Pandey P, Brown G, Torresi J, and the GeoSentinel
Surveillance Group. Respiratory tract infections in travelers: a review of the GeoSentinel
surveillance network. Clin Infect Dis 2003; 36:399-406.
7.
Schwartz E, Parise M, Kozarsky PE, Cetron MS. Delayed onset of malaria - implications for
chemoprophylaxis in travelers. New Eng J Med 2003; 349:1510-1516.
8.
Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, Keystone JS,
Pandey P, Cetron MS; GeoSentinel Surveillance Network. Spectrum of disease and relation to
place of exposure among ill returned travelers. N Engl J Med. 2006 Jan 12;354(2):119-30.
Erratum in: N Engl J Med 2006;355:967
9.
Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia
FJ, Fischer PR, Ryan ET; Infectious Diseases Society of America. The practice of travel medicine:
guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43: 1499-539.
10.
Kozarsky P. The Body of Knowledge for the practice of travel medicine – 2006. J Travel Med.
2006; 13: 251-4.
11.
Schwarrtz E, Kozarsky P, Wilson M, Cetron M. Schistosome infection among river rafters on
Omo River, Ethiopia. J Travel Med 2005;12:3-8.
12.
Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow Fever and Japanese encephalitis
vaccines: indications and complications. Infect Dis Clin North Am 2005;19:151-68.
13.
Franco-Paredes C, Dismukes R, Nicolls D, Workowski K, Rodriguez-Morales A, Wilson M, Jones
D, Manyang P, Kozarsky P. Persistent and untreated tropical infectious diseases among Sudanese
refugees in the United States. American J Trop Med Hyg. 2007;77:633-5.
14.
Davis XM, MacDonald S, Borwein S, Freedman DO, Kozarsky PE, von Sonnenburg F, Keystone
JS, Lim PL, Marano N. for the GeoSentinel Surveillance Network. Health risks in travelers to
China: the GeoSentinel experience and implications for the 2008 Beijing Olympics. Am J Trop
Med Hyg. 2008;79:4-8.
15.
Baggett HC, Kozarsky P, Arguin P, Reed C. Comparison of Health Maintenance
Recommendations for International Travelers among Three Authoritative Sources. J Travel Med.
In press.
16.
Baggett HC, Graham S, Kozarsky P, Gallagher N, Blumensaadt S, Bateman J, Edelson PJ,
Arguin PM, Steele S, Russell M, Reed C. Pre-travel health preparation among US residents
traveling to India to visit friends and relatives: importance of ethnicity in defining VFR. J Travel
Med. In press.
69
17.
Strikas RA, Kozarsky PE, Reed C, Kapella BK, Freedman DO. Should health care providers in
the US have access to influenza vaccines formulated for the Southern hemisphere? J Travel Med.
In press.
18.
Nicolls DJ, Weld LH, Schwartz E, Reed C, Freedman DO, von Sonnenburg F, Kozarsky P.
Characteristics of schistosomiasis in travelers reported to the GeoSentinel surveillance network
1997-2008. American J Trop Med Hyg. In press.
19.
Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett
ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB. Adverse events reports
following yellow fever vaccination. Submitted to Vaccine.
Other Publications
Co editor – U.S. Public Health Service. CDC. Health Information for International Travel 2008
Co-Editor (Keystone J, Kozarsky P, Freedman D, Connor B, Nothdurft H),
Travel Medicine, Mosby (Elsevier), London.Travel Medicine. 2008. Elsevier. Edinburgh, 2008.
David Kuhar, MD
Education:
Medical School:
Residency:
Fellowship:
New York University
Mount Sinai Medical Center
Instructor of Medicine
My research interests are in HIV drug resistance and in clinical trials of new drugs for the
treatment of HIV infection. Also, I'm interested in outpatient parenteral antimicrobial
administration outcomes.
Jeffrey L. Lennox, MD
Education:
Medical School:
Residency:
Fellowship:
University of Colorado
Walter Reed Army Medical Center
Walter Reed Army Medical Center
Emory Chief of Service for Infectious Diseases,
Medical Director, Infectious Disease Program,
Grady Health System
My current research focus is on testing new and improved treatments for HIV infection. I am
also interested in identifying factors which improve adherence and compliance to antiretroviral
therapy.
70
1.
Lawn SD, Subbarao S, Wright TC, Evans-Strickfaden T, Ellerbrock TV, Lennox JL, Butera ST,
Hart CE. Correlation Between HIV-1 RNA Levels in the Female Genital Tract and Immune
Activation Resulting from Ulceration of the Cervix. J Infect Dis 2000; 181:1950-56.
2.
Navin T, Rimland D, Lennox JL, Jernigan J, Cetron M, Hightower A, Roberts JM, Kaplan JE.
Risk Factors for Community Acquired Pneumonia in HIV-infected Adults. J Infect Dis 2000;
181:158-64.
3.
Eron JJ, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, D’Aquila RT, Rogers MD,
Tung R, Murphy RL. The Effects of Protease Inhibitor Therapy on HIV-1 Levels in Semen. J
Infect Dis 2000; 181:1622-8.
4.
Wright TC, Subbarao S, Ellerbrock TV, Lennox JL, Evans-Strickfaden T, Smith DG, Hart CE.
Treatment of Cervical Intraepithelial Neoplasia Increases Vaginal HIV RNA Levels. American
Journal of Obstetrics and Gynecology 2001; 184:1-7.
5.
Ellerbrock TV, Lennox JL, Clancy KA, Schinazi RF, Wright TC, Pratt-Palmore M, EvansStrickfaden T, Schnell C, Pai R, Conley LJ, Parrish-Kohler EE, Bush TJ, Tatti K, Hart CE.
Cellular Replication of HIV-1 Occurs in Vaginal Secretions. J Infect Dis 2001; 184:28-36.
6.
Pilcher CD, Shugars DC, Fiscus SA, Menses P, Giner J, Dean B, Robertson K, Hart CE, Lennox
JL, Eron JJ, Hicks CB. Viral Dynamics in Body Fluids During Primary HIV Infection. AIDS
2001; 15:837-45.
7.
Rimland D, Navin TR, Lennox JL, Jernigan JA, Kaplan J, Erdman D, Morrison CJ, Wahlquist
SP; Pulmonary Opportunistic Infection Study Group. A Prospective Study of Etiologic Agents of
Community-Acquired Pneumonia in HIV-Infected Patients. AIDS 2002: 16: 85-95.
8.
Villanueva J, Lennox JL, Ellerbrock TV, Wright TC, Pratt-Palmore M, Schnell C, Conley LJ,
Hart CE. The Menstrual Cycle Does not Affect HIV-1 Levels in Vaginal Secretions. J Infect Dis
2002; 185:170-7.
9.
Leonard M, Blumberg H, Lennox JL, Horsburgh CR. Increased Survival of Persons with
Tuberculosis and Human Immunodeficiency Virus Infection, 1991-2000. Clin Infect Dis 2002:
34:1002-7.
10.
Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani F, Lennox JL, Dube MP,
MacGregor RR, Currier JS and the ACTG 393 Study Team. A Study of Discontinuing
Maintenance Therapy in HIV-infected Subjects with Disseminated Mycobacterium avium
complex (DMAC): ACTG 393. J Infect Dis 2003, 187:1046-52.
11.
Weintrob AC, Giner J, Menezes P, Patrick E, Benjamin DK, Lennox JL, Pilcher CD, Eron J,
Hicks C. Infrequent Diagnosis of Primary HIV Infection: Missed Opportunities in Acute Care
Settings. Arch of Intern Med 2003, 163:2097-2100.
12.
Freel SA, Fiscus SA, Pilcher CD, Menezes P, Giner J, Patrick E, Lennox JL, Hicks CB, Eron JJ,
and Shugars DC. Envelope diversity, co receptor usage and syncytium-inducing phenotype of
HIV-1 variants in oral fluids and blood during primary infection. AIDS 2003, 17:1-9.
13.
Cummins JE, Villanueva JM, Evans-Strickfaden T, Abner SR, Bush TJ, Green TA, Lennox JL,
Wright T, Folks TM, Hart CE, Dezzutti CS. Detection of infectious HIV-1 in female genital
secretions using a short-term culture method. J Clin Microbiol 2003, 41:4081-8.
14.
Sullivan ST, Mandava U, Evans-Strickfaden T, Lennox JL, Ellerbrock TV Hart C. Diversity,
71
Divergence, and Evolution of Cell-Free HIV Type 1 in Vaginal Secretions and Blood of
Chronically Infected Women: Associations with Immune Status. J Virol 2005, 79:9799-9809.
15.
Cummins JE Jr, Christensen L, Lennox JL, Bush TJ, Wu Z, Malamud D, Evans-Strickfaden T,
Siddig A, Caliendo AM, Hart CE, Dezzutti CS. Mucosal innate immune factors in the female
genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS
Research and Human Retroviruses 2006, 22:788-9.
16.
Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A,
Lawrence J, Pollard RB, El Habib R, Sahner L, Fox L, Aga E, Bosch RJ, Mitsuyasu R for the
ACTG A5024 Protocol Team. A Phase II Randomized, Partially-Blinded Trial of Antiretroviral
Therapy (ART), HIV-specific Immunizations, and IL-2 Cycles to Promote Efficient Control of
Viral Replication (ACTG A5024). J Infect Dis 2006,194(12):1672-6.
17.
Vazquez JA , Skiest D.J, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and Efficacy
of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal
Candidiasis in Patients with HIV Infection. HIV Clinical Trials 2007, 8(2): 86 – 97.
18.
Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/Ritonavir
Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From TwiceDaily to Once-Daily Therapy. J Clin Pharmacol 2007, Jul 5;
19.
Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J,
and Amara RR. HIV-1 Controllers but not Non-Controllers Maintain Triple Cytokine Coexpressing CD4 T Cells. J. Virology 2007; 81:12071-6.
20.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox
JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan
DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ,
Nessly ML, DiNubile MJ, Isaacs RD, Nguyen B-Y, and Teppler H for the BENCHMRK Study
Teams. Efficacy and Safety Of The HIV-Integrase-Inhibitor Raltegravir (MK-0518) Combined
With Optimized Background Therapy In Treatment-Experienced Patients With Unsuppressed
Multi-Drug Resistant HIV-1 Infection- Primary Results of the BENCHMRK 1 and 2 Phase III
Trials. N Engl J Med 2008; 359:339-354
George Marshall Lyon, III, MD
Education:
Medical School:
Graduate School:
Training:
Visiting Scientist:
Clinical Fellow, ID:
EIS Officer:
Internal Medicine &
Pediatric Residency:
Marshall University School of Medicine, Huntington, WV
Harvard University School of Medicine, Boston, MA – MMSc
Fellow, Clinical Investigator
Harvard-MIT Health Sciences and Technology-Beth Israel
Deaconess Medical Center, in collaboration with Pfizer, Inc.
Whitehead Institute for Biomedical Research, Fink Lab
Massachusetts General Hospital and Brigham and Women’s
Hospital combined program. Boston, MA
Public Health Service, Centers for Disease Control and
Prevention, Atlanta, GA
Duke University Medical Center, Durham, NC
72
Guest Researcher, Centers for Diseases Control & Prevention
Research Interests:
Clinical research interests include: The epidemiology and prevention of candidiasis in high risk
patient populations; the detection, prevention, and treatment of infections in solid organ transplant
recipients. Novel diagnostic techniques for invasive fungal infections, and mechanisms of
antifungal resistance among Candida albicans.
Basic/translational research interests include : the virulence, pathogenesis and genetic subtyping
of Candida albicans using DNA microarrays; antifungal susceptibility testing of fungal isolates.
Mechanisms of antifungal resistance among Candida species using DNA microarrays.
1.
Lyon GM, Alspaugh JA, Meredith FT, Harrell LJ, Tapson V, Davis RD, Kanj SS. Mycoplasma
hominis pneumonia complicating bilateral lung transplantation: case report and review of the
literature. Chest 1997; 112:1428 32.
2.
CDC. Outbreak of acute febrile illness among athletes participating in triathlons--Wisconsin and
Illinois, 1998. MMWR 1998; 47:585-8.
3.
CDC. Update: Leptospirosis and Unexplained acute febrile illness among athletes participating in
triathlons -- Illinois and Wisconsin, 1998; 47:673-6.
4.
CDC. Bioterrorism alleging use of anthrax and interim guidelines for management – United
States, 1998. MMWR 1999; 48:69-74.
5.
CDC. Gastrointestinal basidiobolomycosis - Arizona. MMWR 1999; 48:710-4.
6.
Lyon GM, Smilack JD, Komatsu KK, Pasha TM, Leighton JA, Guarner J, et al. Gastrointestinal
basidiobolomycosis in Arizona: Clinical and epidemiologic analysis/characteristics and review of
the literature. Clin Infect Dis 2001; 32:1448-55.
Hajjeh RA, Lyon GM. Epidemiology of Candida infections in the intensive care unit: North
American perspective. In Barnes RA, Warnock DW. Eds. Fungal infection in the intensive care
unit. Norwell, MA Kluwer Academic Publishers, 2002:1-12.
7.
8.
Lyon GM, Zurita S, Casquero J, Holgado W, Guevara J, Brandt ME, et al. Population-based
surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis
in Peru. Clin Infect Dis 2003; 36:34-9.
9.
Lyon GM, Bravo AV, Espino A, et al. Histoplasmosis associated with exploring a bat-inhabited
cave in Costa Rica, 1998-1999. Am J Trop Med Hyg 2004; 70:438-42.
10.
Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan MA,
et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of
isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin
Microbiol 2004; 42:1519-27.
11.
Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, et al. An immune
reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ
transplant recipients. Clin Infect Dis 2005;40:1756-61.
12.
Cano MV, Perz JF, Craig AS, Liu M, Lyon GM, Brandt, et al. Candidemia in pediatric outpatients
receiving home total parental nutrition. Med Mycol 2005;42:219-25.
73
13.
Saha DC, Goldman DL, Shao X, Dasadevall A, Husain S, Limaye AP, Lyon M, Somani J, Pursell
K, Pruett TL, Singh N. Serologic evidence for reactivation of cryptococcosis in solid-organ
transplant recipients. Clin Vaccine Immunol 2007; 14:1550-4.
14.
Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del
Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil
AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA,
Fisher RA, Hietman J, Albert ND, Wagener MM, Singh N. Calcineurin inhibitor agents interact
synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates:
correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob
Agents Chemother 2008; 52:735-8.
15.
Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, Wannemuehler KA, Fridkin SK,
Park BJ. Comparison of the use of administrative data and an active system for surveillance of
invasive aspergillus. Infect Control Hosp Epidemiol 2008; 29:25-30.
16.
Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm
GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL,
Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA,
Hietman J, Wagener MM, Husain S. Pulmonary cryptococcosis in solid organ transplant
recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46:e12-8.
17.
Naik PM, Lyon GM, Ramirez A, Lawrence EC, Neujahr DC, Force S, Pelaez A. Dapsoneinduced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant, 2008; In press.
John E. McGowan, Jr, MD
Education:
Medical School:
Residency:
EIS Officer:
Research Fellow in ID:
Boston City Hospital, Harvard Medical Service
Centers for Disease Control and Prevention
Boston City Hospital, Harvard Medical Service
Director, MD-MPH Program, Emory University Schools of
Medicine and Public Health
Antimicrobial resistance and usage practices; relationship of antimicrobial use and resistance;
epidemiology and mechanisms of antimicrobial resistance, especially those associated with the
healthcare setting; Infectious disease epidemiology.
Selected Publications 2006-2008:
1.
Rao AN, Barlow M, Clark LA, Boring JR III, Tenover FC, McGowan JE Jr. Class 1 integrons in
resistant Escherichia coli and Klebsiella spp, US hospitals. Emerg Infect Dis 2006; 12: 10121014.
2.
Raney PM, Tenover FC, Carey RB, McGowan JE Jr, Patel JB. Investigation of inducible
clindamycin and telithromycin resistance in isolates of β-hemolytic streptococci. Diagn Microbiol
Infect Dis 2006; 55: 213-218.
74
3.
Rowe SY, Olewe MA, Kleinbaum DG, McGowan JE Jr, McFarland DA, Rochat R, Deming MS.
The influence of observation and setting on community health workers’ practices. Int J Quality
Health Care 2006; 18: 299-305.
4.
Tenover, FC, Kalsi RK, Williams PP, CareyRB, Stocker S, Lonsway D, Rasheed JK, Biddle JW,
McGowan JE Jr., Hanna B. Carbapenem resistance in Klebsiella pneumoniae not detected by
automated susceptibility testing. Emerg Infect Dis 2006; 12: 1209-13.
5.
Wu JH, Howard DH, McGowan JE Jr, Turpin RS, Hu XH. Adherence to Infectious Diseases
Society of America guidelines for empiric therapy for patients with community-acquired
pneumonia in a commercially insured cohort. Clin Therapeutics 2006; 28: 1451-61.
6.
Jevitt LA, Thorne GM, Traczewski MM, Jones RN, McGowan JE Jr, Tenover FC, Brown SD.
Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycinsusceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol
2006; 44: 3098-3104.
7.
Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC,
Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooten TM. Infectious
Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for
developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;
44: 159-177.
8.
Stone ND, O’Hara CM, Williams PP, McGowan JE Jr, Tenover FC. Comparison of disk
diffusion, VITEK 2, and broth microdilution antimicrobial susceptibility testing results for unusual
species of Enterobacteriaceae. J Clin Microbiol 2007; 45: 340-346.
9.
Rowe SY, Kelly JM, Olewe MA, Kleinbaum DG, McGowan JE Jr, McFarland DA, Rochat R,
Deming MS. Effect of multiple interventions on community health workers' adherence to clinical
guidelines in Siaya district, Kenya. Trans R Soc Trop Med Hyg 2007; 101: 188-202.
10.
Tenover FC, Vaughn RR, McDougal LK, Fosheim GE, McGowan JE Jr. Multiple Locus
Variable Number Tandem Repeat Assay Analysis of Methicillin-Resistant Staphylococcus aureus
Strains. J Clin Microbiol 2007; 45: 2215-2219.
11.
Rowe SY, Olewe MA, Kleinbaum DG, McGowan JE Jr, McFarland DA, Rochat R, Deming MS.
Longitudinal analysis of community health workers’ adherence to treatment guidelines. Trop Med
Intl Health 2007; 12: 651-663.
12.
Tenover FC, Williams PP, Stocker S, Thompson A, Clark LA, Limbago B, Carey RB, Poppe SM,
Shinabarger D, McGowan JE Jr. Accuracy of six antimicrobial susceptibility methods for testing
linezolid against staphylococci and enterococci. J Clin Microbiol 2007; 45: 2917-2922.
13.
Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L. Antimicrobial resistance prevention
initiative - an update: proceedings of an expert panel on resistance. Am J Med 2007; 120(7): S4S25 (published simultaneously in Amer J Infection Control 2007; 35: S1-S23).
14.
Srinivasan V, McGowan JE Jr, McAllister S, Tenover FC. In vitro activity of ceftobiprole
against coagulase-negative staphylococci isolated in the USA. Internat J Antimicrob Agents 2008;
31: 294-296.
15.
Barlow M, Reik RA, Jacobs SD, Medina M, Meyer MP, McGowan JE Jr, Tenover FC. High rate
of mobilization for blaCTX-Ms. Emerg Infect Dis 2008; 14: 423-428.
16.
Stone ND, Lewis DR, Lowery HK, Darrow LA, Kroll CM, Gaynes RP, Jernigan JA, McGowan
JE Jr, Tenover FC, Richards CL. Importance of bacterial burden among methicillin-resistant
75
Staphylococcus aureus carriers in a long-term care facility. Infect Control Hosp Epidemiol 2008;
29: 143-148.
17.
Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE Jr, Cannon MJ. Influence of sexual
activity on cytomegalovirus seroprevalence in the United States, 1988-1994. Sexually Transmitted
Diseases 2008; 35: 472-479.
18.
Kollef MH, Morrow LE, Baughman PR, Carven DE, McGowan JE Jr, Micek ST, Niederman
MS, Ost D, Paterson DL, Segreti J. Health care-associated pneumonia (HCAP): a critical appraisal
to improve identification, management, and outcomes. Proceedings of the HCAP summit. Clin
Infect Dis 2008; 46: S296-S334.
19.
DiazGranados CA, Cardo DM, McGowan JE Jr. Antimicrobial resistance: international control
strategies, with a focus on limited resource settings. Internat J Antimicrob Agents 2008; 32: 1-9
20.
Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE Jr, Cannon MJ. Cytomegalovirus
seroprevalence and childhood sources of infection: A population-based study among preadolescents in the United States. J Clin Virol (in press).
Abeer A. Moanna, MD
Education:
Medical School:
Residency:
Chief Resident:
Fellowship:
American University of Beirut, Lebanon
Emory University Hospital
HIV immunopathogenesis and HIV clinical/translational research. During fellowship, my
research in the laboratory of Guido Silvestri M.D. at the National Primates Center at Emory
University (Yerkes) involved looking at the role of immune activation in HIV pathogenesis
through studying the role of IL-2 administration to HIV infected subjects and its effect on
markers of immune activation.
Currently, I am working on a study of “Inflammatory markers and biomarkers of endothelial cell
activation in HIV-infected subjects”. Little is known about the role of inflammatory markers in
HIV-infected patients with or at risk of CVD. The specific aims of this study are to explore the
role of inflammatory markers in HIV+ patients. Highly sensitive C-reactive protein (hsCRP) will
be the primary inflammatory marker measured in these analyses. CD40 ligand, intracellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasminogen
activator inhibitor-1 (PAI-1) will also be analyzed as additional prototypical markers of
inflammation.
1.
Moanna A, Dunham R, Paiardini M, Silvestri G: “CD4+ T cell depletion in HIV infection: Killed
by friendly fire?” Current HIV/AIDS Reports 2005; 2(1):16-23.
76
2.
Moanna A, Lennox J, Flenaugh E, Moss M, Vuchetich A. “Severe recurrent respiratory
papillomatosis in an HIV-infected adult on HAART.” Journal of Bronchology 2005; 12(4): 210213.
3.
Dunham R, Pagliardini P, Gordon S, Sumpter B, Engram J, Moanna A, Paiardini M, Mandl JN,
Lawson B, Garg S, McClure H, Xu YX, Ibegbu C, Easley K, Katz N, Pandrea I, Apetrei C, Sodora
DL, Staprans SI, Feinberg MB, Silvestri G: “The AIDS-resistance of naturally SIV-infected sooty
mangabeys is independent of cellular immunity to the virus.” Blood 2006; 108(1): 209-217.
4.
Moanna A, Rahul Bajaj, Carlos del Rio. “Emphysematous cholecystitis due to Salmonella derby”.
Lancet Infectious Diseases 2006; 6:118-20.
5.
Rouphael N, Moanna A, Rimland D. “Seronegative Syphilis in an AIDS Patient: Case Report
and Review of the Literaure”. Infectious Diseases in Clinical Practice 2008; 16(5): 330-332.
Alberto Moreno, MD
Education:
Medical School:
Fogarty Fellowship:
Pontificia Universidad Javeriana, Bogotá, Colombia
New York University School of Medicine, Department of
Medical and Molecular Parasitology, New York, NY
Research and Academic interests:
Malaria Vaccine Development: Design and testing of chimeric constructs as delivery
platforms for effective malaria vaccines. Preclinical assessment of the safety,
immunogenicity and efficacy of malaria vaccines candidates. Cross-sectional studies in
endemic areas of malaria designed to evaluate the natural immunity to malaria vaccine
candidates.
Pathophysiology of severe malaria: Identify molecular mechanisms involved in the
pathogenesis of malarial anemia and coagulopathy. Characterize bone marrow
dysfunction in non-human primate models of severe malaria. Design and testing novel
intervention measures to improve the clinical outcome of malaria.
1.
Patarroyo ME, Romero P, Torres M, Clavijo P, Moreno A, Martinez A, Rodriquez R, Guzman F
and Cabezas E. Induction of protective immunity against experimental infection with malaria
using synthetic peptides. Nature 1987; 328:629-632.
2.
Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R., Franco A,
Murillo LA, Ponton G and Trujillo G. A synthetic vaccine protects humans against challenge with
asexual blood stages of P. falciparum malaria. Nature 1998; 332:158-161.
3.
Rodriguez, R. Moreno A, Guzman F, Calvo M and Patarroyo ME. 1990. Studies in owl monkeys
leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium
falciparum. Am J Trop Med Hyg 43:339-354
77
4.
Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Herrington D and Nardin E. Cytotoxic
CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS
protein. Int Immunol 1991; 3:997-1003.
5.
Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M, Mora AL, Rocha CL,
Alvarado F, Falla JC, Orozco M, Coronell C, Ortega N, Molano A, Velasquez JF, Valero MV,
Franco L, Guzman F, Salazar LM, Espejo F, Mora E, Farfan R, Zapata N, Rosas J, Calvo JC,
Castro J, Quinones T, Nunez F and Patarroyo ME. Safety and immunogenicity of the synthetic
malaria vaccine SPf66 in a large field trial. J Infect Dis 1992; 166:139-144.
6.
Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Sinigaglia F and Nardin E. CD4+ T cell
clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize
polymorphic sequences of the Circumsporozoite protein. J Immunol 1993; 151:489-499.
7.
Moreno A, Rodriguez R, Oliveira GA, Ferreira V, Nussenzweig R, Moya Castro ZR, Calvo-Calle
M and Nardin E. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria
vaccine in Aotus monkeys and mice. Vaccine 1999; 18:89-99.
8.
Puentes F, Guzmán F, Marín V, Alonso C, Patarroyo ME and Moreno A. Leishmania: Fine
mapping of the Leishmanolysin molecule’s Conserved Core domains involved in binding and
internalization. Exp Parasitol 1999; 93:7-22.
9.
Puentes, F., Diaz, D., Hoya, R.D., Gutiérrez, J.A., Lozano, J.M., Patarroyo, M.E. and Moreno A.
Cultivation and characterization of stable Leishmania guyanensis complex axenic amastigotes
derived from infected U937 cells. Am J Trop Med Hyg 2000; 63:102-110.
10.
Kashala, O. Amador, R.L., Valero, M.V., Moreno, A., Barbosa, A., Nickel, B., Daubenberger,
C.A., Guzman, F., Pluschke, G. and Patarroyo, M.E. Safety, tolerability and immunogenicity of
new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with
the immunological adjuvant QS-21. Vaccine 2002; 20:2263-2277.
11.
Caro-Aguilar, I., Rodríguez, A., Calvo-Calle, M., Guzmán, F., De la Vega, P., Patarroyo, M.E.,
Galinski, M.R. and Moreno, A. Plasmodium vivax promiscuous T helper epitopes defined and
evaluated as linear peptide chimera immunogens. Infect Immun 2002; 70:3479-3492.
12.
de Oliveira Ferreira, J., Vargas-Serrato, E., Barnwell, J.W., Moreno A. and Galinski, M.R.
Immunogenicity of Plasmodium vivax Merozoite Surface Protein-9 recombinant proteins
expressed in E. coli. Vaccine 2003; 22:2023-2030.
13.
Tran, TM, Moreno, A., Yazdani, S.S., Chitnis, C.E., Barnwell, J.W., and Galinski. M.R. 2005.
Detection of a Plasmodium vivax erythrocyte binding protein by flow cytometry. Cytometry 63:
59-66.
14.
Tran, T.M., Oliveira-Ferreira J., Moreno, A., Santos, F., Yazdani, S.S., Chitnis, C.E., Altman,
J.D., Meyer, E. V-S, Barnwell, J.W., and Galinski, M.R. Comparison of IgG reactivities to
Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am J Trop Med
Hyg 2005. 73:244-55
15.
Caro-Aguilar, Lapp, S., Pohl, J., Galinski, M.R. and Moreno, A. Chimeric epitopes delivered by
polymeric synthetic linear peptides induces protective immunity to malaria. Microbes Infect.
2005. 7:1324-37.
16.
Moreno, A., Garcia, A., Cabrera-Mora, M., Strobert, E and Galinski, M.R. Case report:
Disseminated intravascular coagulation complicated by peripheral gangrene in a rhesus macaque
(Macaca mulatta) experimentally infected with Plasmodium coatneyi. Am J Trop Med Hyg 2007.
76: 648-654.
78
17.
Jiang, C. G., Charoenvit, Y., Moreno, A., Baraceros, M. F., Banania, G., Richi, N.,
Abot, S.,
Ganeshan, H., Fallarme, V., Patterson, N.B., Geall, A., Weiss, W.R., Strobert, E., Caro-Aquilar,
I., Lanar, D.E., Saul, A., Martin, L.B., Gowda, K., Morrissette, C.R., Kaslow, D.C., Carucci, D.J.,
Galinski, M.R. and Doolan, D.L. 2007. Induction of multi-antigen multi-stage immune responses
against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with
heterologous DNA prime/poxvirus boost immunization. Malaria J. 6: 135
18.
Moreno, A., Caro-Aguilar, I., Yazdani, S.S., Shakri, R., Mukherjee, P., Baniwal, S., Lapp, S.,
Strobert, E., McClure, H., Chitnis, C. and Galinski, M.R. 2008. Preclinical assessment of the
receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in
rhesus macaques. Vaccine 26:4338-4344.
19.
Frevert, U., Moreno, A. Calvo-Calle, M., Klotz, C and Nardin, E. 2008. Imaging effector
functions of human cytotoxic CD4(+) T cells specific for Plasmodium falciparum
circumsporozoite protein. Int J Parasitol. In Press. PMID: 18723023
20.
Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, Santos F, Daniel-Ribeiro CT,
Moreno A, Barnwell JW, Galinski MR, Oliveira-Ferreira J. 2008. Naturally acquired humoral
and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern
Amazon individuals. Vaccine. In Press. PMID: 18832003
Mark Mulligan, MD
Education:
Medical School:
Residency:
Fellowship:
University of Texas Southwestern Medical School, Dallas, TX
University of Alabama at Birmingham
University of Alabama at Birmingham
Executive Director, The Hope Clinic of the Emory Vaccine
Center
Co-Director, Clinical and Translational Research Core, CFAR
Assoc Director for Clinical Trials, The Emory Vaccine Center
Clinical trials and translational studies of vaccines and treatments for infectious diseases affecting
public health. Translational research to understand the basis for protective human immunity to
infectious agents. Clinical and translational research training of a new generation of
vaccinologists.
1.
Mulligan MJ, Kumar P, Hui H, Owens RJ, Ritter GD, Hahn BH, and Compans RW. The env
protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. AIDS Res
Hum. Retro 1990;6:707-720.
2.
Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, Mulligan MJ, Yamshchikov G, Chen D,
Eldridge JH. Protection against vaginal SIV transmission with microencaps. vaccine. Science
1993; 260 (5112): 1323-1327.
79
3.
Goepfert PA, Shaw KL, Ritter GD, Mulligan MJ. A sorting motif localizes the foamy virus
glycoprotein to the endoplasmic reticulum. J. Virol 1997;71:778-784.
4.
Graham BS, McElrath MJ, Connor RL, Schwartz D, Gorse GJ, Keefer MC, Mulligan MJ,
Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB,
Dolin R, Wright PF, Korber BT, Wolf MC, Fast PE, and the AIDS Vaccine Evaluation Group in
collaboration with the Correlates of HIV Immune Protection Group. Analysis of intercurrent HIV1 infection in phase I and II trails of candidate AIDS vaccines. J. Infec. Dis 1998;177:310-319.
5.
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer, MC, Excler J-L, Duliege A-M, Tartaglia
J, Cox WI, McNamara J, Hwang K-L, Bradney A, Montefiori D, and Weinhold K for the NIAID
AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox
(ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers, AIDS
1998;12:2407-2415.
6.
Sabbaj S, Mulligan MJ, Hsieh R-H, Belshe RB, McGhee J, and the NIAID AIDS Vaccine
Evaluation Group. Cytokine profiles in seronegative volunteers immunized with recombinant
canarypox and gp120 prime-boost HIV-1 vaccine. AIDS 2000;14:1365-1374
7.
Goepfert PA, Bansal A, Edwards BH, Ritter GD, Tellez I, McPherson S, Sabbaj S, Mulligan MJ.
A significant number of HIV epitope-specific CTLs detected by tetramer binding do not produce
interferon-g. J Virol 2000;74(21):10249-10255.
8.
Kaslow RA, Rivers C, Tang J, Goepfert PA, Bender TJ, Habib R, Weinhold K, Mulligan MJ.
Polymorphisms in HLA class I genes associated with both favorable prognosis of HIV-1 infection
and positive CTL responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001;
75(18);8681-89.
9.
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE,
Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M,
Goepfert P, and the AIDS Vaccine Evaluation Group. Safety and immunogenicity of a hightitered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1 uninfected
adults: AIDS Vaccine Evaluation Group Protocol 022A. JAIDS 2002; 29(3):254-261.
10.
Sabbaj S, Edwards BH, Ghosh MK, Semrau K, Cheelo S, Thea DM, Kuhn L, Ritter GD,
Mulligan MJ, Goepfert PA, Aldrovandi GM. Human immunodeficiency virus-specific CD8+ T
cells in human breast milk. J Virol 2002; 76(15):7365-7373.
11.
Bansal A, Sabbaj S, Edwards BH, Ritter GD, Perkins C, Tang J, Szinger JJ, Weiss H, Goepfert
PA, Korber B, Wilson CM, Kaslow RA, and Mulligan MJ. T-Cell responses in HIV type 1infected adolescent minorities share similar epitope specificities with whites despite significant
differences in HLA class I alleles. AIDS Res Hum Retro 2003; 19:1017-1026.
12.
Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard
HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, and Celum CL. Breakthrough infections
during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and
booster dose of recombinant gp120 or gp160. J Infect Dis. 2004; 190(5):903-7.
13.
Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ, Sabbaj S, Mulligan MJ,
and Goepfert PA. Paucity of antigen-specific IgA responses in sera and external secretions of
HIV-type 1-infected individuals. AIDS Res Hum Retroviruses. 2004; 20(9):972-88.
14.
Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G, Aldrovandi G, Kaslow RA,
Wilson CM, Mulligan MJ, Kilby JM, Goepfert PA. CD8 T-cell responses in early HIV-1
infection are skewed towards high entropy peptides. AIDS. 2005; 19(3):241-50.
80
15.
Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori D, Ferrari G, Weinhold K,
Smith JM, Amara R, and Robinson HL, for the NIH/NIAID/DAIDS HIV Vaccine Trials
Network. Excellent Safety and Tolerability of the Human Immunodeficiency Virus Type 1
pGA2/JS2 Plasmid DNA Priming Vector Vaccine in HIV-1 Uninfected Adults. AIDS Res Hum
Retro. 2006; 22(7):678-683.
16.
Fu T-M, Dubey S, Mehrotra D, Freed D, Trigona W, Adams-Muhler l, Clair J, Evans T, Steigbigel
R, Jacobson J, Goepfert P, Mulligan M, Kalams S, Rinaldo C, Kalinyak C, Zhu L, Punt K, Guan
L, Long R, Persaud N, Caulfield M, Sadoff J, Emini E, Thaler S, and Shiver J. Evaluation of
Cellular Immune Responses in Subjects Chronically Infected with HIV-1. AIDS Res Hum Retro.
2007; 23(1):67-76.
17.
Russell ND, Graham, BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC,
Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD,
Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L, and the NIAID HIV Vaccine
Trials Unit. Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in
Combination with rgp120. J Acquir Immune Defic Syndr. 2007; 44(2):203-212.
18.
Frew PM, Del Rio C, Clifton S, Archibald ME, Hormes JT, Mulligan MJ. Factors influencing
HIV vaccine community engagement in the Urban South, J Comm Health. 2008; 33:259-269.
19.
Miller JD, Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar
PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD,
Feinberg MB, Ahmed R. Human Effector and Memory CD8+ T Cell Responses to Smallpox and
Yellow Fever Vaccines. Immunity. 2008; 28: 710-722.
20.
Marano, N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H,
Mulligan MJ, Parker SD, Babcock J, Keitel W, Sahly HE, Poland GA, Jacobson RM, Keyserling
HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP. Effects
of a Reduced Dose Schedule and Intramuscular Administration of the Anthrax Vaccine Adsorbed
on Immunogenicity and Safety at 7 Months. In Press, JAMA, 2008
Minh Ly Nguyen, MD, MPH
Education:
Medical School
Residency
Fellowship
Post graduate
Temple University School of Medicine
Lehigh Valley Hospital
Infectious Diseases, University of Pittsburgh
MPH, Rollins School of Medicine
Current appointments:
Attending physician, Women’s Ponce de Leon Clinic
Attending physician, Grady Memorial Hospital
Attending physician, Fulton County Health Department, TB Division
Guest researcher, Center for Diseases Control, Division TB elimination
My interests are varied and currently are centered on using epidemiologic tools to
determine trends in clinical settings. Current projects include outcomes of antiretroviral therapy
in naïve HIV-infected patients, effect of gender and aging on response to HAART, incidence
trends of non-AIDS defining cancers in HIV patients, as well as trends in drug resistance in
tuberculosis-infected patients in Russia.
81
1.
Nguyen ML, Yu VL. Legionella infection. Clin Chest Med 1992; 12:2:257-68.
2.
Nguyen MH, Tanner JE, Nguyen ML, Peacock JE, Morris AS, Wagener M, et al. Therapeutic
approaches in patients with candidemia. Arch Int Med 1995; 155(22):2429-35.
3.
Nguyen MH, Peacock JE, Morris, Tanner, Nguyen ML, et al. The changing face of candidemia.
Am J Med 1996; 100(6):617-23.
4.
Nguyen MH, Nguyen ML, Yu VL, Mc Mahon D, et al. Candida prosthetic valve endocarditis.
Clin Infect Dis 1996; 22(2):262-67.
5.
Jacob J, Nguyen ML, and Ray S: Male genitourinary tuberculosis. Lancet Infect Dis. 2008 May;
8(5): 335-42.
6.
Clancy CJ, Nguyen ML, Cheng S, Huang H, Fan G, Jaber RA, Wingard JR, Cline C, and Nguyen
MH: IgG responses against a panel of Candida albicans antigens are accurate and early markers
for systemic candidiasis. J Clin Microbiol. 2008 May; 46(5): 1647-54.
7.
Farrell K, Hill A, Dent L, Nguyen ML: Mathematical modeling/problem solving in global oxygen
transport. Journal of Surgical Research (in press).
Ighovwerha Ofotokun, MD, MSc
Education:
Medical School:
Residency:
Fellowship:
University of Benin, Nigeria
University of Michigan, Ann Arbor
University of Michigan, Ann Arbor
Staff Physician, Grady Memorial Health System
Research Interests:
My research interest is in translational HIV clinical pharmacology aimed at optimizing
therapeutic outcomes in treatment naïve and in treatment experienced HIV-infected individuals. I
also participate in international HIV/AIDS research activities that are aimed at understanding the
social and sexual network of the spread of HIV in Africa, in addition to exploring cost effective
ways of delivering HIV education to rural communities in Africa.
1.
Ofotokun I, Carlson C, Gitlin S et al. Acute cytomegalovirus infection complicated by vascular
thrombosis: a case report. Clin Infect Dis 2001; 32:983-6.
2.
Ree R, Jennings JR, Ofotokun I. Chronic Mucocutaneous Candidiasis. JAAPA 2002; 15:67-70.
3.
Grim SA, Smith KM, Romaneli F, Ofotokun I. Treatment of azole-resistant oropharyngeal
candidiasis with topical amphotericin B. Ann Pharmacother 2002; 36:1283-6.
4.
Markovitz DM, Gitlin SD, Ofotokun I. Reply to: Thrombosis, vasculitis, and cytomegalovirus
infection. Clin Infect Dis 2002; 34:1659-60.
82
5.
Ofotokun I, Pomeroy C. Sex differences in adverse reactions to the antiretroviral drugs. Top HIV
Med 2003; 11:55-9.
6.
Grim SA, Romanelli F, Jennings PR, Ofotokun I. Late-onset drug fever associated with
minocycline: case report and review of the literature. Pharmacotherapy 2003; 23(12):1659-62.
7.
Ofotokun I, Busch K, Lee Y, Hoven A. Pulmonary mycobacterium avium complex following
immune-reconstitution after HAART therapy. Infect Dis Clin Pract 2004; 12:1-3.
8.
Rapp, R.P., Evans, M.E., Martin, C., Ofotokun, I., Empey, K.L., and Armistead, J.A. Drug Costs
and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university
hospital. Curr Med Res Opinion 2004;20:469-47
9.
Martin C, Ofotokun I, Rapp R, Empey K, Armitstead J, Pomeroy C, Hoven A, Evans M. Results
of an antimicrobial control program at a university hospital. Am J Health Syst Pharm.
2005;62(7):732-8.
10.
Ofotokun I, Sex difference in the pharmacologic effects of the antiretroviral drugs: the potential
roles of P-glycoprotein and the metabolizing enzymes. Top HIV Med. 2005;13(2):79-83.
11.
Ofotokun I, Smithson S, Lu C, Easley KA, Lennox JL. Liver Enzymes Elevation and Immune
Reconstitution among Treatment Naïve HIV-Infected Patients Instituting Antiretroviral. Am J
Med Sci 2007;334(5):334–341.
12.
Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetics: A review of sex differences.
Journal of Gender Medicine. 2007:4;106-119.
13.
Ofotokun I, Chuck S, Binongo J, Palau M, Lennox J, Acosta E. Lopinavir/ritonavir
pharmacokinetic profile: The impact of sex and other covariates following a change from twice
daily to once daily therapy. Clin Pharmacol. 2007;47:970-7.
14.
Ofotokun I, Acosta E, Lennox J, Pan Y, Easley K. Pharmacokinetics of an indinavir-ritonavirfosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy.
2008;28:74-81.
Melissa K. Osborn, MD
Education:
Medical School:
Residency:
Fellowship:
The Ohio State University College of Medicine
Research Interests:
Melissa Osborn has completed a masters in clinical research with the aim of developing a clinical
trials program for patients coinfected with HIV and hepatitis B or C. Current research interests
include mechanisms of response to hepatitis C therapy, hepatitis in hemophilia patients, and
differences in the natural history and treatment response of hepatitis C in HIV.
83
1.
Osborn MK, Lok ASF. Antiviral options for the treatment of chronic hepatitis B. J Antimicrobial
Chemother 2006; 57:1030-34
2.
Osborn MK, Guest JL, Rimland D. Hepatitis B and HIV coinfection: relationship of different
serologic patterns to survival and liver disease. HIV Medicine 2007; 8:271-279.
3.
Osborn MK, Regev A, Han S, Bzowej N, Ishitani M, Tran T, Lok ASF. Outcomes of patients
with hepatitis B who develop viral breakthrough or genotypic resistance to antiviral therapy while
on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007;5:1454-61.
4.
Osborn MK, Steinberg JP. Subdural empyema and other suppurative complications of paranasal
sinusitis. Lancet Infect Dis 2007; 7:62-87.
5.
Hidron AI, Scheutz AN, Nolte FS, Gould CV, Osborn MK. Daptomycin resistance in
Enterococcus faecalis prosthetic valve endocarditis. J Antimicrobial Chemo 2008; 61(6): 1394-5.
6.
Radziewicz H, Ibegbu C, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL,
Workowski KA, Hanson, HL, Grakoui A. Impaired HCV specific effector CD8+ T cells undergo
massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the
chronic phase of infection. J Virol e-published ahead of print, 30 Jul 2008.
Melody Pratt-Palmore, MD
Education:
Medical School:
Residency:
Fellowship:
University of Cincinnati College of Medicine
Presbyterian-University of Pennsylvania Medical Center
Thomas Jefferson University Hospital
Medical Director, Women’s Clinic Grady Infectious
Disease Program, Ponce de Leon Center
My primary interest lies in improving the delivery of health care to HIV infected women. My
research focus thus is centered around this concept. I am currently involved in 3 research projects.
1.
Palmore MP, Swartz AA. Vaginitis. In: Hurst JW, ed. Medicine for the Practicing Physician. 4th
ed. Appleton & Lange, 1996: 360-363.
2.
Hart CE, Lennox JL, Pratt-Palmore M, Wright TC, Schinazi RF, Evans-Strickfaden T, Bush TJ,
Schnell C, Conley LJ, Clancy KA, Ellerbrock TV. Correlation of HIV-1 RNA levels in blood and
the female genital tract. J Infect Dis 1999; 179:871-82.
3.
Gulick RM, Smeaton LM, D’Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi,
JP, Tung R, Snyder S, Kuritzkes DR, Murphy RL, for the AIDS Clinical Trials Group 373 Study
Team. Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency VirusInfected, Amprenavir-Experienced Subjects: AIDS Clinical Trials Group Protocol 373. J Infect
Dis 2001; 183:715-21.
4.
Ellerbrock TV, Lennox JL, Clancy KA, Schinazi RF, Wright TC, Pratt-Palmore M, EvansStrickfaden T, Schnell C, Rekha P, Conley LJ, Parrish-Kohler EE, Bush TJ, Tatti K, Hart CE.
84
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect
Dis 2001; 184:28-36.
5.
Villanueva JM, Ellerbrock TV, Lennox JL, Bush TJ, Wright TC, Pratt-Palmore M, EvansStrickfaden T, Conley LJ, Schnell C, Hart CE. The menstrual cycle does not affect human
immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis 2002; 185:170-7.
Henry Radziewicz, MD
Education:
Medical School:
Internal Medicine &
Psychiatry Residency:
Fellowship:
State University of New York
Duke University School of Medicine
Staff Physician, Grady Health Systems
Research Interests:
Understanding the adaptive CD8+ T cell response in chronic viral infection and the interaction of
negative T cell signals on waning immune responses.
1.
Paiardini M, Cervasi B, Dunham R, Sumpter B, Radziewicz H, Silvestri G. Cell-cycle
dysregulation in the immunopathogenesis of AIDS. Immunol Res 2004;29:253-68.
2.
Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, Radziewicz H,
Piedimonte G, Magnani M, Montroni M, Kaech SM, Weintrob A, Altman JD, Sodora DL,
Feinberg MB, Silvestri G. Loss of CD127 expression defines an expansion of effector CD8+ T
cells in HIV-infected individuals. J Immunol 2005;174:2900-9.
3.
Radziewicz H, Uebelhoer L, Bengsch B, Grakoui A. Memory CD8+ T cell differentiation in viral
infection: a cell for all seasons. World J Gastroenterol 2007;13:4848-57.
4.
Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL,
Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A.
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted
phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:254553.
5.
Radziewicz H, Hanson HL, Ahmed R, Grakoui A. Unraveling the role of PD-1/PD-L interactions
in persistent hepatotropic infections: potential for therapeutic application? Gastroenterology. 2008
Jun;134(7):2168-71. Epub 2008 May 16.
6.
Ibegbu CC, Xu YX, Fillos D, Radziewicz H, Grakoui A, Kourtis AP. Differential expression of
CD26 on virus-specific CD8(+) T cells during active, latent and resolved infection. Immunology.
2008 Jul 22. [Epub ahead of print].
7.
Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL,
Workowski KA, Hanson HL, Grakoui A. Impaired HCV specific effector CD8+ T cells undergo
chronic phase of infection. J Virol 2008 Jul 30 [Epub ahead of print].
85
Susan M. Ray, MD
Education:
Medical School:
Residency:
Chief Resident:
Fellowship:
Atlanta VA Medical Center
Associate Hospital Epidemiologist, Grady Health System
My research activities focus on the epidemiology, prevention and treatment of infectious diseases
affecting the urban indigent minority population both in the community and in the hospital:
• Epidemiology, treatment and prevention of invasive MRSA infections – changes in
healthcare and community settings related to the emergence of CAMRSA
• Clinical trials of therapy of tuberculosis infection and disease
• Clinical presentation and management of HIV/TB
• Prevention of nosocomial TB exposures
• Prevention of needlestick injuries and other blood and body fluid exposures among
HCWs
• Nosocomial bloodstream infections: epidemiology and prevention
• Epidemiology of M. kansasii disease and other NTM at Grady
• Epidemiology and prevention of pneumococcal disease
• Racial and ethnic disparities in adult immunization rates
• Molecular epidemiology of tuberculosis
Service activities/interests:
Protection human research subjects: I serve as a Vice-Chair for Emory Institutional Review
Board.
Needlestick prevention center: I am the founder and physician director of the Woodruff Health
Sciences Center Needlestick Prevention Center (established Sept 2007).
1.
Blumberg HM, Watkins DL, Berschling JD, Antle A, Moore P, White N, Hunter M, Green B, Ray
SM, McGowan JE Jr. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med
1995;122:658-663.
2.
Blumberg HM, Moore P, Blanchard DK, Ray SM. Transmission of Mycobacterium tuberculosis
between HIV-infected health care workers. Clin Infect Dis1996;22:597-8.
3.
Ray SM, Erdman D, Berschling JD, Cooper J, Torok TJ, Blumberg HM. Nosocomial exposure to
Parvovirus B19: Low risk of transmission to Healthcare Workers. Infect Control Hosp Epidemiol
1997;18:109-114.
4.
Sotir MJ, Lewis C, Bisher EW, Ray SM, Soucie JM, Blumberg HM. Epidemiology of deviceassociated infections related to a long-term implantable vascular access device. Infect Control
Hosp Epidemiol 1999; 20:187-191.
86
5.
Jacobsen TA, Thomas D, Morton F, Offutt F, Shevlin J, Ray S. Use of a low-literacy educational
tool to enhance pneumococcal vaccination rates: A randomized controlled trial. JAMA
1999;282:646-50.
6.
Sotir MJ, Mcgowan J, Ray SM, Miller LP, Bock N, Parrott P, Blumberg HM. Tuberculosis in the
inner-city: impact of a continuing epidemic in the 1990s. Clin Infect Dis 1999;29:1138-44.
7.
Shevlin J, Bean C, Thomas D, Whitney C, Todd D, Ray SM. A systematic approach for
increasing pneumococcal vaccination rates at an inner-city public hospital. Am J Prevent Med
2002; 22:92-97.
8.
Eichler M, Ray SM, del Rio C. The effectiveness of HIV post-test counseling in determining
healthcare seeking behavior. AIDS 2002;16:943-945.
9.
Thomas D, Ray SM, Morton F, Shevlin J, Offutt G, Jacobsen T. Patient education strategies to
improve pneumococcal vaccination rates: a randomized trial. J Invest Med 2003; 51:141-8.
10.
Eckhardt C, Halvosa JS, Ray SM, Blumberg HM. Transmission of methicillin-resistant
Staphylococcus aureus in the neonatal intensive care unit from a patient with community-acquired
disease. Infect Control Hosp Epidemiol 2003;24:5-6.
11.
Ray SM, Ahuja SD, Van Gilder T, Blake PA, Farley M, Samuel M, Fiorentino T, Swanson E,
Cassidy M and the FoodNet Working Group. Population-based surveillance for Yersinia
enterocolitica infection: Higher risk of disease in infants and minority populations. Clin Infect
Dis 2004; 38(suppl 3):S181-9.
12.
Miller LS, Kourbatova EV, Goodman S, Ray SM. Risk factors for pneumococcal vaccine refusal
in adults: A case-control study. J Gen Intern Med 2005, 20:650-652.
13.
Kourbatova EV, Halvosa JS, King MD, Ray SM ,White N, Blumberg HM. Emergence of
Community-Associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of
nosocomial infections among patients with prosthetic joint infections. Am J Infect Control 2005,
33:385-91.
14.
Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield
R, Thomas AR, Li J, Campsmith M, Whitney CG, Schuchat A. Changes in invasive
pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal
immunization. Ann Intern Med 2006,144:1-9.
15.
Koehler KM, Lasky T, Fein SB, DeLong SM, Hawkins MA, Rabatsky-Her T, Ray SM, Shiferaw
B, Swanson E, Vugia DJ, for the EIP FoodNet Working Group. Population-based incidence of
infection with selected bacterial enteric pathogens in children less than five years of age, 19961998. Pediatric Infectious Diseases Journal 2006;25:129-134.
16.
Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, Ray SM, Blumberg
HM. Emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA)
USA300 genotype as a major cause of healthcare–associated blood stream infections. Clin Infect
Dis 2006;42:647-56.
17.
King MD, Terrell BJ, Wang YF, Ray SM, Blumberg HM. Emergence of community-acquired
methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of S. aureus
skin and soft tissue infections in Atlanta. Ann Intern Med 2006;144(4):309-317.
18.
Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett N, Long C, Gershman K,
Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM for the Active Bacterial Core
Surveillance Program of the EIP Network. Preventability of invasive pneumococcal disease and
87
assessment of current polysaccharide vaccine recommendations for adults: United States, 20012003. Clin Infect Dis 2006;43:141-50.
19.
Klevens RM, Morrison MA, Fridkin SA, Reingold A, Petit S, Gershman K, Ray S, Harrison L,
Lynfield R, Dumyati G, Townes JM, Craig AS, Tenover FC for the Active Bacterial Core
Surveillance Program of the Emerging Infections Program Network. Spread of communityassociated methicillin-resistant Staphylococcus aureus (MRSA) strains in healthcare settings.
Emerging Infectious Diseases 2006;12:1991-3.
20.
Klevens RM, Morrison MA, Fridkin SA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH,
Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal L, Carey RB for
the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.
Incidence and Burden of Invasive Methicillin-Resistant Staphylococcus aureus (MRSA)
Infections in the United States, 2004-2005. JAMA 2007; 298:1763-71..
Jyothi Rengarajan, PhD
Education:
PhD:
MS:
BSc:
Division of Medical Sciences,
Harvard University, Cambridge, MA
Biological Sciences
Carnegie Mellon University, Pittsburgh, PA
Life Sciences and Biochemistry
St. Xavier’s College, University of Bombay, India
Assistant Professor, Division of Infectious Disease
Core Investigator, Emory Vaccine Center Emory University School of Medicine
Research Interests:
We are interested in understanding how pathogens evade host immunity. Tuberculosis (TB)
provides an excellent system to dissect the molecular basis of infection due to the dynamic
interactions between Mycobacterium tuberculosis and immune cells. M. tuberculosis is one of the
world’s most successful human pathogens and is responsible for the deaths of upto 3 million
people annually. The AIDS pandemic and MDR-TB further underscore the global public health
challenge that TB presents. Developing vaccines and better therapeutics for TB is thus an
important goal in our research efforts.
The major questions that we seek to address are: How does M. tuberculosis survive in the host?
Why does the host fail to eliminate M. tuberculosis? A fundamental aspect of TB that
encompasses both these questions involves the M. tuberculosis-macrophage interface.
Macrophages are central to host defense against microbes, but M. tuberculosis has evolved to
evade their anti-microbial functions. We have used functional genomics to comprehensively
determine the genome-wide requirements for M. tuberculosis survival and adaptation in host
macrophages and in vivo in mice. We are characterizing several mutants that are defective for
intracellular growth to better understand pathogenesis mechanisms and bacterial modulation of
immunity using in vitro and in vivo model systems.
We also aim to dissect the molecular pathways involved in the host innate immune response to
infection. We are developing proteomic approaches to analyzing signaling pathways in infected
88
macrophages and dendritic cells using mass spectrometry techniques. These studies will shed
light on how M. tuberculosis manipulates innate immune function at the molecular level.
We are also interested in translating and enhancing lab-based findings by working in
collaborative projects within human population-based settings of tuberculosis infection. Human
studies are important for understanding tuberculosis latency and host protective immunity for
vaccine development. Other interests include understanding mechanisms of drug resistance in
mycobacteria and identifying targets for new chemotherapeutics and immunomodulatory
therapies.
1.
Hodge MR, Chun HJ, Rengarajan J, Alt A, Lieberson R and Glimcher LH. NFAT-driven
interleukin-4 transcription potentiated by NIP45. Science 1996; 274:1903-1905
2.
Ranger AM, Oukka M, Rengarajan J and Glimcher LH. Inhibitory function of two NFAT family
members in lymphoid homeostasis and Th2 development. Immunity 1998; 9:627-635.
3.
Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, Kroczek RA, Ashwell JD, and Glimcher
LH. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity
2000; 12:293-300.
4.
Rengarajan J and Glimcher LH. Transcriptional regulation of cytokine gene expression.
Cytokines and Autoimmune Diseases 2000, Humana press Inc, Totowa, NJ.
5.
Rengarajan J, Szabo SJ, and Glimcher LH. Transcriptional regulation of Th1/Th2 polarization.
Immunology Today 2000; Vol. 21 No.10: 479-483.
6.
Rengarajan J, Tang B and Glimcher LH. NFATc2 and NFATc3 regulate Th2 differentiation and
modulate TCR-responsiveness of naive Th cells. Nat. Immunol. 2002; 3(1): 48-54.
7.
Rengarajan J, Mowen KA, McBride KD, Singh H and Glimcher LH. Interferon Regulatory
Factor 4 (IRF4) interacts with NFATc2 to modulate IL-4 gene expression. J.Exp.Med 2002.
195(8): 1003-1012.
8.
Sampson, SL, Rengarajan, J and Rubin, EJ. Bacterial Genomics and vaccine design. Expert Rev.
Vaccines 2003. 2(3): 437-445.
9.
Rengarajan, J, Sassetti, CM, Naroditskaya, V, Sloutsky, A, Bloom, BR and Rubin, EJ. The folate
pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol
Microbiol. 2004; 53(1):275-82.
10.
Rengarajan, J, Bloom, BR and Rubin EJ. Genome-wide requirements for Mycobacterium
tuberculosis adaptation and survival in macrophages PNAS. 2005; 102(23) 8327-32.
11.
Rengarajan, J, Murphy, EM, Krone, C, Park, A, Hett, E, Bloom, BR, Glimcher, LH and Rubin,
EJ Mycobacterium tuberculosis Rv2224c modulates innate immune responses. PNAS. 2008:
8;105(1):264-9.
Bruce S. Ribner, MD, MPH
Education:
89
Medical School:
Residency:
Fellowship:
MPH-Epidemiology:
Mount Sinai Hospital
Mount Sinai Hospital
University of Michigan School of Public Health
Epidemiologist, Emory University Hospital and The Emory
Clinic
Epidemiology, prevention, and management of infectious diseases, primarily nosocomial, or
hospital-acquired, infectious diseases: defining risk factors, designing interventions for
prevention, and evaluating newer devices and agents for the prevention of infections with, and
treatment of infections caused by, resistant, hospital-acquired, organisms. Developed protocols
for management of patients with serious communicable diseases, and director of the unit at
Emory University Hospital designed to care for patients with these infections. This is one of only
three such units in the country, one of which is in the Department of Defense. Co-investigator in
studies evaluating interventions to improve the use of peri-operative prophylactic antibiotics and
to decrease sharps injuries in health care workers.
1.
Ribner BS, Landry MN, Gholson GL. Strict versus modified isolation for prevention of
nosocomial transmission of methicillin-resistant Staphylococcus aureus. Infect Cont 1986;
7:317-320.
2.
Ribner BS, Landry MN, Gholson GL, Linden L. Impact of a puncture resistant needle disposal
system upon employee needlesticks. Infect Cont 1987; 8:63-66.
3.
Ribner BS. Endemic multiply-resistant Staphylococcus aureus in a pediatric population. Am J Dis
Child 1987; 141:1183-1187.
4.
Ribner BS, Landry MN, Kidd K, Peninger M, Riddick J. Outbreak of multiply resistant
Staphylococcus aureus in a pediatric intensive care unit after consolidation with a surgical
intensive care unit. Am J Infect Control 1989; 17:244-249.
5.
Ribner BS. An effective educational program to reduce the frequency of needle recapping. Infect
Control Hosp Epidemiol 1990; 11:635-638.
6.
John JF, Ribner BS. Antibiotic resistance in long-term care facilities. Infect Control Hosp
Epidemiol 1991; 12:245-250.
7.
Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus:
a consensus review of the microbiology, pathogenesis, and epidemiology with implications for
prevention and management. Am J Med 1993; 94:313-328.
8.
Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized
double-blind trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole for
methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance
and the effect of host factors on outcome. Antimicrob Agents Chemother 1993; 37:1334-1342.
9.
Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ, Kauffman C, Bradley S, Gafford
G, Elliston D, Beam T, John JF, Ribner B, et al. Immunoprophylaxis against Klebsiella and
Pseudomonas aeruginosa infections. J Inf Diseases 1996; 174:537-543.
90
10.
Donta ST,.., Ribner B, et. al.Benefits and harms of doxycycline treatment for Gulf War veterans'
illnesses. Ann Intern Med 2004; 141:85-94.
11.
Antoine TL, Ribner B, et al. Knowledge, attitudes, and behaviors about
piperacillin/tazobactam prescribing practices: Results from a multi-center study. Infect Control
Hosp Epidemiol. 2006; 27(11):1274-7.
12.
Smith PW, Ribner B, et al. Designing a Biocontainment Unit to Care for Patients with Serious
Communicable Diseases: A Consensus Statement. Biosecur Bioterror 2006;4(4):351-365.
13.
Gazmararian JA, ..., Ribner BS, et al. Influenza Vaccination of Health Care Workers: Policies
and Practices of Hospitals in a Community Setting. Am J Infect Control 2007; 35(7):441-7.
14 .
Ribner BS, Hall C, Steinberg JP, Bornstein WA, Chakkalakal R, Emamifar A, Eichel I, Lee PC,
Castellano PZ, Grossman GD. Utilization of a mandatory declination statement in a healthcare
worker influenza vaccination program. Infect Control Hosp Epidemiol 2008; 29:302-308.
1.
DuPont HL, Ribner BS. Infectious gastroenteritis. In Bennett JV and Brachman PS(eds.).
Hospital Infections, 4th edition, Little, Brown, Boston, 1998.
2.
Ribner BS. Antimicrobial Resistant Flora in The Hospital. In: Mainous, AG (ed.). Optimal Use of
Antimicrobials in an Era of Antibiotic Resistance (2001).
3.
Ribner BS. Salmonella. In Schlossberg D(ed.). Current Therapy of Infectious Disease, Mosby
Year Book, Inc, St. Louis., 2001.
4.
Ribner BS. Nosocomial infections associated with procedures performed in radiology. In Mayhall
CG(ed.). Hospital Epidemiology and Infection Control, 3rd edition, Williams and Wilkins,
Baltimore, 2004.
5.
Ribner BS. Developing a unit to care for patients with highly communicable, serious infectious
diseases. In Richmond JY (ed.) Anthology of Biosafety: IX. Exploring the performance envelope
for BSL-3 and BSL-4 laboratories. Am Biological Safety Assoc, Mundelein, IL, 2006
6.
Ribner BS. Salmonella. In Schlossberg D(ed). Clinical Infectious Diseases, Cambridge University
Press, New York, NY, 2008
David Rimland, MD
Education:
Medical School:
Residency:
Fellowship:
Barnes Hospital, St. Louis, Missouri
Chief, Infectious Diseases, VA Medical Center
Director, HIV Program, VA Medical Center
91
In the initial part of my career my research centered on host defenses in alcoholics and
the epidemiology of nosocomial infections. My research focus in the last 20 years has
been on the epidemiology and treatment of opportunistic infections in AIDS and the use
of antiretroviral therapy.
1.
Navin TR, Beard CB, Huang L, del Rio C, Lee S, Pieniazek NJ, Carter J, Le T, Hightower A,
Rimland D. Mutations in the Pneumocystis carinii dihydropteroate synthase gene do not affect
outcome of P. carinii pneumonia in HIV-infected patients. Lancet 2001; 18:545-549.
2.
Rimland D, Navin TR, Lennox J, Jernigan J, Kaplan J, Erdman D et al: Prospective study of
etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002;
16:83-95.
3.
Nimri LF, Moura INS, Huang L, del Rio C, Rimland D, Duchin JS, Dostson EM, Beard CB.
Genetic diversity of Pneumocystis carinii f. sp. hominis based on variations in nucleotide
sequences of internal transcribed spacers of rRNA genes. J Clin Microbiol 2002; 40:1146-1151.
4.
Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, Gardner T, Sattah M, Ponce
de Leon G, Baughman W, Hajjeh RA. The changing epidemiology of Cryptococcosis: an update
from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect
Dis 2003; 36:789-94.
5.
Guest JL, Ruffin C, Tschampa JM, DeSilva KE, Rimland D. Differences in rates of diarrhea in
patients with human immunodeficiency virus receiving lopinavir/ritonavir or nelfinavir.
Pharmacotherapy 2004: 24:727-735.
6.
Gaynes R, Rimland D, Killum E, Lowery HK, Johnson T, Killgore G, Tenover FC. Outbreak of
Clostridium difficile infections in a long-term nursing facility: association with gatifloxacin use.
Clin Infect Dis 2004; 38:640-645.
7.
Anderson KB, Guest JL, Rimland D. Hepatitis C coinfection increases mortality in HIV-infected
patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort
Study. Clin Infect Dis 2004; 39: 1507-13.
8.
Cantey PT, Stephens DS and Rimland D. Prevention of cryptococcosis in HIV-infected patients
with limited access to HAART: evidence for primary azole prophylaxis. HIV Med 2005; 6:253-9.
9.
Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS,
2005: 14;19(15):1702-4.
10.
Beard CB, Fox MR, Lawrence GG, Guarner J, Hanzlick RL, Huang L, del Rio C, Rimland D,
Duchin JS, Colley DG. Genetic differences in Pneumocystis isolates from immunocompetent
infants and from adults with AIDS- epidemiologic implications. J Infect Dis 2005; 192:1815-8.
11.
Cook RL, McGinnis KA, Kraemer KL, Gordon AJ, Conigliaro J, Maisto SA, Samet JH, Crystal S,
Rimland D, Bryant KJ, Braithwaite RS, Justice AC. Intoxication before intercourse and risky
sexual behavior in men with and without HIV infection. Med Care, 2006 Aug;44(8 Suppl 2):S316.
12.
Rimland D, Guest JL, Hernández-Ramos I, Del Rio C, Le NA, Brown WV. Antiretroviral
therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol.
J Acquir Immune Defic Syndr. 2006;42(3):307-13.
92
13.
Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, Goulet JL,
Simberkoff M, Butt A, Rimland D, Rodriquez-Barradas MC, Gibert CL, Ousler KK, Brown S,
Leaf DA, Goetz MB, Bryant K. Veterans Aging Cohort Study (VACS): Overview and
Description. Med Care 2006; 44 (Supplement 2): S13-S24.
14.
Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV positive patients:
case-series and review of the literature. JAIDS, 2007; 21:771-4.
15.
Osborn M, Guest J, Rimland D. Hepatitis B and HIV coinfection: relationship of different
serologic patterns to survival and liver disease. HIV Med, 2007; 8 (5):271-279.
16.
Grunfeld C, Rimland D, Gibert C, Powderly W, Sidney S, Shlipak M, Bacchetti P, Scherzer R,
Haffner S, Heymsfeld S for FRAM. Association of insulin resistance with upper trunk and visceral
adipose tissue volume. JAIDS, 2007; 46(3):283-290.
17.
Tien PC, Bacchetti P, Gripshover B, Overton ET, Rimland D, Kotler D, and the FRAM study
investigators. Association between hepatitis C virus coinfection and regional adipose tissue
volume in HIV-infected men and women. JAIDS, 2007; 45:60-65.
18.
Goulet J, Fultz S, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice A. Do
patterns of comorbidity vary by HIV status, age and HIV severity? Clin Infect Dis 2007; 45:15931601.
19.
Rodriguez-Barrradas M, Goulet J, Brown S, Goetz MB, Rimland D, Simberkoff M, Crothers K,
Justice AC. Impact of pneumococcal vaccination by HIV status on the incidence of pneumonia
among subjects enrolled in the Veterans Aging Cohort Five-Site Study. Clin Infect Dis, 2008;
46:1093-1100.
20.
Rouphael N, Rimland D. Seronegative syphilis in an AIDS patient: Case report and review of the
literature. Infect Dis Clin Practice, 2008; 16:330-1.
Nadine G. Rouphael, MD
Education:
Medical School:
Masters in Health Economics:
Residency:
Fellowship:
Saint Joseph University- Lebanon
Jean Moulin, Lyon 3- France
Instructor
Staff Physician, Emory Crawford Long Hospital
Co-PI, VTEU, The Hope Clinic of the Emory Vaccine Center
Guest Researcher, Centers for Disease Control and Prevention
My laboratory research interests concern immunology of vaccines of bacterial pathogens such as
Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. I am currently
working on the evaluation of innate immunity in meningococcal and pneumococcal vaccines and
the role of memory B cells in elderly receiving pneumococcal vaccines.
93
My clinical research interest is in vaccine evaluation. I am a co-PI at the Emory VTEU where
many new vaccines are being investigated. I am also part of a collaborative work between Emory
University and the Meningitis Vaccine Project in Africa.
1.
Rouphael N, Atwell-Melnick N, Longo D, Whaley M, Carlone GM, Sampson JS, Ades EW.
Proof of Utility for Real-Time Polymerase Chain Reaction in the Diagnosis of Streptococcus
pneumoniae Bacteremia using a Murine Bacteremia Model. Diagn Microbiol Infect Dis 2008 Sep;
62(1):23-5.
2.
Talati N, Rouphael N. Evolution (Vancomycin induced linear IgA bullous disease). Am J Med
2008 Jul; 121(7):583-5.
3.
Cartwright E, Rouphael N, Jain S, Ilksoy N. Pleural effusion in an AIDS patient. Clin Infect Dis
2008 Jun 15; 46(12):1887-8, 1926-7.
4.
Talati N, Rouphael N, Kuppalli K, Franco-Paredes C. Spectrum of central nervous system
disease due to rapidly growing mycobacteria. Lancet Infect Dis 2008 Jun; 8(6):390-8.
5.
Rouphael N, O'Donnell JA, Bhatnagar J, Lewis F, Polgreen PM, Beekmann S, Guarner J,
Killgore GE, Coffman B, Campbell J, Zaki SR, McDonald LC. Clostridium difficile associated
diarrhea: emerging threat to pregnant women. Am J Obstet Gynecol 2008 Jun; 198(6):635.e1-6.
6.
Rouphael N, Talati N, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated
with hemophagocytic syndrome. Lancet Infect Dis 2007 Dec; 7(12):814-22.
7.
Cardiac manifestations of parasitic infections part 3: pericardial and miscellaneous
cardiopulmonary manifestations. Clin Cardiol 2007 June; 30(6): 277-280.
8.
Cardiac manifestations of parasitic infections part 2: parasitic myocardial disease. Clin Cardiol
2007 May; 30(5):218-22.
9.
Cardiac manifestations of parasitic infections part 1: overview and immunopathogenesis. Clin
Cardiol 2007 Apr; 30(4):195-9.
10.
Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV positive
patients: case-series and review of the literature. AIDS 2007 Mar 30; 21(6):771-4.
11.
Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and Doxycycline
use among Patients with Multi-Drug Resistant Acinetobacter baumannii infections. Ann
Pharmacother. 2006 Nov; 40(11):1939-4.
12.
Franco-Paredes C, Rouphael N, del Rio C, Santos-Preciado JI. Vaccination strategies to prevent
tuberculosis in the new millennium: from BCG to new vaccine candidates. Int J Infect Dis 2006
Mar; 10(2):93-102.
94
Sarah Satola, PhD
Education:
Undergraduate:
Graduate:
Current Titles and Affiliations:
B.A., Biology, Goucher College
Ph.D., Emory University Department of Microbiology
and Immunology
Senior Associate of Medicine,
Director EIP Laboratory, Georgia Emerging Infections
Program, Atlanta, GA
1. Genetics and pathogenesis of Haemophilus influenzae
2. Examination of the role of pili in mucosal attachment and pathogenesis.
3. Population-based surveillance and epidemiology of bacterial meningitis
pathogens including H. influenzae, N. meningitidis, groups A and B
Streptococcus, S. pneumoniae
4. Genetic characterization of non-encapsulated H. influenzae for potential vaccine
development
5. MRSA surveillance, molecular epidemiology and vancomycin MIC-creep.
1.
Reith, W, SW Satola, C Herrero-Sanchez, I Amaldi, and B Mach. Congenital
immunodeficiencywith a regulatory defect in MHC class II gene expression lacks a specific HLSDR promoter binging protein (RFX). Cell, 1988; 53: 897-906.
2.
Reith, W, E Barras, SW Satola, M Kobr, D Reinhart, C Herrero-Sanchez and B Mach. Cloning of
the MHC Class II promoter binding protein affected in a hereditary defect in class II gene
regulation. Proc. Natl. Acad. Sci. USA, 1988; 86: 4200-4204.
3.
Satola, SW, P Kirchman, CP Moran, Jr. SpoOA binds to a promoter used by σA RNA polymerase
during sporulation in Bacillus subtilis. Proc. Natl. Acad. Sci. USA, 1991; 88: 4533-4537.
4.
Satola, SW, J Baldus, CP Moran, Jr., Binding of SpoOA stimulates spoIIG promoter activity in
Bacillus subtilis. J Bacteriol, 1992; 174: 1448-1443.
5.
York, K, T Kenney, SW Satola, CP Moran, Jr., H Poth and P Youngman. SpoOA controls the σA
dependent activation of Bacillus subtilis sporulation-specific transcription unit spoIIE. J Bacteriol,
1992; 174: 2648-2658.
6.
Read, TD, M Dowdell, SW Satola, MM Farley. Duplication of pilus gene complexes of
Haemophilus influenzae biogroup aegyptius. J Bacteriol, 1996; 178: 6564-6570.
7.
Read, TD, SW Satola, J Opdyke, MM Farley. Copy number of Haemophilus influenzae pilus
clusters and variation in the hifE gene. Infection & Immunity, 1997; 66(4): 1622-1631.
8.
Read, TD, SW Satola, MM Farley. Nucleotide Sequence Analysis of Hypervariable Junctions of
Haemophilus influenzae Pilus Gene Clusters. Infection & Immunity, 2000; 68(12) 6896-6902.
95
9.
Satola, SW, PL Schirmer, MM Farley. Complete sequence of the cap locus of Haemophilus
influenzae serotype b and the nonencapsulated b- variant. Infection & Immunity, 2003; 71(6)
3639-3644.
10.
Satola, SW, PT Schirmer, MM Farley. Genetic Analysis of the Capsule Locus of Haemophilus
influenzae serotype f. Infect Immun 2003; 71:7236-7237.
11.
Kapogiannis, BG, SW Satola, MM Farley. Invasive Infections with Haemophilus influenzae
Type a Containing an IS1016-bexA Deletion: Possible Association with Virulence. Clin Infect Dis
2005;41(11) e97-103
12.
Satola, SW, JT Collins, R Napier, MM Farley. Capsule Gene Analysis of Invasive Haemophilus
influenzae: Accuracy of Serotyping and Prevalence of IS1016 among Nontypeable Isolates. J Clin
Microbiol. 2007. 45(10):3230-8.
13.
Satola, SW, BA Napier, MM Farley. Association of IS1016 with the hia Adhesin Gene and
Biotype V and I in Invasive Nontypeable Haemophilus influenzae. Infection & Immunity
2008;Sept 15.
Education:
Medical School:
Residency:
Fellowship:
Sir William Osler Internal Medicine Service, Johns Hopkins
University Hospital
Johns Hopkins University Hospital
Team Leader, Response Team
Commander, US Public Health Service Commissioned Corps
Epidemiology of healthcare associated infections with an emphasis on investigations of outbreaks
related to healthcare delivery. Antimicrobial resistance and multi-drug resistant organisms with
an emphasis on the epidemiology of antibiotic resistant gram negative bacteria and on reducing
the incidence of antimicrobial resistance in healthcare settings.
1.
Srinivasan A, Wolfenden LL, Song X, Mackie K, Hartsell TL, Jones HD, Diette GB, Orens JB,
Yung RC, Ross TL, Merz W, Scheel PJ, Haponik EF, Perl TM.
An outbreak of Pseudomonas aeruginosa Infections Associated with Flexible Bronchoscopes. N
Engl J Med 2003;348:219-25.
2.
Granowitz EV, Srinivasan A, Clynes ND. Using the Internet to Identify Infectious Disease
Outbreaks. N Engl J Med 2004;351:2558-9.
3.
Maragakis LL, Cosgrove SE, Song X, Kim D, Rosenbaum P, Ciesla N, Srinivasan A, Ross T,
Carroll K, Perl TM. An Outbreak of Multidrug-Resistant Acinetobacter baumannii Associated
With Pulsatile Lavage Wound Treatment. JAMA 2004;292:3006-3011
96
4.
Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister
S, Anderson J, Jensen B, Dodson D, Lonsway D, McDougal LK, Arduino M, Fraser VJ, Killgore
G, Tenover FC, Cody S, Jernigan DB. A Clone of Methicillin-Resistant Staphylococcus aureus
Among Professional Football Players. N Engl J Med 2005;352:468-75.
5.
Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD,
Guarner J, Shieh WJ, Goldsmith C, Hanlon CA, Zoretic J, Fischbach B, Niezgoda M, El-Feky
WH, Orciari L, Sanchez EQ, Likos A, Klintmalm GB, Cardo D, LeDuc J, Chamberland ME,
Jernigan DB, Zaki SR; Rabies in Transplant Recipients Investigation Team. Transmission of
Rabies Virus from an Organ Donor to Four Transplant Recipients. N Engl J Med 2005 Mar
17;352(11):1103-11.
6.
Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Comer JA,
Guarner J, Paddock CD, DeMeo DL, Shieh WJ, Erickson BR, Bandy U, DeMaria A Jr, Davis JP,
Delmonico FL, Pavlin B, Likos A, Vincent MJ, Sealy TK, Goldsmith CS, Jernigan DB, Rollin PE,
Packard MM, Patel M, Rowland C, Helfand RF, Nichol ST, Fishman JA, Ksiazek T, Zaki SR;
LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic
choriomeningitis virus by organ transplantation. N Engl J Med 2006;354:2235-49.
7.
Chang DC, Grant GB, O'Donnell K, Wannemuehler KA, Noble-Wang J, Rao CY, Jacobson LM,
Crowell CS, Sneed RS, Lewis FM, Schaffzin JK, Kainer MA, Genese CA, Alfonso EC, Jones DB,
Srinivasan A, Fridkin SK, Park BJ; Fusarium Keratitis Investigation Team. Multistate outbreak
of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006; 296(8):953-63.
8.
Sunenshine RH MD, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE,
Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A.
Multidrug-Resistant Acinetobacter Infection- Mortality and Length of Hospitalization. Emerg
Infect Dis 2007;13:97-103.
9.
Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain J, Craft D, Riddell S,
Lindler L, Mancuso J, Milstrey E, Bautista CT, Patel J, Ewell A, Hamilton T, Gaddy C, Tenney
M, Christopher G, Petersen K, Endy T, Petruccelli B. An outbreak of multidrug-resistant
Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system
associated with military operations in Iraq. Clin Infect Dis 2007;44(12):1577-84.
10.
Jhung MA, Sunenshine RH, Noble-Wang J, Coffin SE, St John K, Lewis FM, Jensen B, Peterson
A, LiPuma J, Arduino MJ, Holzmann-Pazgal G, Atkins JT, Srinivasan A. A national outbreak of
Ralstonia mannitolilytica associated with use of a contaminated oxygen-delivery device among
pediatric patients. Pediatrics 2007;119(6):1061-8.
11.
Kutty PK, Forster TS, Wood-Koob C, Thayer N, Nelson RB, Berke SJ, Pontacolone L, Beardsley
TL, Edelhauser HF, Arduino MJ, Mamalis N, Srinivasan A. Multistate outbreak of toxic anterior
segment syndrome, 2005. J Cataract Refr Surg 2008;34:585-90.
12.
Kallen AJ, Lederman E, Balaji A, Trevino I, Petersen EE, Shoulson R, Saiman L, Horn EM,
Gomberg-Maitland M, Barst RJ, Srinivasan A. Bloodstream infections in patients given
treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008;29:342-9.
13.
Blossom DB, Srinivasan A. Drug-resistant Acinetobacter baumannii-calcoaceticus complex: an
emerging nosocomial pathogen with few treatment options. Infect Dis Clin Pract 2008;16(1):1-3.
14.
Lessa F, Tak S, Devader SR, Goswami R, Anderson M, Williams I, Gensheimer KF, Srinivasan
A. Risk of infections associated with improperly reprocessed transrectal ultrasound-guided
prostate biopsy equipment. Infect Control Hosp Epidemiol 2008;29:289-93.
97
15.
Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, Brudney K, Della-Latta
P, Estivariz C, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV.
Outbreak of Mycobacterium abscessus wound infections among "lipotourists" from the United
States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008;46:11818.
James P. Steinberg, MD, FACP
Education:
Medical School:
Residency:
Fellowship:
University of Nebraska College of Medicine
Northwestern University Medical School
Chief Medical Officer, Emory Crawford Long Hospital
Hospital Epidemiologist, Crawford Long Hospital
Staff Physician: Emory Crawford Long, Emory University
Hospital, Grady Memorial Hospital
Research interests include 1) Epidemiology and prevention of healthcare associated infections
including surgical site infections and intravascular device-related infections, 2) Bloodstream
infections, 3) Antibiotic use and antibiotic resistance, 4) Staphylococcus aureus infections, 5)
healthcare worker safety.
1.
Ostrowsky B, Steinberg JP, Farr B, Sohn AH, Sinkowitz-Cochran RL, Jarvis WR. Reality Check:
Should We Try to Detect and Isolate VRE Colonized/infected Patients? Inf Control Hosp Epidem
2001; 22:116-9.
2.
Steinberg JP. 2002. Combating antibiotic resistance: Expanding the role of the clinician. J Med
Assoc Ga, 91(2):24-6
3.
Diaz-Granados CA, Franco-Paredes C, Steinberg JP. A Long Suffering Patient with New
Abdominal Pain. Clin Infect Dis 2002; 34(9):1213-4, 1267-8.
4.
Franco-Paredes C, Hidron A, Steinberg J. 2006. A Woman from British Guyana with Recurrent
Back Pain and Fever. Clin Infect Dis. 2006;421:297, 1340-1
5.
Williams BR, Steinberg JP. Muller’s Sign. N Engl J Med. 2006;355(3):e3
6.
Weems JJ, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF,
Kubin CJ, Talwani R, Moore T, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler Jr. VG.
A Phase II, Randomized, double-blind, multi-center study comparing safety and pharmacokinetics
of tefibazumab to placebo for the treatment of Staphylococcus aureus bacteremia. Antimicrob
Agent Chemother. 2006;50:2751-55
7.
Gould CV, Steinberg JP. Antibiotic Resistance in Long-Term Acute Care Hospitals (LTACHs):
The Perfect Storm. Infect Control Hosp Epidemiol. 2006;27:920-25
8.
Antoine TL, Curtis, Blumberg HM, DeSilva K, Fransua M, Gould CV, King M, Kraman AA,
Pack J, Ribner B, Seybold U, Steinberg JP, Wells JB, Sinkowitz-Cochran RL, Denise Cardo D,
98
Jernigan JA, Gaynes RP. Knowledge, Attitudes, and Behaviors about Piperacillin/tazobactam
Prescribing Practices: Results from a Multi-center Study. Inf Control Hosp Epidem.
2006;27:1274-77
9.
Osborn MK, Steinberg JP, Subdural Empyema and other Suppurative Complications of Paranasal
Sinusitis. Lancet Inf Dis. 2007;7:62-67
10.
Camins BC, Farley, MM, Jernigan JJ, Ray SM, Steinberg JP, Blumberg HM. A PopulationBased Investigation of Invasive Vancomycin-Resistant Enterococcus Infection in Metropolitan
Atlanta, Georgia, and Predictors of Mortality. Infect Control Hosp Epidemiol 2007; 28:983-91
11.
Ribner BS, Hall C, Steinberg JP, Bornstein WA, Chakkalakal R, Emamifar A, Eichel I, Lee PC,
Castellano PZ, Grossman GD. 2008. Use of a Mandatory Declination Form in a Program for
Influenza Vaccination of Healthcare Workers. Inf Control Hosp Epidem. 27:1274-77
1.
Steinberg JP, DelRio C. 2005, Other Gram-Negative and Gram-Variable Bacilli. In: Mandell GL,
Bennett JE, Dolin R, (eds). Principles and Practice of Infectious Diseases. 6th edition. Philadelphia.
Elsevier Science. 2751-2768
2.
Steinberg JP. Principles of Anitmicrobial Use. In: Minneman K, Wecker L, Lucchesi B. (eds).
Brody’s Human Pharmacology. 4th edition. Philadelphia. Elsevier, 2005; 551-566.
3.
Steinberg JP. Selection of an Antibacterial Agent. In: Minneman K, Wecker L, Lucchesi B.
(eds). Brody’s Human Pharmacology. 4th edition. Philadelphia. Elsevier, 2005; 619-623.
4.
Steinberg JP, Zimmer SM. Fever and Infection in the Postoperative Setting. In: Lubin MF, (ed).
Medical Management of the Surgical Patient. 4th edition. Cambridge University Press, 2006; 317325
Nimalie D. Stone, MD
Education:
Medical School:
Fellowship:
University of Kentucky
Johns Hopkins University School of Medicine
Director of Antimicrobial Infections and Wesley
Woods Center Epidemiologist
Staff Physician, Wesley Woods Hospital and Emory
University Hospital, Atlanta
My research interests are in understanding the epidemiology and microbiology of infections in
the elderly, with a specific focus on antibiotic resistant organisms. My current research projects
are on methicillin-resistant Staphylococcus aureus (MRSA) colonization, transmission and
clinical outcomes in the long-term care setting. My laboratory collaborations also enable me to
99
study the molecular epidemiology of MRSA transmission using techniques such as pulse-field gel
electrophoresis.
As part of my clinical work I am the director of antimicrobial management and campus
epidemiologist for Wesley Woods, a multi-center campus with a focus in geriatric care. I am
developing quality improvement initiatives to improve antibiotic utilization for the elderly in both
the acute and long-term care settings.
1.
Stone ND, Lewis DL, Lowery HK, Darrow L, Kroll CM, Gaynes RP, Jernigan JA, McGowan JE,
Richards CL. Importance of Bacterial Burden among Methicillin-Resistant Staphylococcus aureus
Carriers in a Long-Term Care Facility. Infect Contr Hosp Epidemiol. 2008; 29(2): 143-148.
2.
Stone ND, O’Hara CM, Williams PP, McGowan JE, Tenover FC, Comparison of Disk
Diffusion, VITEK 2, and Broth Microdilution Antimicrobial Susceptibility Testing Results for
Unusual Species of Enterobacteriaceae. J.Clin. Microbiol. 2007; 45(2): 340-346.
Naasha J. Talati, MD
Education:
Medical School:
Fellowship:
The Aga Khan University
Duke University Medical Center
Instructor, Division of Infectious Disease
My main area of interest in Infectious Diseases is in Tuberculosis. I am interested more
specifically in TB/HIV coinfection, the development of new diagnostic tests for latent and
active TB and research in developing countries.
I have worked on projects that analyze the utility of Interferon Gamma Release Assays in the
diagnosis of Latent Tubercuosis Infection in the US. Currently I am conducting a study in
Zambia, (funded by the Global Health Institution at Emory) that is evaluating the utility of
Interferon Gamma Release Assays in diagnosis of Latent Tuberculosis Infection among HIV
positive individuals.
1.
Talati NJ, Rouphael N, Kuppalli K, Franco-Paredes C. Spectrum of CNS disease caused by
rapidly growing mycobacteria. Lancet Infect Dis. 2008 Jun;8(6):390-8.
2.
Talati NJ, Rouphael NG. Evolution. Am J Med. 2008 Jul;121(7):583-5.
100
3.
Seybold U, Talati NJ, Kizilbash Q, Shah M, Blumberg HM, Franco-Paredes C. Hematogenous
osteomyelitis mimicking osteosarcoma due to Community Associated Methicillin-Resistant
Staphylococcus aureus. Infection. 2007 Jun;35(3):190-3.
4.
Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive
patients: case series and review of the literature. AIDS. 2007 Mar 30;21(6):771-4. Review.
5.
Talati NJ, Pervez S. Soft tissue sarcomas: pattern diagnosis or entity? J Pak Med Assoc. 1998
Sep;48(9):272-5.
6.
Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated
with haemophagocytic syndrome. Lancet Infect Dis. 2007 Dec;7(12):814-22.
Yih-Ling Tzeng, PhD
Education:
BS:
MS:
PhD:
Chemistry, National Taiwan University, Taipei, Taiwan
Organic Chemistry, National Taiwan University, Taipei, Taiwan
Bioorganic Chemistry, The University of Chicago
My laboratory studies molecular mechanisms of N. meningitidis pathogenesis and the signal
transduction pathways by which meningococci sense and interact with the host. Specifically,
much of the lab focuses on meningococcal regulation of capsular polysaccharides, stress response
and iron uptake by a novel two-component regulatory system.
1.
Tzeng Y-L and Hoch JA. Molecular recognition in signal transduction: The interaction surfaces of
Spo0F with its cognate phosphorelay proteins revealed by alanine-scanning mutagenesis. J Mol
Biol 1997; 272:200-12.
2.
Feher VA, Tzeng Y-L, Hoch JA, and Cavanagh J. Identification of communication networks in
Spo0F: A model for phosphorylation induced conformational change and implications for
activation of multiple domain bacterial response regulator proteins. FEBS Lett., 1998; 425:1-6.
3.
Tzeng Y-L, Zhou XZ, and Hoch JA. Phosphorylation of the Spo0B response regulator
phosphotransferase of the phosphorelay initiating development in Bacillus subtilis. J Biol Chem
1998; 273:23849-55.
4.
Tzeng Y-L, Feher VA, Cavanagh J, Perego M, and Hoch JA. Characterization of Interactions
between a two-component response regulator, Spo0F, and its phosphatase, RapB. Biochemistry
1998; 37:16538-45.
5.
Jiang M, Tzeng Y-L, Feher VA, Perego M, and Hoch JA. Alanine mutants of the Spo0F response
regulator modifying specificity for sensor kinases in sporulation initiation. Mol Microbiol 1999;
33:389-395.
101
6.
Tzeng Y-L, Stephens DS. The epidemiology and pathogenesis of Neisseria meningitidis.
Microbes Infect 2000; 2:687-700.
7.
Tzeng Y-L, Swartley JS, Miller YK, Nisbet RE, Liu L-J, Ahn JH, and Stephens DS.
Transcriptional regulation of divergent capsule biosynthesis and transport operon promoters in
serogroup B Neisseria meningitidis. Infect Immun 2001; 69:2502-11.
8.
Kahler CM, Martin L, Tzeng Y-L, Stephens DS, Sharkey K, and Davies JD. Polymorphisms in
pilin glycosylation locus of Neisseria meningitidis expressing class II pili. Infect Immun 2001; 69:
3597.
9.
Tzeng Y-L, Datta A, Kumar Kolli V, Carlson RW, and Stephens DS. Endotoxin of Neisseria
meningitidis composed only of intact lipid A: Inactivation of the meningococcal 3-deoxy-Dmanno-octulosonic acid transferase. J Bacteriol 2002; 184:2379-88.
10.
Tzeng Y-L, Datta A, Strole C, Kumar Kolli VS, Birck MR, Taylor WP, Carlson RW, Woodard
RW, and Stephens DS. KpsF is the arabinose 5-phosphate isomerase required for 3-deoxy-Dmanno-octulosonic acid (Kdo) biosynthesis and for both lipooligosaccharide assembly and
capsular polysaccharide expression in Neisseria meningitidis. J Biol Chem 2002; 277:24103-13.
11.
Tzeng Y-L, Noble C, and Stephens DS. Genetic basis for biosynthesis of the (α1→4)-linked Nacetyl-D-glucosamine 1-phosphate capsule of serogroup X Neisseria meningitidis. Infect Immun
2003, 71:6712-20.
12.
Zughaier SM, Tzeng Y-L, Zimmer SM, Datta A, Carlson RW, and Stephens DS. Neisseria
meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like
receptor 4 pathway. Infect Immun, 2004, 72:371-80.
13.
Tzeng Y-L, Datta A, Ambrose K, Lo M, Davies JK, Carlson, RW, Stephens DS, and Kahler CM.
The misR/misS two-component regulatory system influences inner core structure and immunotype
of lipooligosaccharide in Neisseria meningitidis. J Biol Chem 2004, 279: 35053-62.
14.
Gudlavalleti S, Datta A, Tzeng Y-L, Carlson RW, and Stephens DS. The Neisseria meningitidis
serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase. J Biol Chem 2004, 279:
42765-73.
15.
Tzeng Y-L, Datta A, Strole CA, Lobritz MA, Carlson RW, and Stephens DS. Translocation and
surface expression of lipidated serogroup B capsular polysaccharide in Neisseria meningitidis.
Infect Immun, 2005, 73:1491-505.
16.
Kahler CM, Datta A, Tzeng Y-L, Carlson RW, and Stephens DS. Inner core assembly and
structure of the lipooligosaccharide of Neisseria meningitidis: capacity of strain NMB to express
all known immunotype epitopes. Glycobiology, 2005, 15:409-19.
17.
Tzeng Y-L, Ambrose K, Zughaier SM, Zhou, X, Miller YK, Shafer, WM, and Stephens DS.
Cationic antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol 2005,187:53875396.
18.
Tzeng Y-L, Zhou, X, Bao, S, Zhao, S, Noble, C and Stephens DS. Autoregulation of the
MisR/MisS two-component signal transduction system in Neisseria meningitidis. J Bacteriol 2006,
188:5055-65.
19.
Dunning Hotopp JC, Grifantini R, Kumar N, Tzeng Y-L, Fouts D, Frigimelica E, Draghi M,
Guiliani MM, Rappuoli R, Stephens DS, Grandi G, Tettelin T. Comparative Genomics of
Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes.
Microbiology 2006, 152: 3733-49.
102
20.
Tzeng Y-L, Kahler CM, Zhang, X and Stephens DS. The MisR/MisS Two-Component Regulon in
Neisseria meningitidis. Infect. Immun 2008, 76:704-16.
David S. Weiss, PhD
Education:
Undergraduate :
Graduate:
Postdoctoral:
Brandeis University, 1998, B.S.
New York University, 2004, Ph.D.
Stanford University, 2007
Research Interests:
Our lab is interested in understanding mechanisms of bacterial pathogenesis and the host’s
response to infection. We are currently focusing on the Gram-negative bacterial pathogen
Francisella tularensis which causes tularemia. Critical to Francisella’s pathogenesis are its
ability to replicate within macrophages, the primary niche for replication in vivo, and to subvert
the host immune system. We recently identified a novel Francisella gene that is required for
bacterial virulence in vivo and suppresses macrophage activation of host defense pathways.
Current experiments are focused on how this novel virulence factor functions at the molecular
level. Future work will elucidate the roles of other novel Francisella virulence factors we have
identified, as well as identifying the host defense pathways that they modulate. Our work will
allow us to gain insights into host-pathogen interactions, while leading us towards an F.
tularensis vaccine and the identification of critical targets for therapeutics to treat tularemia.
1.
Aliprantis AO, Yang RB*, Weiss DS*, Godowski P, Zychlinsky, A. The apoptotic signaling
pathway activated by Toll-like receptor-2. EMBO Journal. 2000; 19:3325-3336. (*contributed
equally)
2.
Aliprantis AO, Weiss DS, Zychlinsky A. Toll-like receptor-2 transduces signals for NF-kappaB
activation, apoptosis and reactive oxygen species production. J Endotoxin Res 2001; 7:287-291.
3.
Aliprantis AO, Weiss DS, Radolf JD, Zychlinsky A. Release of Toll-Like Receptor-2-activating
bacterial lipoproteins in Shigella flexneri culture supernatants. Infection and Immunity. 2001;
69:6248-6255.
4.
Weiss DS, Zychlinsky A. Methods for studying bacteria-induced host cell death. Methods in
Microbiology: in Molecular Cellular Microbiology. 2002; 31:439-460. Academic Press. (Review).
5.
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y,
Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004; 303:1532-1535.
6.
Weiss DS, Raupach B, Takeda K, Akira S, Zychlinsky A. Toll-Like Receptors are temporally
involved in host defense. J Immunol 2004; 172:4463-9.
7.
Manterola L, Moriyón I, Moreno E, Sola-Landa A, Weiss DS, Koch MHJ, Howe J, Brandenburg
K, López-Goñi I. The lipopolysaccharide of Brucella abortus BvrS/BvrR mutants contains lipid A
modifications and has higher affinity for bactericidal cationic peptides. J Bacteriol 2005;
187:5631-5639.
103
8.
Weiss DS, Takeda K, Akira S, Zychlinsky A, Moreno E. MyD88, but not TLR4 or TLR2, is
required for efficient clearance of Brucella. Infection and Immunity. 2005; 73:5137-43.
9.
Mariathasan S*, Weiss DS*, Dixit VM, Monack D. The ASC/caspase-1 axis is required for innate
defense against Francisella. J Experimental Med. 2005; 202:1043-9. (*contributed equally)
10.
Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M, Lee WP,
Weinrauch Y, Monack D, Dixit VM. Cryopyrin activates the inflammasome in response to toxins
and ATP. Nature. 2006; 440:228-32
11.
Brotcke A, Weiss DS, Kim C, Malfatti S, Chain P, Garcia E, Monack DM. Identification of
MglA-regulated genes reveals novel virulence factors in F. tularensis. Infection and Immunity.
2006; 74:6642-55.
12.
Barquero-Calvo E, Chaves-Olarte E, Weiss DS, Guzmán-Verri C, Chacón C, Rucavado A,
Moriyón I, Moreno E. Brucella abortus uses a stealthy strategy to avoid activation of the innate
immune system during the onset of infection. PLoS ONE 2007;2:e631.
13.
Henry T, Brotcke A*, Weiss DS*, Thompson L, Monack DM. Type I interferon signaling is
required for inflammasome activation during Francisella infection. J Experimental Med
2007;204:987-94. (*contributed equally)
14.
Weiss DS, Brotcke A, Henry T, Margolis J, Chan K, Monack DM. In vivo negative selection
screen identifies novel Francisella virulence genes. Proc Natl Acad Sci USA 2007; 104:6037-42.
15.
Weiss DS, Henry T, Monack DM. Francisella tularensis activation of the inflammasome. In
Francisella tularensis: Biology, Pathogenicity, Epidemiology and Biodefense. Ann NY Acad Sci
(Review). 2007;1105:219-37.
Kimberly A. Workowski, MD
Education:
Medical School:
Residency:
Fellowship:
University of South Florida
University of Chicago
University of Washington
Staff Physician: Crawford Long Hospital
Staff Physician: Grady Memorial Hospital
Chief, Guidelines Unit, Epidemiology & Surveillance
Branch, Division of Sexually Transmitted Diseases
Prevention, CDC
Sexually transmitted diseases; Hepatitis C; HIV/AIDS; Vaginal microbicides; STD guidelines
development; vaccine clinical trials.
1.
Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug resistant
Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181:1421-7.
104
2.
Koumans EH, Kendrick J, CDC Bacterial Vaginosis Working Group: Bruce C, Hogan V, Joesoef
R, Markowitz L, Schmid G, Schuchat A, St Louis M, Sutton M, Workowski K. Prevention of the
Adverse Sequelae of Bacterial Vaginosis. Sex Trans Dis 2001; 28(5):292-297.
3.
Linden PK, Moellering RC, Wood CA, Rehm SJ, Flaherty J, Bompart F, Talbot GH, for the
Synercid Emergency-Use Study Group (Workowski KA). Treatment of Vancomycin-Resistant
Enterococcus Faecium Infections with Quinupristin/Dalfopristin. Clin Infect Dis 2001; 33:181623.
4.
Workowski KA, Levine W, Wasserheit JN. CDC Sexually Transmitted Diseases Treatment
Guidelines: An opportunity to unify clinical and public health practice. Ann Int Med 2002;
137(4):255-262.
5.
Koumans EH, Hogan V, Markowitz LE, for the BV Working Group: Bruce C, Joesoef R, Schmid
G, Schuchat A, Sutton M, Workowski KA. Indications for therapy and treatment
recommendations for bacterial vaginosis in non-pregnant women and pregnant women: a synthesis
of data. Clin Infect Dis 2002; 35(Supp 2):S152-172.
6.
CDC, HRSA, NIH, HIV Medicine Association of the Infectious Diseases Society of America, and
the HIV Prevention in Clinical Care Working Group (Workowski, KA). Recommendations for
Incorporating Human Immunodeficiency Virus Prevention (HIV) into the Medical Care of Persons
Living with HIV. Clin Infect Dis 2004; 38:104-121.
7.
Workowski KA, Berman SM. Sexually Transmitted Diseases Treatment Guidelines. Clin Inf Dis
2002; 5:S135-7
8.
Berman SM, Moran JS, Wang SA, Workowski KA. Fluoroquinolones, gonorrhea, and the CDC
STD Treatment Guidelines. Sex Trans Dis 2003; 30 (6): 528-9
9.
CDC, Workowski KA (Coordinator). 2006 CDC Sexually Transmitted Diseases Treatment
Guidelines. MMWR 2006; 55 (RR-11): 1-94.
10.
FitzGerald M, Workowski K. Developing sexually transmitted disease guidelines in the USA and
the UK. Int J STDs AIDS 2007; 18:7-10
11.
Wendel K, Workowski KA. Trichomoniasis: Challenges to Appropriate Management. Clin Infect
Dis 2007; 44 (Supp 3); S123-9.
12.
Newman LM, Moran JS, Workowski KA. Update on the Management of Gonorrhea in Adults in
the United States. Clin Infect Dis 2007; 44 (Supp 3): S84-101.
13.
McLean C, Stoner B, Workowski KA. Treatment of Lymphogranuloma Venereum. Clin Infect
Dis 2007; 44 (Supp 3): S147-152.
14.
Workowski KA, Berman S. Sexually Transmitted Treatment Guidelines. Clin Infect Dis 2007; 44
(Supp 3): S73-76.
15.
Radziewicz H, Ibegbu CC, Fernandez M, Workowski KA, Obeideen K, Wehbi M, Hanson H,
Steinberg J, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A.
Liver infiltrating lymphocytes in chronic HCV infection display an exhausted phenotype with high
PD-1 and low CD127 expression. J Virology 2007;81(6):2545-53.
16.
Gorwitz R, Fridken S, Workowski KA. More Challenges in the Prevention and Management of
Community-Associated MRSA skin disease. Ann Intern Med 2008;148(4): 310-12.
105
17.
Helms D, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in
women with suspected metronidazole hypersensitivity. American Journal of OB/Gyn 2008;
198(4):370.e1-7.
18.
Workowski KA, Berman SM, Douglas JM. Emerging Antimicrobial Resistance in Neisseria
gonorrhoeae: Urgent Need to Strengthen Prevention Strategies. Ann Intern Med 2008; 148:60613.
19.
Radziewicz H, Ibegbu CC, Hon H, Osborn M, Obideen K, Wehbi M, Freeman G, Lennox L,
Workowski K, Hanson H, Grakoui A. Impaired HCV specific effector CD8+ T cells undergo
chronic phase of infection. J Virol 2008 (in press).
20.
Tai E, Sanchez T, Lansky A, Mahle K, Heffelfinger J, Workowski K. Self-reported syphilis and
gonorrhea testing among men who have sex with men, National HIV Behavioral Surveillance
System, 2003-2005. Sex Transm Infect 2008 (in press).
Susu Zughaier, PhD
Education:
BSc:
MSc:
PhD:
Yarmouk University, Irbid, Jordan
University of Wales College of Medicine, UK
University of Wales College of Medicine, UK
Host-pathogen (namely Neisseria meningitidis) interactions, Toll-like receptor-mediated
macrophage activation / signaling, ligand structure-function and adjuvant mechanism are the core
of my studies. My basic science research interests focus on macrophage and dendritic cells innate
immune responses (oxidative burst, cytokines, chemokines and cationic peptides release) to
lipopolysaccharides and capsular polysaccharide of invading pathogens. Other research interests
include macrolide resistance in Streptococcus pneumoniae before and after the introduction of the
pneumococcal conjugate vaccine in a population-based surveillance.
1.
Mitchelmore IJ, Reilly PG, Hay AJ, Zughaier SM, Tabaqchali S. Tonsil surface and core
cultures in recurrent tonsillitis: prevalence of anaerobes and b-lactamase-producing organisms.
Eur J Cli Micro Infec Diseases 1994: 13 (No. 7): 542-48.
2.
Sughayer G, Doudin A, Zughaier SM, Thalji A. Study of nasopharyngeal colonisation pattern
and antibiotic susceptibility among Palestinian children from birth to aged 5 years. Bulletin of
Palestinian Children Society. February 1995: 1 (No. 3): 225-234.
3.
Zughaier SM, Ryley HC, Jackson SK. A melanin pigment purified from an epidemic strain of
B.cepacia attenuated monocyte respiratory burst activity by scavenging superoxide anion. Infect
Immun 1999 : 67: 908-913
4.
Zughaier, SM, Ryley HC, Jackson SK. LPS from Burkholderia cepacia is more active than LPS
from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating TNFα from
106
human monocytes. Infect and Immun 1999: 67 : 1505-7
5.
Guttormsen, HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper DL.
Type III Group B Streptococcal polysaccheride induces antibodies that cross-react with
Streptococcus pneumoniae Type 14. Infect and Immun 2002: 70: 1724- 38.
6.
Zughaier SM, Tzeng YL, Zimmer SM, Datta A, Carlson RW, Stephens DS. Neisseria
meningitides lipooligosaccharide structure-dependent activation of the macrophage CD14/TLR4
pathway. Infect and Immun 2004: 72: 371-380.
7.
Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Gay K, Jackson D, Arnold K,
Schuchat A, Farley MM. Rapid Decline of incidence of macrolide resistance in Streptococcus
pneumoniae following introduction of the pneumococcal conjugate vaccine: A population-based
assessment. Lancet 2005; 365: 855-63
8.
Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS. Differential induction of the
TLR4-MyD88-dependent and -independent signalling pathways by endotoxin. Infect Immun.
2005. 73, No 5: 2940-2950
9.
Plant L, Sundqvist J, Zughaier SM, Lovkvist L, Stephens DS, Jonsson AB. Structural variations
in lipooligosaccharide affect the virulence of Neisseria meningitidis. Infect and Immun. 2006. 74,
No 2: 1360-1367
10.
Zughaier SM, Shafer W, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and
nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell
Microbiol. 2005. Vol. 7 No. 9: 1251-62.
11.
Tzeng YL, Ambrose K, Zughaier SM, Zhou X, Miller Y, Shafer W, Stephens DS. Cationic
antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol. 2005. Vol. 187, No. 15:
5387-96
12.
Zughaier SM, Agrawal S, Stephens DS, Pulendran B. Hexa-acylation and KDO2-glycosylation
determine the selective immunostimulatory activity of Neisseria meningitidis lipid A for human
monocyte derived dendritic cells. Vaccine. 2006. Vol. 24, No 9: 1291-7
13.
Zimmer S, Zughaier SM, Tzeng YL, Stephens DS. Human MD-2 discrimination of
meningococcal lipid A structures and activation of TLR4. Glycobiology 2007. Vol. 8: 847-56
14.
Zughaier SM, Steeghs L, van der Ley P, Stephens DS. TLR4-dependent adjuvant activity of
Neisseria meningitidis lipid A. Vaccine 2007. Vol. 25, No. 22: 4410-4409
15.
Zughaier SM, Lindner B, Howe J, Gardiel P, Koch MHJ, Brandenburg K, Stephens DS.
Physicochemical characterization and biological activity of lipopolysaccharide and lipid A from
Neisseria meningitidis. J Endotoxin Res. 2007;13(6):343-57
C.
CLINICAL (VOLUNTEER) FACULTY
The teaching and research activities of the Division are also supported by our
clinical (volunteer) faculty. Many of these individuals are located at the Centers for
Disease Control and Prevention (CDC). The CDC is the primary federal agency engaged
in infectious disease control and prevention strategies. The Division of Infectious
107
Diseases and the CDC maintain a close collaborative affiliation for teaching, research,
seminars, conferences and library facilities.
Paul Arguin, MD
Sharon Bloom, MD
William Bower, MD
Philip S. Brachman, MD
John Brooks, MD
Kenneth G. Castro, MD
J. Peter Cegielski, MD, MPH
Martin Cetron, MD
Louisa E. Chapman, MD
Thomas Chiller, MD
Terence L. Chorba, MD
Mitchell L. Cohen, MD
John M. Douglas, Jr., MD
D. Peter Drotman, MD
Tedd Ellerbrock, MD
Scott Filler, MD
Anthony Fiore, MD
Scott Fridkin, MD
Julie Gerberding, MD
D.
Susan Goldstein, MD
Lisa Grohskopf, MD, PhD
Shannon Hader, MD
Rana Hajjeh, MD
Theresa A. Harrington, MD, MPH
James Heffelinger, MD
Timothy Holtz, MD
Bryan Kapella, MD
Jonathan E. Kaplan, MD
Rima Khabbaz, MD
Matthew Kuehnert, MD
Lauri Markowitz, MD
Barbara Marston, MD
Catherine A. McLean, MD
Juliette Morgan, MD
Mathew Moore, MD
Pragna Patel, MD
Philip J. Peters, MD
Robert W. Pinner, MD
Drew Posey, MD
Christie Reed, MD
Anne Schuchat, MD
Craig N. Shapiro, MD
Patricia Simone, MD
Steven L. Solomon, MD
Thomas J. Spira, MD
Philip R. Spradling, MD
David L. Swerdlow, MD
Melissa Tobin-D’Angelo, MD
Andrew A. Vernon, MD
Charles Vitek, MD
John Ward, MD
Michele Weinberg, MD, PhD
Melinda Wharton, MD
Cynthia G. Whitney, MD, MPH
ASSOCIATED AND ADJUNCT FACULTY
The Division also maintains strong collaborative ties with Emory's Department of
Microbiology and Immunology, Department of Pathology and Laboratory Medicine, the
Graduate Programs in Microbiology and Molecular Genetics and in Immunology and
Molecular Pathogenesis, the Emory’s Rollins School of Public Health, the Department of
International Health and the Carter Center for International Studies. Collaborators at
these sites include:
Rafi Ahmed, PhD
Susan Allen, MD, MPH
Ruth Berkelman, MD
John Boring, PhD
John Bryan, MD
Richard Compans, PhD
James Curran, MD, MPH
Bruce Levin, PhD
Christine Moe, PhD
Charles Moran, PhD
Leslie Real, PhD
John C. Salerno, PhD
June Scott, PhD
Richard Rothenberg, MD
William M. Shafer, PhD
A separate pediatric infectious disease group also interacts with the Division in joint
conferences, teaching, and research activities. Investigative collaborators in the pediatric
infectious diseases group include Division Director Paul Spearman, MD, Harry Keyserling,
MD, Sheryl Henderson, MD, PhD, Joseph Hilinski, MD, and Andi Shane, MD.
E.
CURRENT TRAINEES
First Year Fellows
108
Ameeta Kalokhe, MD – Wayne State University School of Medicine; Residency: Emory
University, Atlanta, GA
Krutika Kuppalli, MD – Virginia Commonwealth University School of Medicine; Residency:
Emory University, Atlanta, GA
Daniel Livorsi, MD – University of Illinois School of Medicine; Residency: Baylor University,
Houston, TX
Anandi Sheth, MD – Johns Hopkins University School of Medicine; Residency: Johns Hopkins
University, Baltimore, MD
Zandraetta Tims-Cook, MD - Weill Cornell Medical College; Residency: Vanderbilt
University, Nashville, TN
Second Year Fellows
Natasha S. Hochberg, MD, MPH – Case Western Reserve School of Medicine; Residency:
Brigham and Women's Hospital , Boston, MA.
Colleen F. Kelley, MD, MPH – Emory University School of Medicine; Residency: UC-San
Francisco, San Francisco, CA.
Russell R. Kempker, MD – University of Miami School of Medicine; Residency: Emory
University School of Medicine, Atlanta, GA.
Jacek Skarbinski, MD – Stanford University School of Medicine; Residency: UC-San
Francisco, San Francisco, CA.
Nicholas Vogenthaler, MD, MPH – UC-San Francisco School of Medicine; Residency: UC-San
Francisco, San Francisco, CA
Third Year Fellows
Jodie A. Dionne-Odom, MD – Dartmouth Medical School, Hanover, NH; Residency and Chief
Residency: New York University, New York, NY
Alicia Hidron, MD – Instituto de Ciencias de la Salud, CES, Medellin, Colombia; Residency
and Chief Residency: Emory University School of Medicine, Atlanta, GA
Colleen Kraft, MD – Indiana University School of Medicine; Residency: Emory University
School of Medicine, Atlanta, GA; Chief Residency: Atlanta VA Medical Center
Aneesh Mehta, MD – University of Oklahoma College of Medicine, Oklahoma City, OK;
Residency: Emory University School of Medicine, Atlanta, GA
Alexandra (Sasha) Yamshchikov, MD – University of Virginia School of Medicine,
Charlottesville, VA; Residency: Yale University New Haven Hospital, New Haven, CT
GRADUATES:
2008
Jesse T. Jacob, MD – Assistant Professor of Medicine, Division of Infectious Diseases, Emory
University School of Medicine, Atlanta, GA
Seema Jain, MD – Medical Epidemiologist, Division of Influenza, Centers for Disease Control
and Prevention
109
Nadine G. Rouphael , MD – Instructor in Medicine, Division of Infectious Diseases, Emory
Naasha Talati, MD - Instructor in Medicine, Division of Infectious Diseases, Emory University
School of Medicine, Atlanta, GA
2007
Nimalie Stone, MD – Assistant Professor of Medicine, Division of Infectious Diseases, Emory
2006
Laura Broyles, MD – Assistant Professor of Medicine, Division of Infectious Diseases, Emory
Deblina Datta, MD – Medical Epidemiologist, Division of STD Prevention, Centers for Disease
Control and Prevention, Atlanta, GA
Neel Gandhi, MD – Assistant Professor of Medicine, Albert Einstein College of Medicine, New
York, NY
Deborah Nicolls, MD – Infectious Diseases, New Orleans, LA.
Melissa Osborn, MD - Assistant Professor of Medicine, Division of Infectious Diseases, Emory
Philip Peters, MD – EIS Fellow, Centers for Disease Control and Prevention, Atlanta, GA
Zachary Rubin, MD – Assistant Professor of Medicine, Division of Infectious Diseases, David
Geffen- UCLA School of Medcine, Los Angeles, CA.
2005
Werner Albrich, MD – Attending Physician, University of Berne, Berne, Switzerland.
Adam M. Bressler, MD – Private Practice, Atlanta, GA
Eileen Farnon, MD – Medical Epidemiologist, Division of Viral and Rickettsial Diseases,
Centers for Disease Control and Prevention, Atlanta, GA
Bill Kapogiannis, MD – Director, NIH Adolescent HIV Medicine Trials Network, Bethesda, MD
Abeer A. Moanna, MD – Senior Associate of Medicine, Division of Infectious Diseases, Emory
2004
Bernard Camins, MD – Assistant Professor of Medicine, Division of Infectious Diseases,
Washington University School of Medicine, St. Louis, MO
Peter M. Dull, MD – Head of Development of Meningococcal Conjugate Vaccines, Novartis
Vaccines and Diagnostics, Emeryville, CA
Henry T. Radziewicz, MD – Assistant Professor of Medicine, Division of Infectious Diseases,
Emory University School of Medicine, Atlanta, GA
Shanta M. Zimmer, MD – Assistant Professor of Medicine, Division of General Internal
Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.
2003
Carlos DiazGranados, MD - Assistant Professor of Medicine, Division of Infectious Diseases,
Shannon Hader, MD, MPH – Director, HIV/AIDS Administration, Washington, DC Department
of Health
Robin Hampton, MD, PhD - Private Practice, Susquehanna Health System, Williamsport, PA
Alexander Kessler, MD – Private Practice, Susquehanna Health System, Acworth, GA
Michael C. Thigpen, MD – Medical Epidemiologist Epidemiology Branch, Division of
HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA.
2002
Wayne Duffus, MD, PhD – Medical Director, HIV and STD Medicine, South Carolina
Department of Health and Environmental Control; Clinical Assistant Professor, Division of
Infectious Diseases, University of South Carolina School of Medicine, Columbia, SC
Tamara Fisk, MD – (deceased 3/05) – formerly, Assistant Professor of Medicine, Division of
Infectious Diseases, Emory University School of Medicine, Atlanta, GA
Melissa Tobin-D’Angelo, MD, MPH – Medical Epidemiologist, Georgia DHR/Division of
Public Health, Atlanta, GA
2001
William Blake, MD – Private Practice, Atlanta, GA
110
Carlos Franco-Paredes, MD – Assistant Professor of Medicine, Division of Infectious Diseases,
Mark D. King, MD – Private Practice, Boulder, CO
Michael Leonard, Jr, MD - Associate Professor of Medicine, Division of Infectious Diseases,
Charles Vitek, MD, MPH – Director, Global AIDS Program in Russia, CDC, Moscow, Russia
2000
Michael Martin, MD, MPH – Chief, HIV Vaccine and Clinical Research Section, Thai MOPHU.S. CDC Collaboration, Bangkok, Thailand
Margaret Williamson, MD – Private Practice, Atlanta, GA
1999
Helmut Albrecht, MD- Professor of Medicine and Chief, Division of Infectious Diseases,
University of South Carolina School of Medicine, Columbia, SC
Mitchell Blass, MD - Private Practice of Infectious Diseases, Atlanta, GA
Matthew J. Kuehnert, MD- Medical Epidemiologist, Associate Director for Blood Safety,
Division of Healthcare Quality Promotion, NCID, CDC, Atlanta, GA
Ronald Reisler, MD- USAMRIID, Division of Medicine, Special Immunization Program, Fort
Detrick, MD
1998
Henry Baffoe-Bonnie, MD – Private Practice of Infectious Diseases, Lakeland, FL
Ben Barnett, MD - Associate Professor of Medicine, Division of Infectious Diseases, University
of Texas at Houston
William Bower, MD – Medical Epidemiologist, Division of Viral Hepatitis/Epidemiology
Branch, CDC, Atlanta, GA
Richard Hengel, MD – Private Practice, Atlanta, GA
Jyoti Somani, MD – Private Practice, Atlanta, GA
Charles Wells, MD – Medical Director, TB Products Unit, Otsuka Pharmaceutical Development
and Commercialization, Rockville, Maryland (formerly Director, International Research
Activities, Division of Tuberculosis Elimination, CDC, Atlanta, GA)
1997
Sri Edupuganti, MD – Assistant Professor of Medicine, Division of Infectious Diseases, Emory
Christine Zurawski, MD - Private Practice of Infectious Diseases, Atlanta GA
1996
Kathryn E. Arnold, MD - Chief, Medical Consultation & Liaison Activity Epidemiology
Section, Division of Public Health, Georgia Department of Human, Atlanta, GA
Sue Anne Brenner, MD - Assistant Professor, Division of Family and Preventative Medicine,
Jay C. Butler, MD - Chief, Arctic Investigations Branch, CDC, Anchorage, AK
Rafael A. Caputi, MD - Chief, Infectious Diseases, SOLCA Hospital, Guayaquil, Ecuador
Juliette Morgan, MD – Medical Epidemiologist, Emerging Pathogens, CDC, Atlanta, GA
Nigel J. Raymond, MD - Hospital Practice and Clinical Senior Lecturer, Infectious Diseases,
University of Otago, Wellington, New Zealand
1995
Susan McLellan, MD – Associate Professor of Medicine, Division of Infectious Diseases, Tulane
University School of Medicine, New Orleans, LA
1994
Jonathan Krohn, MD - Private Practice, East Setauket, NY
Barbara Marston, MD - Technical Officer, HIV Care and Treatment Team, Global AIDS
Program, Centers for Disease Control and Prevention, Atlanta, GA
R. Scott Stienecker, MD – Private Practice of Infectious Diseases; Epidemiologist, St. Ritas
Medical Center (SCCI) Inc., Lima, OH
1993
Rana Ahmad Hajjeh, MD - Director, Hib Initiative, CDC, Atlanta, GA
Susan M. Ray, MD – Associate Professor of Medicine, Division Infectious Diseases, Emory
University School of Medicine; Associate Hospital Epidemiologist, Grady Memorial Hospital,
111
Atlanta, GA
1992
Henry M. Blumberg, MD - Professor of Medicine and Epidemiology, Program Director,
Division of Infectious Diseases, Emory University School of Medicine, Program Director,
Research Education, Training and Career Development, Atlanta Clinical and Translational Science
Institute; Hospital Epidemiologist, Grady Memorial Hospital, Atlanta, GA
Philip S. Brachman, MD - Private Practice of Infectious Diseases; Clinical Faculty, Division of
Molly E. Eaton, MD - Assistant Professor of Medicine, Division of Infectious Diseases, Emory
Steven M. Gordon, MD – Professor of Medicine and Chief, Infectious Diseases, Cleveland
Clinic Foundation, Cleveland, OH
Joseph A. Havlik, MD - Private Practice of Infectious Diseases Atlanta, GA
Lincoln P. Miller, MD – Private Practice, Newark, NJ
Thomas R. Navin, MD – Branch Chief, Surveillance Branch, Division of Tuberculosis
Elimination, CDC; Clinical Faculty, Division of Infectious Diseases, Emory University School of
Medicine, Atlanta, GA
1991
Clifford J. Gunthel, MD - Assistant Professor of Medicine, Division of Infectious Diseases,
Edward F. Hendershot, MD – Assistant Professor of Medicine, Duke University, Durham, NC
1990
Paul D. Martin, MD - Private Practice of Infectious Diseases, Atlanta, GA
Robert W. Yancey, MD - Private Practice of Infectious Diseases, Gainesville, FL
1989
Kenneth G. Castro, MD - Director, Division of Tuberculosis Elimination, National Center for
HIV, STD and TB Prevention, CDC; Assistant Surgeon General, U.S. Public Health Service;
Clinical Faculty, Division of Infectious Diseases, Emory University School of Medicine, Atlanta,
GA
Stuart W. Haber, MD - Private Practice of Infectious Diseases, Westchester County, NY
Lee H. Harrison, MD - Professor of Epidemiology and Medicine; Director, Public Health
Infectious Diseases Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, PA
1988
Michael L. Butera, MD - Private Practice of Infectious Diseases and Internal Medicine, San
Diego, CA
Carlos C. del Rio, MD - Professor of Medicine, Division of Infectious Diseases, Emory
University School of Medicine, and Chief of Medicine, Grady Memorial Hospital, Atlanta, GA
Carmelo M. Licitra, MD - Private Practice of Infectious Diseases, Orlando, FL
Robert W. Pinner, MD – Director, Office of Surveillance, NCID, CDC; Clinical Faculty,
Jonathan M. Zenilman, MD - Professor of Medicine, Infectious Diseases, Johns Hopkins University
School of Medicine, Baltimore, MD
1987
John M. Maloney, III, MD – Private Practice of Infectious Diseases, Atlanta, GA
1986
William A. Alexander, MD - Associate Professor, Morehouse School of Medicine, Atlanta, GA
John F. Campbell, MD - Chief of Infectious Diseases, Moses Cone Hospital, Greensboro, NC
John W. Holman, MD - Private Practice of Internal Medicine and Infectious Diseases,
Greenwood, SC
Alan J. Morrison, MD - Private Practice, Managing Partner of Infectious Diseases, Annandale,
VA; Hospital Epidemiologist, Inova Health System
1985
John C. Durham, MD – Consultant, Medical Software Development, Atlanta, GA
Monica M. Farley, MD –Professor of Medicine and Associate Director, Division of Infectious
Diseases, Emory University School of Medicine, Atlanta, GA
112
Eimear M. Kennedy, MD (deceased) - Private Practice of Internal Medicine and Infectious
Diseases, Atlanta, GA
1984
Peter Katona, MD – Associate Professor of Medicine, UCLA School of Medicine, Los
Angeles, CA
Phyllis E. Kozarsky, MD - Professor of Medicine, Division of Infectious Diseases, Emory
University School of Medicine; Director, Travel Well Clinic, Atlanta, GA; Chief of Traveler’s
Health, CDC
Bryan P. Simmons, MD – Clinical Professor of Medicine and Medical Director Infection
Control, Methodist University Hospitals, Memphis, TN
Thomas H. Steinberg, MD - Professor of Medicine, Division of Infectious Diseases, Washington
University School of Medicine; St. Louis, MO
1983
Robin H. Dretler, MD - Private Practice of Internal Medicine and Infectious Diseases, Decatur,
GA; Clinical Assistant Professor of Medicine, Infectious Diseases, Emory University School of
Medicine, Atlanta, GA
1982
Don C. Bartley, MD - Private Practice of Internal Medicine and Infectious Diseases, Jacksonville,
FL
Rafael L. Jurado, MD - Associate Professor of Medicine, Division of Infectious Diseases, Emory
Richard C. Rose, III, MD - Private Practice of Internal Medicine and Infectious Diseases,
Knoxville, TN
1981
Don T. Allegra, MD - Private Practice of Internal Medicine and Infectious Diseases,
Randolph, NJ
Richard Prokesch, MD Physician, Private Practice of ID and Internal Medicine, Board Member,
Out-patient Intravenous Antibiotic Registry, Chairman, P&T Infection Control Committees, South
Fulton Med Center and Southern Regional Medical Center, Chairman, Southern Regional Health
System, Atlanta, GA
1980
Joseph Brewer, MD - Private Practice of Internal Medicine and Infectious Diseases, Kansas
City, MO
Samuel Webster, MD - Private Practice of Internal Medicine and Infectious Diseases,
Atlanta, GA
1979
John Drummond, MD - Private Practice of Internal Medicine and Infectious Diseases,
Atlanta, GA
J. Boyd Francis, MD – deceased (6/99); formerly Professor of Medicine, University of Virginia
School of Medicine, Charlottesville, VA
Daniel Rawson, MD - Private Practice of Internal Medicine and Infectious Diseases, Salt Lake City,
UT
1978
William Corwin, MD - Associate Medical Director, Harvard Community Health Plan/NE,
Providence, RI
Patricia DuBose, MD - Private Practice of Internal Medicine and Infectious Diseases, Atlanta,
GA
1977
Norman F. Jacobs, Jr, MD - Private Practice of Internal Medicine and Infectious Diseases;
Hospital Epidemiologist, DeKalb Medical Center, Atlanta, GA
David Rimland, MD - Professor of Medicine, Division of Infectious Diseases, Emory University
School of Medicine; Chief, Infectious Diseases, VAMC, Atlanta, GA, Director of HIV Programs,
VAMC, Atlanta, GA
1976
David Lowe, MD - Private Practice of Internal Medicine and Infectious Diseases, Providence, RI
113
David Schlossberg, MD – Director, TB Clinic, Philadelphia Department of Health, Professor of
Medicine, Temple University School of Medicine,
John Walker, MD - Private Practice of Internal Medicine and Infectious Diseases, Atlanta, GA
1975
Sumner Thompson, III, MD - Deceased (11/95), formerly Professor of Medicine (Division of
Infectious Diseases), Emory University School of Medicine; Director of AIDS Programs at Grady
Health System, Atlanta, GA
Fernando Zacarias, MD - Epidemiologist, Pan American Health Organization (PAHO)
1974
Dorothy Karandanias, MD
Carl A. Perlino, MD – Emeritus Associate Professor of Medicine, Division Infectious Diseases,
1973
Robert Cantey, MD - Professor of Medicine and Director, Division of Infectious Diseases,
Medical University of South Carolina, Charleston, SC
1972
Victor del Bene, MD - Professor of Medicine, Medical University of South Carolina, Charleston,
SC
1970
Richard E. DuBois, MD - Private Practice of Internal Medicine and Infectious Diseases, Atlanta,
GA
Allen H. Johnson, MD - Professor of Medicine, Medical University of South Carolina,
Charleston, SC
Stephen Schwarzmann, MD – Emeritus Professor of Medicine, Division of Infectious Diseases,
1968
Charles Hamilton, MD
114

Subspecialty Training in Infectious Diseases at Emory

Transcription

Similar documents

WRRC flyer for Staceyann Chin and Dr. E

www .emory.edu/CME

Conservatory at Druid Hills

SeminarICarroll_Farr..

http://medmyst.rice.edu

www.emory.edu/CME

Volume 6 Issue 2 Special Edition March 2014

File - East Nashville Hope Exchange

OSO Meeting Minutes for 4/1/15 Minutes Recorded by Kasey

May 17, 2012 - Emory University